

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use LAMICTAL safely and effectively. See full prescribing information for LAMICTAL.

LAMICTAL (lamotrigine) Tablets
LAMICTAL (lamotrigine) Chewable Dispersible Tablets
LAMICTAL ODT (lamotrigine) Orally Disintegrating Tablets
Initial U.S. Approval: 1994

WARNING: SERIOUS SKIN RASHES

See full prescribing information for complete boxed warning. Cases of life-threatening serious rashes, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and/or rash-related death, have been caused by LAMICTAL. The rate of serious rash is greater in pediatric patients than in adults. Additional factors that may increase the risk of rash include (5.1):

- coadministration with valproate
 - exceeding recommended initial dose of LAMICTAL
 - exceeding recommended dose escalation of LAMICTAL
- Benign rashes are also caused by LAMICTAL; however, it is not possible to predict which rashes will prove to be serious or life-threatening. LAMICTAL should be discontinued at the first sign of rash, unless the rash is clearly not drug-related. (5.1)

RECENT MAJOR CHANGES

Warnings and Precautions, Aseptic Meningitis (5.7) October 2010

INDICATIONS AND USAGE

LAMICTAL is an antiepileptic drug (AED) indicated for:

Epilepsy—adjunctive therapy in patients ≥2 years of age: (1.1)

- partial seizures.
- primary generalized tonic-clonic seizures.
- generalized seizures of Lennox-Gastaut syndrome.

Epilepsy—monotherapy in patients ≥16 years of age: conversion to monotherapy in patients with partial seizures who are receiving treatment with carbamazepine, phenobarbital, phenytoin, primidone, or valproate as the single AED. (1.1)

Bipolar Disorder in patients ≥18 years of age: maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. (1.2)

DOSAGE AND ADMINISTRATION

- Dosing is based on concomitant medications, indication, and patient age. (2.2, 2.4)
- To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations should not be exceeded. LAMICTAL Starter Kits and LAMICTAL ODT Patient Titration Kits are available for the first 5 weeks of treatment. (2.1, 16)
- Do not restart LAMICTAL in patients who discontinued due to rash unless the potential benefits clearly outweigh the risks. (2.1)
- Adjustments to maintenance doses will in most cases be required in patients starting or stopping estrogen-containing oral contraceptives. (2.1, 5.9)
- LAMICTAL should be discontinued over a period of at least 2 weeks (approximately 50% reduction per week). (2.1, 5.10)

Epilepsy

- Adjunctive therapy—See Table 1 for patients >12 years of age and Tables 2 and 3 for patients 2 to 12 years. (2.2)
- Conversion to monotherapy—See Table 4. (2.3)

Bipolar Disorder: See Tables 5 and 6. (2.4)

DOSAGE FORMS AND STRENGTHS

Tablets: 25 mg, 100 mg, 150 mg, and 200 mg scored. (3.1, 16)

Chewable Dispersible Tablets: 2 mg, 5 mg, and 25 mg. (3.2, 16)
Orally Disintegrating Tablets: 25 mg, 50 mg, 100 mg, and 200 mg. (3.3, 16)

CONTRAINDICATIONS

Hypersensitivity to the drug or its ingredients. (Boxed Warning, 4)

WARNINGS AND PRECAUTIONS

- Life-threatening serious rash and/or rash-related death may result. (Boxed Warning, 5.1)
- Hypersensitivity reaction may be fatal or life-threatening. Early signs of hypersensitivity (e.g., fever, lymphadenopathy) may present without rash; if signs present, patient should be evaluated immediately. LAMICTAL should be discontinued if alternate etiology for hypersensitivity signs is not found. (5.2)
- Acute multiorgan failure has resulted (some cases fatal). (5.3)
- Blood dyscrasias (e.g., neutropenia, thrombocytopenia, pancytopenia), may result either with or without an associated hypersensitivity syndrome. (5.4)
- Suicidal behavior and ideation. (5.5)
- Clinical worsening, emergence of new symptoms, and suicidal ideation/behaviors may be associated with treatment of bipolar disorder. Patients should be closely monitored, particularly early in treatment or during dosage changes. (5.6)
- Aseptic meningitis reported in pediatric and adult patients. (5.7)
- Medication errors involving LAMICTAL have occurred. In particular the names LAMICTAL or lamotrigine can be confused with names of other commonly used medications. Medication errors may also occur between the different formulations of LAMICTAL. (3.4, 5.8, 16, 17.9)

ADVERSE REACTIONS

- Most common adverse reactions (incidence ≥10%) in adult epilepsy clinical studies were dizziness, headache, diplopia, ataxia, nausea, blurred vision, somnolence, rhinitis, and rash. Additional adverse reactions (incidence ≥10%) reported in children in epilepsy clinical studies included vomiting, infection, fever, accidental injury, pharyngitis, abdominal pain, and tremor. (6.1)
- Most common adverse reactions (incidence >5%) in adult bipolar clinical studies were nausea, insomnia, somnolence, back pain, fatigue, rash, rhinitis, abdominal pain, and xerostomia. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Valproate increases lamotrigine concentrations more than 2-fold. (7, 12.3)
- Carbamazepine, phenytoin, phenobarbital, and primidone decrease lamotrigine concentrations by approximately 40%. (7, 12.3)
- Oral estrogen-containing contraceptives and rifampin also decrease lamotrigine concentrations by approximately 50%. (7, 12.3)

USE IN SPECIFIC POPULATIONS

- Hepatic impairment: Dosage adjustments required. (2.1)
- Healthcare professionals can enroll patients in the Lamotrigine Pregnancy Registry (1-800-336-2176). Patients can enroll themselves in the North American Antiepileptic Drug Pregnancy Registry (1-888-233-2334). (8.1)
- Efficacy of LAMICTAL, used as adjunctive treatment for partial seizures, was not demonstrated in a small randomized, double-blind, placebo-controlled study in very young pediatric patients (1 to 24 months). (8.4)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised:

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: SERIOUS SKIN RASHES

1 INDICATIONS AND USAGE

- 1.1 Epilepsy
- 1.2 Bipolar Disorder

2 DOSAGE AND ADMINISTRATION

- 2.1 General Dosing Considerations

- 2.2 Epilepsy – Adjunctive Therapy
- 2.3 Epilepsy – Conversion From Adjunctive Therapy to Monotherapy
- 2.4 Bipolar Disorder
- 2.5 Administration of LAMICTAL Chewable Dispersible Tablets

- 2.6 Administration of LAMICTAL ODT Orally Disintegrating Tablets
- 3 DOSAGE FORMS AND STRENGTHS**
 - 3.1 Tablets
 - 3.2 Chewable Dispersible Tablets
 - 3.3 Orally Disintegrating Tablets
 - 3.4 Potential Medication Errors
- 4 CONTRAINDICATIONS**
- 5 WARNINGS AND PRECAUTIONS**
 - 5.1 Serious Skin Rashes [see *Boxed Warning*]
 - 5.2 Hypersensitivity Reactions
 - 5.3 Acute Multiorgan Failure
 - 5.4 Blood Dyscrasias
 - 5.5 Suicidal Behavior and Ideation
 - 5.6 Use in Patients With Bipolar Disorder
 - 5.7 Aseptic Meningitis
 - 5.8 Potential Medication Errors
 - 5.9 Concomitant Use With Oral Contraceptives
 - 5.10 Withdrawal Seizures
 - 5.11 Status Epilepticus
 - 5.12 Sudden Unexplained Death in Epilepsy (SUDEP)
 - 5.13 Addition of LAMICTAL to a Multidrug Regimen That Includes Valproate
 - 5.14 Binding in the Eye and Other Melanin-Containing Tissues
 - 5.15 Laboratory Tests
- 6 ADVERSE REACTIONS**
 - 6.1 Clinical Trials
 - 6.2 Other Adverse Reactions Observed in All Clinical Trials
 - 6.3 Postmarketing Experience
- 7 DRUG INTERACTIONS**
- 8 USE IN SPECIFIC POPULATIONS**
 - 8.1 Pregnancy

- 8.2 Labor and Delivery
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Patients With Hepatic Impairment
- 8.7 Patients With Renal Impairment
- 10 OVERDOSAGE**
 - 10.1 Human Overdose Experience
 - 10.2 Management of Overdose
- 11 DESCRIPTION**
- 12 CLINICAL PHARMACOLOGY**
 - 12.1 Mechanism of Action
 - 12.2 Pharmacodynamics
 - 12.3 Pharmacokinetics
- 13 NONCLINICAL TOXICOLOGY**
 - 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 14 CLINICAL STUDIES**
 - 14.1 Epilepsy
 - 14.2 Bipolar Disorder
- 16 HOW SUPPLIED/STORAGE AND HANDLING**
- 17 PATIENT COUNSELING INFORMATION**
 - 17.1 Rash
 - 17.2 Suicidal Thinking and Behavior
 - 17.3 Worsening of Seizures
 - 17.4 CNS Adverse Effects
 - 17.5 Blood Dyscrasias and/or Acute Multiorgan Failure
 - 17.6 Pregnancy
 - 17.7 Oral Contraceptive Use
 - 17.8 Discontinuing LAMICTAL
 - 17.9 Aseptic Meningitis
 - 17.10 Potential Medication Errors

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: SERIOUS SKIN RASHES

LAMICTAL[®] can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.8% (8 per 1,000) in pediatric patients (2 to 16 years of age) receiving LAMICTAL as adjunctive therapy for epilepsy and 0.3% (3 per 1,000) in adults on adjunctive therapy for epilepsy. In clinical trials of bipolar and other mood disorders, the rate of serious rash was 0.08% (0.8 per 1,000) in adult patients receiving LAMICTAL as initial monotherapy and 0.13% (1.3 per 1,000) in adult patients receiving LAMICTAL as adjunctive therapy. In a prospectively followed cohort of 1,983 pediatric patients (2 to 16 years of age) with epilepsy taking adjunctive LAMICTAL, there was 1 rash-related death. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate.

Other than age, there are as yet no factors identified that are known to predict the risk of occurrence or the severity of rash caused by LAMICTAL. There are suggestions, yet to be proven, that the risk of rash may also be increased by (1) coadministration of LAMICTAL with valproate (includes valproic acid and divalproex sodium), (2) exceeding the recommended initial dose of LAMICTAL, or (3) exceeding the recommended dose escalation for LAMICTAL. However, cases have occurred in the absence of these factors.

Nearly all cases of life-threatening rashes caused by LAMICTAL have occurred within 2 to 8 weeks of treatment initiation. However, isolated cases have occurred after prolonged treatment (e.g., 6 months). Accordingly, duration of therapy cannot be relied upon as means to predict the potential risk heralded by the first appearance of a rash.

Although benign rashes are also caused by LAMICTAL, it is not possible to predict reliably which rashes will prove to be serious or life-threatening. Accordingly, LAMICTAL should ordinarily be discontinued at the first sign of rash, unless the rash is clearly not drug-related. Discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring [*see Warnings and Precautions (5.1)*].

1 INDICATIONS AND USAGE

1.1 Epilepsy

Adjunctive Therapy: LAMICTAL is indicated as adjunctive therapy for the following seizure types in patients ≥ 2 years of age:

- partial seizures
- primary generalized tonic-clonic seizures
- generalized seizures of Lennox-Gastaut syndrome

Monotherapy: LAMICTAL is indicated for conversion to monotherapy in adults (≥ 16 years of age) with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED).

Safety and effectiveness of LAMICTAL have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs.

1.2 Bipolar Disorder

LAMICTAL is indicated for the maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (≥ 18 years of age) treated for acute mood episodes with standard therapy. The effectiveness of LAMICTAL in the acute treatment of mood episodes has not been established.

The effectiveness of LAMICTAL as maintenance treatment was established in 2 placebo-controlled trials in patients with Bipolar I Disorder as defined by DSM-IV [see *Clinical Studies (14.2)*]. The physician who elects to prescribe LAMICTAL for periods extending beyond 16 weeks should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

2 DOSAGE AND ADMINISTRATION

2.1 General Dosing Considerations

Rash: There are suggestions, yet to be proven, that the risk of severe, potentially life-threatening rash may be increased by (1) coadministration of LAMICTAL with valproate, (2) exceeding the recommended initial dose of LAMICTAL, or (3) exceeding the recommended dose escalation for LAMICTAL. However, cases have occurred in the absence of these factors [see *Boxed Warning*]. Therefore, it is important that the dosing recommendations be followed closely.

The risk of nonserious rash may be increased when the recommended initial dose and/or the rate of dose escalation of LAMICTAL is exceeded and in patients with a history of allergy or rash to other AEDs.

LAMICTAL Starter Kits and LAMICTAL[®] ODT[™] Patient Titration Kits provide LAMICTAL at doses consistent with the recommended titration schedule for the first 5 weeks of treatment, based upon concomitant medications for patients with epilepsy (> 12 years of age) and Bipolar I Disorder (≥ 18 years of age) and are intended to help reduce the potential for rash. The use of LAMICTAL Starter Kits and LAMICTAL ODT Patient Titration Kits is recommended for appropriate patients who are starting or restarting LAMICTAL [see *How Supplied/Storage and Handling (16)*].

It is recommended that LAMICTAL not be restarted in patients who discontinued due to rash associated with prior treatment with lamotrigine, unless the potential benefits clearly outweigh the risks. If the decision is made to restart a patient who has discontinued lamotrigine, the need to restart with the initial dosing recommendations should be assessed. The greater the

interval of time since the previous dose, the greater consideration should be given to restarting with the initial dosing recommendations. If a patient has discontinued lamotrigine for a period of more than 5 half-lives, it is recommended that initial dosing recommendations and guidelines be followed. The half-life of lamotrigine is affected by other concomitant medications [*see Clinical Pharmacology (12.3)*].

LAMICTAL Added to Drugs Known to Induce or Inhibit Glucuronidation: Drugs other than those listed in the Clinical Pharmacology section [*see Clinical Pharmacology (12.3)*] have not been systematically evaluated in combination with lamotrigine. Because lamotrigine is metabolized predominantly by glucuronic acid conjugation, drugs that are known to induce or inhibit glucuronidation may affect the apparent clearance of lamotrigine and doses of LAMICTAL may require adjustment based on clinical response.

Target Plasma Levels for Patients With Epilepsy or Bipolar Disorder: A therapeutic plasma concentration range has not been established for lamotrigine. Dosing of LAMICTAL should be based on therapeutic response [*see Clinical Pharmacology (12.3)*].

Women Taking Estrogen-Containing Oral Contraceptives: Starting LAMICTAL in Women Taking Estrogen-Containing Oral Contraceptives: Although estrogen-containing oral contraceptives have been shown to increase the clearance of lamotrigine [*see Clinical Pharmacology (12.3)*], no adjustments to the recommended dose-escalation guidelines for LAMICTAL should be necessary solely based on the use of estrogen-containing oral contraceptives. Therefore, dose escalation should follow the recommended guidelines for initiating adjunctive therapy with LAMICTAL based on the concomitant AED or other concomitant medications (see Table 1 or Table 5). See below for adjustments to maintenance doses of LAMICTAL in women taking estrogen-containing oral contraceptives.

Adjustments to the Maintenance Dose of LAMICTAL In Women Taking Estrogen-Containing Oral Contraceptives:

(1) ***Taking Estrogen-Containing Oral Contraceptives:*** For women not taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin that induce lamotrigine glucuronidation [*see Drug Interactions (7), Clinical Pharmacology (12.3)*], the maintenance dose of LAMICTAL will in most cases need to be increased, by as much as 2-fold over the recommended target maintenance dose, in order to maintain a consistent lamotrigine plasma level [*see Clinical Pharmacology (12.3)*].

(2) ***Starting Estrogen-Containing Oral Contraceptives:*** In women taking a stable dose of LAMICTAL and not taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin that induce lamotrigine glucuronidation [*see Drug Interactions (7), Clinical Pharmacology (12.3)*], the maintenance dose will in most cases need to be increased by as much as 2-fold in order to maintain a consistent lamotrigine plasma level. The dose increases should begin at the same time that the oral contraceptive is introduced and continue, based on clinical response, no more rapidly than 50 to 100 mg/day every week. Dose increases should not exceed the recommended rate (see Table 1 or Table 5) unless lamotrigine plasma

levels or clinical response support larger increases. Gradual transient increases in lamotrigine plasma levels may occur during the week of inactive hormonal preparation (“pill-free” week), and these increases will be greater if dose increases are made in the days before or during the week of inactive hormonal preparation. Increased lamotrigine plasma levels could result in additional adverse reactions, such as dizziness, ataxia, and diplopia. If adverse reactions attributable to LAMICTAL consistently occur during the “pill-free” week, dose adjustments to the overall maintenance dose may be necessary. Dose adjustments limited to the “pill-free” week are not recommended. For women taking LAMICTAL in addition to carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin that induce lamotrigine glucuronidation [see *Drug Interactions (7)*, *Clinical Pharmacology (12.3)*], no adjustment to the dose of LAMICTAL should be necessary.

(3) Stopping Estrogen-Containing Oral Contraceptives: For women not taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin that induce lamotrigine glucuronidation [see *Drug Interactions (7)*, *Clinical Pharmacology (12.3)*], the maintenance dose of LAMICTAL will in most cases need to be decreased by as much as 50% in order to maintain a consistent lamotrigine plasma level. The decrease in dose of LAMICTAL should not exceed 25% of the total daily dose per week over a 2-week period, unless clinical response or lamotrigine plasma levels indicate otherwise [see *Clinical Pharmacology (12.3)*]. For women taking LAMICTAL in addition to carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin that induce lamotrigine glucuronidation [see *Drug Interactions (7)*, *Clinical Pharmacology (12.3)*], no adjustment to the dose of LAMICTAL should be necessary.

Women and Other Hormonal Contraceptive Preparations or Hormone Replacement Therapy: The effect of other hormonal contraceptive preparations or hormone replacement therapy on the pharmacokinetics of lamotrigine has not been systematically evaluated. It has been reported that ethinylestradiol, not progestogens, increased the clearance of lamotrigine up to 2-fold, and the progestin-only pills had no effect on lamotrigine plasma levels. Therefore, adjustments to the dosage of LAMICTAL in the presence of progestogens alone will likely not be needed.

Patients With Hepatic Impairment: Experience in patients with hepatic impairment is limited. Based on a clinical pharmacology study in 24 patients with mild, moderate, and severe liver impairment [see *Use in Specific Populations (8.6)*, *Clinical Pharmacology (12.3)*], the following general recommendations can be made. No dosage adjustment is needed in patients with mild liver impairment. Initial, escalation, and maintenance doses should generally be reduced by approximately 25% in patients with moderate and severe liver impairment without ascites and 50% in patients with severe liver impairment with ascites. Escalation and maintenance doses may be adjusted according to clinical response.

Patients With Renal Impairment: Initial doses of LAMICTAL should be based on patients’ concomitant medications (see Tables 1-3 or Table 5); reduced maintenance doses may

be effective for patients with significant renal impairment [*see Use in Specific Populations (8.7), Clinical Pharmacology (12.3)*]. Few patients with severe renal impairment have been evaluated during chronic treatment with LAMICTAL. Because there is inadequate experience in this population, LAMICTAL should be used with caution in these patients.

Discontinuation Strategy: Epilepsy: For patients receiving LAMICTAL in combination with other AEDs, a reevaluation of all AEDs in the regimen should be considered if a change in seizure control or an appearance or worsening of adverse reactions is observed.

If a decision is made to discontinue therapy with LAMICTAL, a step-wise reduction of dose over at least 2 weeks (approximately 50% per week) is recommended unless safety concerns require a more rapid withdrawal [*see Warnings and Precautions (5.10)*].

Discontinuing carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin that induce lamotrigine glucuronidation should prolong the half-life of lamotrigine; discontinuing valproate should shorten the half-life of lamotrigine.

Bipolar Disorder: In the controlled clinical trials, there was no increase in the incidence, type, or severity of adverse reactions following abrupt termination of LAMICTAL. In clinical trials in patients with Bipolar Disorder, 2 patients experienced seizures shortly after abrupt withdrawal of LAMICTAL. However, there were confounding factors that may have contributed to the occurrence of seizures in these bipolar patients. Discontinuation of LAMICTAL should involve a step-wise reduction of dose over at least 2 weeks (approximately 50% per week) unless safety concerns require a more rapid withdrawal [*see Warnings and Precautions (5.10)*].

2.2 Epilepsy – Adjunctive Therapy

This section provides specific dosing recommendations for patients greater than 12 years of age and patients 2 to 12 years of age. Within each of these age-groups, specific dosing recommendations are provided depending upon concomitant AED or other concomitant medications (Table 1 for patients greater than 12 years of age and Table 2 for patients 2 to 12 years of age). A weight-based dosing guide for patients 2 to 12 years of age on concomitant valproate is provided in Table 3.

Patients Over 12 Years of Age: Recommended dosing guidelines are summarized in Table 1.

Table 1. Escalation Regimen for LAMICTAL in Patients Over 12 Years of Age With Epilepsy

	For Patients TAKING Valproate ^a	For Patients NOT TAKING Carbamazepine, Phenytoin, Phenobarbital, Primidone, ^b or Valproate ^a	For Patients TAKING Carbamazepine, Phenytoin, Phenobarbital, or Primidone ^b and NOT TAKING Valproate ^a
Weeks 1 and 2	25 mg every other day	25 mg every day	50 mg/day
Weeks 3 and 4	25 mg every day	50 mg/day	100 mg/day (in 2 divided doses)
Week 5 onwards to maintenance	Increase by 25 to 50 mg/day every 1 to 2 weeks	Increase by 50 mg/day every 1 to 2 weeks	Increase by 100 mg/day every 1 to 2 weeks
Usual Maintenance Dose	100 to 200 mg/day with valproate alone 100 to 400 mg/day with valproate and other drugs that induce glucuronidation (in 1 or 2 divided doses)	225 to 375 mg/day (in 2 divided doses)	300 to 500 mg/day (in 2 divided doses)

^a Valproate has been shown to inhibit glucuronidation and decrease the apparent clearance of lamotrigine [see *Drug Interactions (7)*, *Clinical Pharmacology (12.3)*].

^b These drugs induce lamotrigine glucuronidation and increase clearance [see *Drug Interactions (7)*, *Clinical Pharmacology (12.3)*]. Other drugs which have similar effects include estrogen-containing oral contraceptives [see *Drug Interactions (7)*, *Clinical Pharmacology (12.3)*]. Dosing recommendations for oral contraceptives can be found in General Dosing Considerations [see *Dosage and Administration (2.1)*]. Patients on rifampin, or other drugs that induce lamotrigine glucuronidation and increase clearance, should follow the same dosing titration/maintenance regimen as that used with anticonvulsants that have this effect.

Patients 2 to 12 Years of Age: Recommended dosing guidelines are summarized in Table 2.

Smaller starting doses and slower dose escalations than those used in clinical trials are recommended because of the suggestion that the risk of rash may be decreased by smaller starting doses and slower dose escalations. Therefore, maintenance doses will take longer to reach in clinical practice than in clinical trials. It may take several weeks to months to achieve an

individualized maintenance dose. Maintenance doses in patients weighing less than 30 kg, regardless of age or concomitant AED, may need to be increased as much as 50%, based on clinical response.

The smallest available strength of LAMICTAL Chewable Dispersible Tablets is 2 mg, and only whole tablets should be administered. If the calculated dose cannot be achieved using whole tablets, the dose should be rounded down to the nearest whole tablet [see How Supplied/Storage and Handling (16) and Medication Guide].

Table 2. Escalation Regimen for LAMICTAL in Patients 2 to 12 Years of Age With Epilepsy

	For Patients TAKING Valproate ^a	For Patients NOT TAKING Carbamazepine, Phenytoin, Phenobarbital, Primidone, ^b or Valproate ^a	For Patients TAKING Carbamazepine, Phenytoin, Phenobarbital, or Primidone ^b and NOT TAKING Valproate ^a
Weeks 1 and 2	0.15 mg/kg/day in 1 or 2 divided doses, rounded down to the nearest whole tablet (see Table 3 for weight based dosing guide)	0.3 mg/kg/day in 1 or 2 divided doses, rounded down to the nearest whole tablet	0.6 mg/kg/day in 2 divided doses, rounded down to the nearest whole tablet
Weeks 3 and 4	0.3 mg/kg/day in 1 or 2 divided doses, rounded down to the nearest whole tablet (see Table 3 for weight based dosing guide)	0.6 mg/kg/day in 2 divided doses, rounded down to the nearest whole tablet	1.2 mg/kg/day in 2 divided doses, rounded down to the nearest whole tablet
Week 5 onwards to maintenance	The dose should be increased every 1 to 2 weeks as follows: calculate 0.3 mg/kg/day, round this amount down to the nearest whole tablet, and add this amount to the previously administered daily dose	The dose should be increased every 1 to 2 weeks as follows: calculate 0.6 mg/kg/day, round this amount down to the nearest whole tablet, and add this amount to the previously administered daily dose	The dose should be increased every 1 to 2 weeks as follows: calculate 1.2 mg/kg/day, round this amount down to the nearest whole tablet, and add this amount to the previously administered daily dose

Usual Maintenance Dose	1 to 5 mg/kg/day (maximum 200 mg/day in 1 or 2 divided doses) 1 to 3 mg/kg/day with valproate alone	4.5 to 7.5 mg/kg/day (maximum 300 mg/day in 2 divided doses)	5 to 15 mg/kg/day (maximum 400 mg/day in 2 divided doses)
Maintenance dose in patients less than 30 kg	May need to be increased by as much as 50%, based on clinical response	May need to be increased by as much as 50%, based on clinical response	May need to be increased by as much as 50%, based on clinical response

Note: Only whole tablets should be used for dosing.

- ^a Valproate has been shown to inhibit glucuronidation and decrease the apparent clearance of lamotrigine [see *Drug Interactions (7), Clinical Pharmacology (12.3)*].
- ^b These drugs induce lamotrigine glucuronidation and increase clearance [see *Drug Interactions (7), Clinical Pharmacology (12.3)*]. Other drugs which have similar effects include estrogen-containing oral contraceptives [see *Drug Interactions (7), Clinical Pharmacology (12.3)*]. Dosing recommendations for oral contraceptives can be found in General Dosing Considerations [see *Dosage and Administration (2.1)*]. Patients on rifampin, or other drugs that induce lamotrigine glucuronidation and increase clearance, should follow the same dosing titration/maintenance regimen as that used with anticonvulsants that have this effect.

Table 3. The Initial Weight-Based Dosing Guide for Patients 2 to 12 Years Taking Valproate (Weeks 1 to 4) With Epilepsy

If the patient's weight is		Give this daily dose, using the most appropriate combination of LAMICTAL 2-mg and 5-mg tablets	
Greater than	And less than	Weeks 1 and 2	Weeks 3 and 4
6.7 kg	14 kg	2 mg every <i>other</i> day	2 mg every day
14.1 kg	27 kg	2 mg every day	4 mg every day
27.1 kg	34 kg	4 mg every day	8 mg every day
34.1 kg	40 kg	5 mg every day	10 mg every day

Usual Adjunctive Maintenance Dose for Epilepsy: The usual maintenance doses identified in Tables 1 and 2 are derived from dosing regimens employed in the placebo-controlled adjunctive studies in which the efficacy of LAMICTAL was established. In patients receiving multidrug regimens employing carbamazepine, phenytoin, phenobarbital, or primidone **without valproate**, maintenance doses of adjunctive LAMICTAL as high as 700 mg/day have been used. In patients receiving **valproate alone**, maintenance doses of adjunctive LAMICTAL as high as 200 mg/day have been used. The advantage of using doses above those recommended in Tables 1 through 4 has not been established in controlled trials.

2.3 Epilepsy – Conversion From Adjunctive Therapy to Monotherapy

The goal of the transition regimen is to effect the conversion to monotherapy with LAMICTAL under conditions that ensure adequate seizure control while mitigating the risk of serious rash associated with the rapid titration of LAMICTAL.

The recommended maintenance dose of LAMICTAL as monotherapy is 500 mg/day given in 2 divided doses.

To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations of LAMICTAL should not be exceeded [see *Boxed Warning*].

Conversion From Adjunctive Therapy With Carbamazepine, Phenytoin, Phenobarbital, or Primidone to Monotherapy With LAMICTAL: After achieving a dose of 500 mg/day of LAMICTAL according to the guidelines in Table 1, the concomitant AED should be withdrawn by 20% decrements each week over a 4-week period. The regimen for the withdrawal of the concomitant AED is based on experience gained in the controlled monotherapy clinical trial.

Conversion From Adjunctive Therapy With Valproate to Monotherapy With LAMICTAL: The conversion regimen involves 4 steps outlined in Table 4.

Table 4. Conversion From Adjunctive Therapy With Valproate to Monotherapy With LAMICTAL in Patients ≥16 Years of Age With Epilepsy

	LAMICTAL	Valproate
Step 1	Achieve a dose of 200 mg/day according to guidelines in Table 1 (if not already on 200 mg/day).	Maintain previous stable dose.
Step 2	Maintain at 200 mg/day.	Decrease to 500 mg/day by decrements no greater than 500 mg/day/week and then maintain the dose of 500 mg/day for 1 week.
Step 3	Increase to 300 mg/day and maintain for 1 week.	Simultaneously decrease to 250 mg/day and maintain for 1 week.
Step 4	Increase by 100 mg/day every week to achieve maintenance dose of 500 mg/day.	Discontinue.

Conversion From Adjunctive Therapy With AEDs Other Than Carbamazepine, Phenytoin, Phenobarbital, Primidone, or Valproate to Monotherapy With LAMICTAL: No specific dosing guidelines can be provided for conversion to monotherapy with LAMICTAL with AEDs other than carbamazepine, phenobarbital, phenytoin, primidone, or valproate.

2.4 Bipolar Disorder

The goal of maintenance treatment with LAMICTAL is to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy. The target dose of LAMICTAL is 200 mg/day (100

mg/day in patients taking valproate, which decreases the apparent clearance of lamotrigine, and 400 mg/day in patients not taking valproate and taking either carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin that increase the apparent clearance of lamotrigine). In the clinical trials, doses up to 400 mg/day as monotherapy were evaluated; however, no additional benefit was seen at 400 mg/day compared with 200 mg/day [see *Clinical Studies (14.2)*]. Accordingly, doses above 200 mg/day are not recommended. Treatment with LAMICTAL is introduced, based on concurrent medications, according to the regimen outlined in Table 5. If other psychotropic medications are withdrawn following stabilization, the dose of LAMICTAL should be adjusted. For patients discontinuing valproate, the dose of LAMICTAL should be doubled over a 2-week period in equal weekly increments (see Table 6). For patients discontinuing carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin that induce lamotrigine glucuronidation, the dose of LAMICTAL should remain constant for the first week and then should be decreased by half over a 2-week period in equal weekly decrements (see Table 6). The dose of LAMICTAL may then be further adjusted to the target dose (200 mg) as clinically indicated.

If other drugs are subsequently introduced, the dose of LAMICTAL may need to be adjusted. In particular, the introduction of valproate requires reduction in the dose of LAMICTAL [see *Drug Interactions (7)*, *Clinical Pharmacology (12.3)*].

To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations of LAMICTAL should not be exceeded [see *Boxed Warning*].

Table 5. Escalation Regimen for LAMICTAL for Patients With Bipolar Disorder

	For Patients TAKING Valproate ^a	For Patients NOT TAKING Carbamazepine, Phenytoin, Phenobarbital, Primidone, ^b or Valproate ^a	For Patients TAKING Carbamazepine, Phenytoin, Phenobarbital, or Primidone ^b and NOT TAKING Valproate ^a
Weeks 1 and 2	25 mg every <i>other</i> day	25 mg daily	50 mg daily
Weeks 3 and 4	25 mg daily	50 mg daily	100 mg daily, in divided doses
Week 5	50 mg daily	100 mg daily	200 mg daily, in divided doses
Week 6	100 mg daily	200 mg daily	300 mg daily, in divided doses
Week 7	100 mg daily	200 mg daily	up to 400 mg daily, in divided doses

- ^a Valproate has been shown to inhibit glucuronidation and decrease the apparent clearance of lamotrigine [see *Drug Interactions (7), Clinical Pharmacology (12.3)*].
- ^b These drugs induce lamotrigine glucuronidation and increase clearance [see *Drug Interactions (7), Clinical Pharmacology (12.3)*]. Other drugs which have similar effects include estrogen-containing oral contraceptives [see *Drug Interactions (7), Clinical Pharmacology (12.3)*]. Dosing recommendations for oral contraceptives can be found in General Dosing Considerations [see *Dosage and Administration (2.1)*]. Patients on rifampin, or other drugs that induce lamotrigine glucuronidation and increase clearance, should follow the same dosing titration/maintenance regimen as that used with anticonvulsants that have this effect.

Table 6. Dosage Adjustments to LAMICTAL for Patients With Bipolar Disorder Following Discontinuation of Psychotropic Medications

	Discontinuation of Psychotropic Drugs (excluding Carbamazepine, Phenytoin, Phenobarbital, Primidone, ^b or Valproate ^a)	After Discontinuation of Valproate ^a	After Discontinuation of Carbamazepine, Phenytoin, Phenobarbital, or Primidone ^b
		Current dose of LAMICTAL (mg/day) 100	Current dose of LAMICTAL (mg/day) 400
Week 1	Maintain current dose of LAMICTAL	150	400
Week 2	Maintain current dose of LAMICTAL	200	300
Week 3 onward	Maintain current dose of LAMICTAL	200	200

- ^a Valproate has been shown to inhibit glucuronidation and decrease the apparent clearance of lamotrigine [see *Drug Interactions (7), Clinical Pharmacology (12.3)*].
- ^b These drugs induce lamotrigine glucuronidation and increase clearance [see *Drug Interactions (7), Clinical Pharmacology (12.3)*]. Other drugs which have similar effects include estrogen-containing oral contraceptives [see *Drug Interactions (7), Clinical Pharmacology (12.3)*]. Dosing recommendations for oral contraceptives can be found in General Dosing Considerations [see *Dosage and Administration (2.1)*]. Patients on rifampin, or other drugs that induce lamotrigine glucuronidation and increase clearance, should follow the same dosing titration/maintenance regimen as that used with anticonvulsants that have this effect.

The benefit of continuing treatment in patients who had been stabilized in an 8- to 16-week open-label phase with LAMICTAL was established in 2 randomized, placebo-controlled clinical maintenance trials [see *Clinical Studies (14.2)*]. However, the optimal duration of

treatment with LAMICTAL has not been established. Thus, patients should be periodically reassessed to determine the need for maintenance treatment.

2.5 Administration of LAMICTAL Chewable Dispersible Tablets

LAMICTAL Chewable Dispersible Tablets may be swallowed whole, chewed, or dispersed in water or diluted fruit juice. If the tablets are chewed, consume a small amount of water or diluted fruit juice to aid in swallowing.

To disperse LAMICTAL Chewable Dispersible Tablets, add the tablets to a small amount of liquid (1 teaspoon, or enough to cover the medication). Approximately 1 minute later, when the tablets are completely dispersed, swirl the solution and consume the entire quantity immediately. *No attempt should be made to administer partial quantities of the dispersed tablets.*

2.6 Administration of LAMICTAL ODT Orally Disintegrating Tablets

LAMICTAL ODT Orally Disintegrating Tablets should be placed onto the tongue and moved around in the mouth. The tablet will disintegrate rapidly, can be swallowed with or without water, and can be taken with or without food.

3 DOSAGE FORMS AND STRENGTHS

3.1 Tablets

25 mg, white, scored, shield-shaped tablets debossed with “LAMICTAL” and “25”
100 mg, peach, scored, shield-shaped tablets debossed with “LAMICTAL” and “100”
150 mg, cream, scored, shield-shaped tablets debossed with “LAMICTAL” and “150”
200 mg, blue, scored, shield-shaped tablets debossed with “LAMICTAL” and “200”

3.2 Chewable Dispersible Tablets

2 mg, white to off-white, round tablets debossed with “LTG” over “2”
5 mg, white to off-white, caplet-shaped tablets debossed with “GX CL2”
25 mg, white, super elliptical-shaped tablets debossed with “GX CL5”

3.3 Orally Disintegrating Tablets

25 mg, white to off-white, round, flat-faced, radius edge, tablets debossed with “LMT” on one side and “25” on the other side.

50 mg, white to off-white, round, flat-faced, radius edge, tablets debossed with “LMT” on one side and “50” on the other side.

100 mg, white to off-white, round, flat-faced, radius edge, tablets debossed with “LAMICTAL” on one side and “100” on the other side.

200 mg, white to off-white, round, flat-faced, radius edge, tablets debossed with “LAMICTAL” on one side and “200” on the other side.

3.4 Potential Medication Errors

Patients should be strongly advised to visually inspect their tablets to verify that they are receiving LAMICTAL as well as the correct formulation of LAMICTAL each time they fill their prescription. Depictions of the LAMICTAL Tablets, Chewable Dispersible Tablets, and Orally Disintegrating Tablets can be found in the Medication Guide that accompanies the product.

4 CONTRAINDICATIONS

LAMICTAL is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients [see *Boxed Warning, Warnings and Precautions (5.1), (5.2)*].

5 WARNINGS AND PRECAUTIONS

5.1 Serious Skin Rashes [see *Boxed Warning*]

Pediatric Population: The incidence of serious rash associated with hospitalization and discontinuation of LAMICTAL in a prospectively followed cohort of pediatric patients (2 to 16 years of age) with epilepsy receiving adjunctive therapy was approximately 0.8% (16 of 1,983). When 14 of these cases were reviewed by 3 expert dermatologists, there was considerable disagreement as to their proper classification. To illustrate, one dermatologist considered none of the cases to be Stevens-Johnson syndrome; another assigned 7 of the 14 to this diagnosis. There was 1 rash-related death in this 1,983-patient cohort. Additionally, there have been rare cases of toxic epidermal necrolysis with and without permanent sequelae and/or death in US and foreign postmarketing experience.

There is evidence that the inclusion of valproate in a multidrug regimen increases the risk of serious, potentially life-threatening rash in pediatric patients. In pediatric patients who used valproate concomitantly, 1.2% (6 of 482) experienced a serious rash compared with 0.6% (6 of 952) patients not taking valproate.

Adult Population: Serious rash associated with hospitalization and discontinuation of LAMICTAL occurred in 0.3% (11 of 3,348) of adult patients who received LAMICTAL in premarketing clinical trials of epilepsy. In the bipolar and other mood disorders clinical trials, the rate of serious rash was 0.08% (1 of 1,233) of adult patients who received LAMICTAL as initial monotherapy and 0.13% (2 of 1,538) of adult patients who received LAMICTAL as adjunctive therapy. No fatalities occurred among these individuals. However, in worldwide postmarketing experience, rare cases of rash-related death have been reported, but their numbers are too few to permit a precise estimate of the rate.

Among the rashes leading to hospitalization were Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, and a rash associated with a variable number of the following systemic manifestations: fever, lymphadenopathy, facial swelling, and hematologic and hepatologic abnormalities.

There is evidence that the inclusion of valproate in a multidrug regimen increases the risk of serious, potentially life-threatening rash in adults. Specifically, of 584 patients administered LAMICTAL with valproate in epilepsy clinical trials, 6 (1%) were hospitalized in association with rash; in contrast, 4 (0.16%) of 2,398 clinical trial patients and volunteers administered LAMICTAL in the absence of valproate were hospitalized.

Patients With History of Allergy or Rash to Other AEDs: The risk of nonserious rash may be increased when the recommended initial dose and/or the rate of dose escalation of LAMICTAL is exceeded and in patients with a history of allergy or rash to other AEDs.

5.2 Hypersensitivity Reactions

Hypersensitivity reactions, some fatal or life threatening, have also occurred. Some of these reactions have included clinical features of multiorgan failure/dysfunction, including hepatic abnormalities and evidence of disseminated intravascular coagulation. It is important to note that early manifestations of hypersensitivity (e.g., fever, lymphadenopathy) may be present even though a rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. LAMICTAL should be discontinued if an alternative etiology for the signs or symptoms cannot be established.

Prior to initiation of treatment with LAMICTAL, the patient should be instructed that a rash or other signs or symptoms of hypersensitivity (e.g., fever, lymphadenopathy) may herald a serious medical event and that the patient should report any such occurrence to a physician immediately.

5.3 Acute Multiorgan Failure

Multiorgan failure, which in some cases has been fatal or irreversible, has been observed in patients receiving LAMICTAL. Fatalities associated with multiorgan failure and various degrees of hepatic failure have been reported in 2 of 3,796 adult patients and 4 of 2,435 pediatric patients who received LAMICTAL in epilepsy clinical trials. No such fatalities have been reported in bipolar patients in clinical trials. Rare fatalities from multiorgan failure have also been reported in compassionate plea and postmarketing use. The majority of these deaths occurred in association with other serious medical events, including status epilepticus and overwhelming sepsis, and hantavirus, making it difficult to identify the initial cause.

Additionally, 3 patients (a 45-year-old woman, a 3.5-year-old boy, and an 11-year-old girl) developed multiorgan dysfunction and disseminated intravascular coagulation 9 to 14 days after LAMICTAL was added to their AED regimens. Rash and elevated transaminases were also present in all patients and rhabdomyolysis was noted in 2 patients. Both pediatric patients were receiving concomitant therapy with valproate, while the adult patient was being treated with carbamazepine and clonazepam. All patients subsequently recovered with supportive care after treatment with LAMICTAL was discontinued.

5.4 Blood Dyscrasias

There have been reports of blood dyscrasias that may or may not be associated with the hypersensitivity syndrome. These have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red cell aplasia.

5.5 Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including LAMICTAL, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior

compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated. There were 4 suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number of events is too small to allow any conclusion about drug effect on suicide.

The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.

The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanism of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed.

Table 7 shows absolute and relative risk by indication for all evaluated AEDs.

Table 7. Risk by Indication for Antiepileptic Drugs in the Pooled Analysis

Indication	Placebo Patients With Events Per 1,000 Patients	Drug Patients With Events Per 1,000 Patients	Relative Risk: Incidence of Events in Drug Patients/ Incidence in Placebo Patients	Risk Difference: Additional Drug Patients With Events Per 1,000 Patients
Epilepsy	1.0	3.4	3.5	2.4
Psychiatric	5.7	8.5	1.5	2.9
Other	1.0	1.8	1.9	0.9
Total	2.4	4.3	1.8	1.9

The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.

Anyone considering prescribing LAMICTAL or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or

worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

5.6 Use in Patients With Bipolar Disorder

Acute Treatment of Mood Episodes: Safety and effectiveness of LAMICTAL in the acute treatment of mood episodes have not been established.

Children and Adolescents (less than 18 years of age): Safety and effectiveness of LAMICTAL in patients below the age of 18 years with mood disorders have not been established [*see Suicidal Behavior and Ideation (5.5)*].

Clinical Worsening and Suicide Risk Associated With Bipolar Disorder: Patients with bipolar disorder may experience worsening of their depressive symptoms and/or the emergence of suicidal ideation and behaviors (suicidality) whether or not they are taking medications for bipolar disorder. Patients should be closely monitored for clinical worsening (including development of new symptoms) and suicidality, especially at the beginning of a course of treatment or at the time of dose changes.

In addition, patients with a history of suicidal behavior or thoughts, those patients exhibiting a significant degree of suicidal ideation prior to commencement of treatment, and young adults are at an increased risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment [*see Suicidal Behavior and Ideation (5.5)*].

Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients who experience clinical worsening (including development of new symptoms) and/or the emergence of suicidal ideation/behavior especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.

Prescriptions for LAMICTAL should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose. Overdoses have been reported for LAMICTAL, some of which have been fatal [*see Overdosage (10.1)*].

5.7 Aseptic Meningitis

Therapy with LAMICTAL increases the risk of developing aseptic meningitis. Because of the potential for serious outcomes of untreated meningitis due to other causes, patients should also be evaluated for other causes of meningitis and treated as appropriate.

Postmarketing cases of aseptic meningitis have been reported in pediatric and adult patients taking LAMICTAL for various indications. Symptoms upon presentation have included headache, fever, nausea, vomiting, and nuchal rigidity. Rash, photophobia, myalgia, chills, altered consciousness, and somnolence were also noted in some cases. Symptoms have been reported to occur within 1 day to one and a half months following the initiation of treatment. In most cases, symptoms were reported to resolve after discontinuation of LAMICTAL. Re-exposure resulted in a rapid return of symptoms (from within 30 minutes to 1 day following re-initiation of treatment) that were frequently more severe. Some of the patients treated with

LAMICTAL who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus or other autoimmune diseases.

Cerebrospinal fluid (CSF) analyzed at the time of clinical presentation in reported cases was characterized by a mild to moderate pleocytosis, normal glucose levels, and mild to moderate increase in protein. CSF white blood cell count differentials showed a predominance of neutrophils in a majority of the cases, although a predominance of lymphocytes was reported in approximately one third of the cases. Some patients also had new onset of signs and symptoms of involvement of other organs (predominantly hepatic and renal involvement), which may suggest that in these cases the aseptic meningitis observed was part of a hypersensitivity reaction [see *Warnings and Precautions (5.2)*].

5.8 Potential Medication Errors

Medication errors involving LAMICTAL have occurred. In particular, the names LAMICTAL or lamotrigine can be confused with the names of other commonly used medications. Medication errors may also occur between the different formulations of LAMICTAL. To reduce the potential of medication errors, write and say LAMICTAL clearly. Depictions of the LAMICTAL Tablets, Chewable Dispersible Tablets, and Orally Disintegrating Tablets can be found in the Medication Guide that accompanies the product to highlight the distinctive markings, colors, and shapes that serve to identify the different presentations of the drug and thus may help reduce the risk of medication errors. To avoid the medication error of using the wrong drug or formulation, patients should be strongly advised to visually inspect their tablets to verify that they are LAMICTAL, as well as the correct formulation of LAMICTAL, each time they fill their prescription.

5.9 Concomitant Use With Oral Contraceptives

Some estrogen-containing oral contraceptives have been shown to decrease serum concentrations of lamotrigine [see *Clinical Pharmacology (12.3)*]. **Dosage adjustments will be necessary in most patients who start or stop estrogen-containing oral contraceptives while taking LAMICTAL** [see *Dosage and Administration (2.1)*]. During the week of inactive hormone preparation (“pill-free” week) of oral contraceptive therapy, plasma lamotrigine levels are expected to rise, as much as doubling at the end of the week. Adverse reactions consistent with elevated levels of lamotrigine, such as dizziness, ataxia, and diplopia, could occur.

5.10 Withdrawal Seizures

As with other AEDs, LAMICTAL should not be abruptly discontinued. In patients with epilepsy there is a possibility of increasing seizure frequency. In clinical trials in patients with Bipolar Disorder, 2 patients experienced seizures shortly after abrupt withdrawal of LAMICTAL; however, there were confounding factors that may have contributed to the occurrence of seizures in these bipolar patients. Unless safety concerns require a more rapid withdrawal, the dose of LAMICTAL should be tapered over a period of at least 2 weeks (approximately 50% reduction per week) [see *Dosage and Administration (2.1)*].

5.11 Status Epilepticus

Valid estimates of the incidence of treatment-emergent status epilepticus among patients treated with LAMICTAL are difficult to obtain because reporters participating in clinical trials did not all employ identical rules for identifying cases. At a minimum, 7 of 2,343 adult patients had episodes that could unequivocally be described as status epilepticus. In addition, a number of reports of variably defined episodes of seizure exacerbation (e.g., seizure clusters, seizure flurries, etc.) were made.

5.12 Sudden Unexplained Death in Epilepsy (SUDEP)

During the premarketing development of LAMICTAL, 20 sudden and unexplained deaths were recorded among a cohort of 4,700 patients with epilepsy (5,747 patient-years of exposure).

Some of these could represent seizure-related deaths in which the seizure was not observed, e.g., at night. This represents an incidence of 0.0035 deaths per patient-year. Although this rate exceeds that expected in a healthy population matched for age and sex, it is within the range of estimates for the incidence of sudden unexplained deaths in patients with epilepsy not receiving LAMICTAL (ranging from 0.0005 for the general population of patients with epilepsy, to 0.004 for a recently studied clinical trial population similar to that in the clinical development program for LAMICTAL, to 0.005 for patients with refractory epilepsy). Consequently, whether these figures are reassuring or suggest concern depends on the comparability of the populations reported upon to the cohort receiving LAMICTAL and the accuracy of the estimates provided. Probably most reassuring is the similarity of estimated SUDEP rates in patients receiving LAMICTAL and those receiving other AEDs, chemically unrelated to each other, that underwent clinical testing in similar populations. Importantly, that drug is chemically unrelated to LAMICTAL. This evidence suggests, although it certainly does not prove, that the high SUDEP rates reflect population rates, not a drug effect.

5.13 Addition of LAMICTAL to a Multidrug Regimen That Includes Valproate

Because valproate reduces the clearance of lamotrigine, the dosage of lamotrigine in the presence of valproate is less than half of that required in its absence.

5.14 Binding in the Eye and Other Melanin-Containing Tissues

Because lamotrigine binds to melanin, it could accumulate in melanin-rich tissues over time. This raises the possibility that lamotrigine may cause toxicity in these tissues after extended use. Although ophthalmological testing was performed in one controlled clinical trial, the testing was inadequate to exclude subtle effects or injury occurring after long-term exposure. Moreover, the capacity of available tests to detect potentially adverse consequences, if any, of lamotrigine's binding to melanin is unknown [*see Clinical Pharmacology (12.2)*].

Accordingly, although there are no specific recommendations for periodic ophthalmological monitoring, prescribers should be aware of the possibility of long-term ophthalmologic effects.

5.15 Laboratory Tests

The value of monitoring plasma concentrations of lamotrigine in patients treated with LAMICTAL has not been established. Because of the possible pharmacokinetic interactions between lamotrigine and other drugs including AEDs (see Table 15), monitoring of the plasma levels of lamotrigine and concomitant drugs may be indicated, particularly during dosage adjustments. In general, clinical judgment should be exercised regarding monitoring of plasma levels of lamotrigine and other drugs and whether or not dosage adjustments are necessary.

6 ADVERSE REACTIONS

The following adverse reactions are described in more detail in the *Warnings and Precautions* section of the label:

- Serious skin rashes [see *Warnings and Precautions* (5.1)]
- Hypersensitivity reactions [see *Warnings and Precautions* (5.2)]
- Acute multiorgan failure [see *Warnings and Precautions* (5.3)]
- Blood dyscrasias [see *Warnings and Precautions* (5.4)]
- Suicidal behavior and ideation [see *Warnings and Precautions* (5.5)]
- Aseptic meningitis [see *Warnings and Precautions* (5.7)]
- Withdrawal seizures [see *Warnings and Precautions* (5.10)]
- Status epilepticus [see *Warnings and Precautions* (5.11)]
- Sudden unexplained death in epilepsy [see *Warnings and Precautions* (5.12)]

6.1 Clinical Trials

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

LAMICTAL has been evaluated for safety in patients with epilepsy and in patients with Bipolar I Disorder. Adverse reactions reported for each of these patient populations are provided below. Excluded are adverse reactions considered too general to be informative and those not reasonably attributable to the use of the drug.

Epilepsy: *Most Common Adverse Reactions in All Clinical Studies: Adjunctive Therapy in Adults With Epilepsy:* The most commonly observed ($\geq 5\%$ for LAMICTAL and more common on drug than placebo) adverse reactions seen in association with LAMICTAL during adjunctive therapy in adults and not seen at an equivalent frequency among placebo-treated patients were: dizziness, ataxia, somnolence, headache, diplopia, blurred vision, nausea, vomiting, and rash. Dizziness, diplopia, ataxia, blurred vision, nausea, and vomiting were dose-related. Dizziness, diplopia, ataxia, and blurred vision occurred more commonly in patients receiving carbamazepine with LAMICTAL than in patients receiving other AEDs with LAMICTAL. Clinical data suggest a higher incidence of rash, including serious rash, in patients receiving concomitant valproate than in patients not receiving valproate [see *Warnings and Precautions* (5.1)].

Approximately 11% of the 3,378 adult patients who received LAMICTAL as adjunctive therapy in premarketing clinical trials discontinued treatment because of an adverse reaction. The

adverse reactions most commonly associated with discontinuation were rash (3.0%), dizziness (2.8%), and headache (2.5%).

In a dose-response study in adults, the rate of discontinuation of LAMICTAL for dizziness, ataxia, diplopia, blurred vision, nausea, and vomiting was dose-related.

Monotherapy in Adults With Epilepsy: The most commonly observed ($\geq 5\%$ for LAMICTAL and more common on drug than placebo) adverse reactions seen in association with the use of LAMICTAL during the monotherapy phase of the controlled trial in adults not seen at an equivalent rate in the control group were vomiting, coordination abnormality, dyspepsia, nausea, dizziness, rhinitis, anxiety, insomnia, infection, pain, weight decrease, chest pain, and dysmenorrhea. The most commonly observed ($\geq 5\%$ for LAMICTAL and more common on drug than placebo) adverse reactions associated with the use of LAMICTAL during the conversion to monotherapy (add-on) period, not seen at an equivalent frequency among low-dose valproate-treated patients, were dizziness, headache, nausea, asthenia, coordination abnormality, vomiting, rash, somnolence, diplopia, ataxia, accidental injury, tremor, blurred vision, insomnia, nystagmus, diarrhea, lymphadenopathy, pruritus, and sinusitis.

Approximately 10% of the 420 adult patients who received LAMICTAL as monotherapy in premarketing clinical trials discontinued treatment because of an adverse reaction. The adverse reactions most commonly associated with discontinuation were rash (4.5%), headache (3.1%), and asthenia (2.4%).

Adjunctive Therapy in Pediatric Patients With Epilepsy: The most commonly observed ($\geq 5\%$ for LAMICTAL and more common on drug than placebo) adverse reactions seen in association with the use of LAMICTAL as adjunctive treatment in pediatric patients 2 to 16 years of age and not seen at an equivalent rate in the control group were infection, vomiting, rash, fever, somnolence, accidental injury, dizziness, diarrhea, abdominal pain, nausea, ataxia, tremor, asthenia, bronchitis, flu syndrome, and diplopia.

In 339 patients 2 to 16 years of age with partial seizures or generalized seizures of Lennox-Gastaut syndrome, 4.2% of patients on LAMICTAL and 2.9% of patients on placebo discontinued due to adverse reactions. The most commonly reported adverse reaction that led to discontinuation of LAMICTAL was rash.

Approximately 11.5% of the 1,081 pediatric patients 2 to 16 years of age who received LAMICTAL as adjunctive therapy in premarketing clinical trials discontinued treatment because of an adverse reaction. The adverse reactions most commonly associated with discontinuation were rash (4.4%), reaction aggravated (1.7%), and ataxia (0.6%).

Controlled Adjunctive Clinical Studies in Adults With Epilepsy: Table 8 lists treatment-emergent adverse reactions that occurred in at least 2% of adult patients with epilepsy treated with LAMICTAL in placebo-controlled trials and were numerically more common in the patients treated with LAMICTAL. In these studies, either LAMICTAL or placebo was added to the patient's current AED therapy. Adverse reactions were usually mild to moderate in intensity.

Table 8. Treatment-Emergent Adverse Reaction Incidence in Placebo-Controlled Adjunctive Trials in Adult Patients With Epilepsy^a (Adverse reactions in at least 2% of patients treated with LAMICTAL and numerically more frequent than in the placebo group.)

Body System/Adverse Reaction	Percent of Patients Receiving Adjunctive LAMICTAL (n = 711)	Percent of Patients Receiving Adjunctive Placebo (n = 419)
Body as a whole		
Headache	29	19
Flu syndrome	7	6
Fever	6	4
Abdominal pain	5	4
Neck pain	2	1
Reaction aggravated (seizure exacerbation)	2	1
Digestive		
Nausea	19	10
Vomiting	9	4
Diarrhea	6	4
Dyspepsia	5	2
Constipation	4	3
Anorexia	2	1
Musculoskeletal		
Arthralgia	2	0
Nervous		
Dizziness	38	13
Ataxia	22	6
Somnolence	14	7
Incoordination	6	2
Insomnia	6	2
Tremor	4	1
Depression	4	3
Anxiety	4	3
Convulsion	3	1
Irritability	3	2
Speech disorder	3	0
Concentration disturbance	2	1

Respiratory		
Rhinitis	14	9
Pharyngitis	10	9
Cough increased	8	6
Skin and appendages		
Rash	10	5
Pruritus	3	2
Special senses		
Diplopia	28	7
Blurred vision	16	5
Vision abnormality	3	1
Urogenital		
Female patients only	(n = 365)	(n = 207)
Dysmenorrhea	7	6
Vaginitis	4	1
Amenorrhea	2	1

^a Patients in these adjunctive studies were receiving 1 to 3 of the following concomitant AEDs (carbamazepine, phenytoin, phenobarbital, or primidone) in addition to LAMICTAL or placebo. Patients may have reported multiple adverse reactions during the study or at discontinuation; thus, patients may be included in more than one category.

In a randomized, parallel study comparing placebo and 300 and 500 mg/day of LAMICTAL, some of the more common drug-related adverse reactions were dose-related (see Table 9).

Table 9. Dose-Related Adverse Reactions From a Randomized, Placebo-Controlled Adjunctive Trial in Adults With Epilepsy

Adverse Reaction	Percent of Patients Experiencing Adverse Reactions		
	Placebo (n = 73)	LAMICTAL 300 mg (n = 71)	LAMICTAL 500 mg (n = 72)
Ataxia	10	10	28 ^{ab}
Blurred vision	10	11	25 ^{ab}
Diplopia	8	24 ^a	49 ^{ab}
Dizziness	27	31	54 ^{ab}
Nausea	11	18	25 ^a
Vomiting	4	11	18 ^a

^a Significantly greater than placebo group ($p < 0.05$).

^b Significantly greater than group receiving LAMICTAL 300 mg ($p < 0.05$).

The overall adverse reaction profile for LAMICTAL was similar between females and males, and was independent of age. Because the largest non-Caucasian racial subgroup was only 6% of patients exposed to LAMICTAL in placebo-controlled trials, there are insufficient data to support a statement regarding the distribution of adverse reaction reports by race. Generally, females receiving either LAMICTAL as adjunctive therapy or placebo were more likely to report adverse reactions than males. The only adverse reaction for which the reports on LAMICTAL were greater than 10% more frequent in females than males (without a corresponding difference by gender on placebo) was dizziness (difference = 16.5%). There was little difference between females and males in the rates of discontinuation of LAMICTAL for individual adverse reactions.

Controlled Monotherapy Trial in Adults With Partial Seizures: Table 10 lists treatment-emergent adverse reactions that occurred in at least 5% of patients with epilepsy treated with monotherapy with LAMICTAL in a double-blind trial following discontinuation of either concomitant carbamazepine or phenytoin not seen at an equivalent frequency in the control group.

Table 10. Treatment-Emergent Adverse Reaction Incidence in Adults With Partial Seizures in a Controlled Monotherapy Trial^a (Adverse reactions in at least 5% of patients treated with LAMICTAL and numerically more frequent than in the valproate group.)

Body System/ Adverse Reaction	Percent of Patients Receiving LAMICTAL as Monotherapy ^b (n = 43)	Percent of Patients Receiving Low-Dose Valproate ^c Monotherapy (n = 44)
Body as a whole		
Pain	5	0
Infection	5	2
Chest pain	5	2
Digestive		
Vomiting	9	0
Dyspepsia	7	2
Nausea	7	2
Metabolic and nutritional		
Weight decrease	5	2

Nervous		
Coordination abnormality	7	0
Dizziness	7	0
Anxiety	5	0
Insomnia	5	2
Respiratory		
Rhinitis	7	2
Urogenital (female patients only)	(n = 21)	(n = 28)
Dysmenorrhea	5	0

^a Patients in these studies were converted to LAMICTAL or valproate monotherapy from adjunctive therapy with carbamazepine or phenytoin. Patients may have reported multiple adverse reactions during the study; thus, patients may be included in more than one category.

^b Up to 500 mg/day.

^c 1,000 mg/day.

Adverse reactions that occurred with a frequency of less than 5% and greater than 2% of patients receiving LAMICTAL and numerically more frequent than placebo were:

Body as a Whole: Asthenia, fever.

Digestive: Anorexia, dry mouth, rectal hemorrhage, peptic ulcer.

Metabolic and Nutritional: Peripheral edema.

Nervous System: Amnesia, ataxia, depression, hypesthesia, libido increase, decreased reflexes, increased reflexes, nystagmus, irritability, suicidal ideation.

Respiratory: Epistaxis, bronchitis, dyspnea.

Skin and Appendages: Contact dermatitis, dry skin, sweating.

Special Senses: Vision abnormality.

Incidence in Controlled Adjunctive Trials in Pediatric Patients With Epilepsy: Table 11 lists adverse reactions that occurred in at least 2% of 339 pediatric patients with partial seizures or generalized seizures of Lennox-Gastaut syndrome, who received LAMICTAL up to 15 mg/kg/day or a maximum of 750 mg/day. Reported adverse reactions were classified using COSTART terminology.

Table 11. Treatment-Emergent Adverse Reaction Incidence in Placebo-Controlled Adjunctive Trials in Pediatric Patients With Epilepsy (Adverse reactions in at least 2% of patients treated with LAMICTAL and numerically more frequent than in the placebo group.)

Body System/ Adverse Reaction	Percent of Patients Receiving LAMICTAL (n = 168)	Percent of Patients Receiving Placebo (n = 171)
Body as a whole		
Infection	20	17
Fever	15	14
Accidental injury	14	12
Abdominal pain	10	5
Asthenia	8	4
Flu syndrome	7	6
Pain	5	4
Facial edema	2	1
Photosensitivity	2	0
Cardiovascular		
Hemorrhage	2	1
Digestive		
Vomiting	20	16
Diarrhea	11	9
Nausea	10	2
Constipation	4	2
Dyspepsia	2	1
Hemic and lymphatic		
Lymphadenopathy	2	1
Metabolic and nutritional		
Edema	2	0

Nervous system		
Somnolence	17	15
Dizziness	14	4
Ataxia	11	3
Tremor	10	1
Emotional lability	4	2
Gait abnormality	4	2
Thinking abnormality	3	2
Convulsions	2	1
Nervousness	2	1
Vertigo	2	1
Respiratory		
Pharyngitis	14	11
Bronchitis	7	5
Increased cough	7	6
Sinusitis	2	1
Bronchospasm	2	1
Skin		
Rash	14	12
Eczema	2	1
Pruritus	2	1
Special senses		
Diplopia	5	1
Blurred vision	4	1
Visual abnormality	2	0
Urogenital		
Male and female patients		
Urinary tract infection	3	0

Bipolar Disorder: The most commonly observed ($\geq 5\%$) treatment-emergent adverse reactions seen in association with the use of LAMICTAL as monotherapy (100 to 400 mg/day) in adult patients (≥ 18 years of age) with Bipolar Disorder in the 2 double-blind, placebo-controlled trials of 18 months' duration, and numerically more frequent than in placebo-treated patients are included in Table 12. Adverse reactions that occurred in at least 5% of patients and were numerically more common during the dose-escalation phase of LAMICTAL in these trials (when patients may have been receiving concomitant medications) compared with the monotherapy phase were: headache (25%), rash (11%), dizziness (10%), diarrhea (8%), dream abnormality (6%), and pruritus (6%).

During the monotherapy phase of the double-blind, placebo-controlled trials of 18 months' duration, 13% of 227 patients who received LAMICTAL (100 to 400 mg/day), 16% of 190 patients who received placebo, and 23% of 166 patients who received lithium discontinued therapy because of an adverse reaction. The adverse reactions which most commonly led to discontinuation of LAMICTAL were rash (3%) and mania/hypomania/mixed mood adverse reactions (2%). Approximately 16% of 2,401 patients who received LAMICTAL (50 to 500 mg/day) for Bipolar Disorder in premarketing trials discontinued therapy because of an adverse reaction, most commonly due to rash (5%) and mania/hypomania/mixed mood adverse reactions (2%).

The overall adverse reaction profile for LAMICTAL was similar between females and males, between elderly and nonelderly patients, and among racial groups.

Table 12. Treatment-Emergent Adverse Reaction Incidence in 2 Placebo-Controlled Trials in Adults With Bipolar I Disorder^a (Adverse reactions in at least 5% of patients treated with LAMICTAL as monotherapy and numerically more frequent than in the placebo group.)

Body System/ Adverse Reaction	Percent of Patients Receiving LAMICTAL (n = 227)	Percent of Patients Receiving Placebo (n = 190)
General		
Back pain	8	6
Fatigue	8	5
Abdominal pain	6	3
Digestive		
Nausea	14	11
Constipation	5	2
Vomiting	5	2
Nervous System		
Insomnia	10	6
Somnolence	9	7
Xerostomia (dry mouth)	6	4
Respiratory		
Rhinitis	7	4
Exacerbation of cough	5	3
Pharyngitis	5	4
Skin		
Rash (nonserious) ^b	7	5

^a Patients in these studies were converted to LAMICTAL (100 to 400 mg/day) or placebo monotherapy from add-on therapy with other psychotropic medications. Patients may have

reported multiple adverse reactions during the study; thus, patients may be included in more than one category.

- ^b In the overall bipolar and other mood disorders clinical trials, the rate of serious rash was 0.08% (1 of 1,233) of adult patients who received LAMICTAL as initial monotherapy and 0.13% (2 of 1,538) of adult patients who received LAMICTAL as adjunctive therapy [*see Warnings and Precautions (5.1)*].

These adverse reactions were usually mild to moderate in intensity. Other reactions that occurred in 5% or more patients but equally or more frequently in the placebo group included: dizziness, mania, headache, infection, influenza, pain, accidental injury, diarrhea, and dyspepsia.

Adverse reactions that occurred with a frequency of less than 5% and greater than 1% of patients receiving LAMICTAL and numerically more frequent than placebo were:

General: Fever, neck pain.

Cardiovascular: Migraine.

Digestive: Flatulence.

Metabolic and Nutritional: Weight gain, edema.

Musculoskeletal: Arthralgia, myalgia.

Nervous System: Amnesia, depression, agitation, emotional lability, dyspraxia, abnormal thoughts, dream abnormality, hypoesthesia.

Respiratory: Sinusitis.

Urogenital: Urinary frequency.

Adverse Reactions Following Abrupt Discontinuation: In the 2 maintenance trials, there was no increase in the incidence, severity, or type of adverse reactions in Bipolar Disorder patients after abruptly terminating therapy with LAMICTAL. In clinical trials in patients with Bipolar Disorder, 2 patients experienced seizures shortly after abrupt withdrawal of LAMICTAL. However, there were confounding factors that may have contributed to the occurrence of seizures in these bipolar patients [*see Warnings and Precautions (5.10)*].

Mania/Hypomania/Mixed Episodes: During the double-blind, placebo-controlled clinical trials in Bipolar I Disorder in which patients were converted to monotherapy with LAMICTAL (100 to 400 mg/day) from other psychotropic medications and followed for up to 18 months, the rates of manic or hypomanic or mixed mood episodes reported as adverse reactions were 5% for patients treated with LAMICTAL (n = 227), 4% for patients treated with lithium (n = 166), and 7% for patients treated with placebo (n = 190). In all bipolar controlled trials combined, adverse reactions of mania (including hypomania and mixed mood episodes) were reported in 5% of patients treated with LAMICTAL (n = 956), 3% of patients treated with lithium (n = 280), and 4% of patients treated with placebo (n = 803).

6.2 Other Adverse Reactions Observed in All Clinical Trials

LAMICTAL has been administered to 6,694 individuals for whom complete adverse reaction data was captured during all clinical trials, only some of which were placebo controlled.

During these trials, all adverse reactions were recorded by the clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals having adverse reactions, similar types of adverse reactions were grouped into a smaller number of standardized categories using modified COSTART dictionary terminology. The frequencies presented represent the proportion of the 6,694 individuals exposed to LAMICTAL who experienced an event of the type cited on at least one occasion while receiving LAMICTAL. All reported adverse reactions are included except those already listed in the previous tables or elsewhere in the labeling, those too general to be informative, and those not reasonably associated with the use of the drug.

Adverse reactions are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: *frequent* adverse reactions are defined as those occurring in at least 1/100 patients; *infrequent* adverse reactions are those occurring in 1/100 to 1/1,000 patients; *rare* adverse reactions are those occurring in fewer than 1/1,000 patients.

Body as a Whole: *Infrequent:* Allergic reaction, chills, and malaise.

Cardiovascular System: *Infrequent:* Flushing, hot flashes, hypertension, palpitations, postural hypotension, syncope, tachycardia, and vasodilation.

Dermatological: *Infrequent:* Acne, alopecia, hirsutism, maculopapular rash, skin discoloration, and urticaria. *Rare:* Angioedema, erythema, exfoliative dermatitis, fungal dermatitis, herpes zoster, leukoderma, multiforme erythema, petechial rash, pustular rash, Stevens-Johnson syndrome, and vesiculobullous rash.

Digestive System: *Infrequent:* Dysphagia, eructation, gastritis, gingivitis, increased appetite, increased salivation, liver function tests abnormal, and mouth ulceration. *Rare:* Gastrointestinal hemorrhage, glossitis, gum hemorrhage, gum hyperplasia, hematemesis, hemorrhagic colitis, hepatitis, melena, stomach ulcer, stomatitis, and tongue edema.

Endocrine System: *Rare:* Goiter and hypothyroidism.

Hematologic and Lymphatic System: *Infrequent:* Ecchymosis and leukopenia. *Rare:* Anemia, eosinophilia, fibrin decrease, fibrinogen decrease, iron deficiency anemia, leukocytosis, lymphocytosis, macrocytic anemia, petechia, and thrombocytopenia.

Metabolic and Nutritional Disorders: *Infrequent:* Aspartate transaminase increased. *Rare:* Alcohol intolerance, alkaline phosphatase increase, alanine transaminase increase, bilirubinemia, general edema, gamma glutamyl transpeptidase increase, and hyperglycemia.

Musculoskeletal System: *Infrequent:* Arthritis, leg cramps, myasthenia, and twitching. *Rare:* Bursitis, muscle atrophy, pathological fracture, and tendinous contracture.

Nervous System: *Frequent:* Confusion and paresthesia. *Infrequent:* Akathisia, apathy, aphasia, CNS depression, depersonalization, dysarthria, dyskinesia, euphoria, hallucinations, hostility, hyperkinesia, hypertonia, libido decreased, memory decrease, mind racing, movement disorder, myoclonus, panic attack, paranoid reaction, personality disorder, psychosis, sleep disorder, stupor, and suicidal ideation. *Rare:* Choreoathetosis, delirium, delusions, dysphoria,

dystonia, extrapyramidal syndrome, faintness, grand mal convulsions, hemiplegia, hyperalgesia, hyperesthesia, hypokinesia, hypotonia, manic depression reaction, muscle spasm, neuralgia, neurosis, paralysis, and peripheral neuritis.

Respiratory System: *Infrequent:* Yawn. *Rare:* Hiccup and hyperventilation.

Special Senses: *Frequent:* Amblyopia. *Infrequent:* Abnormality of accommodation, conjunctivitis, dry eyes, ear pain, photophobia, taste perversion, and tinnitus. *Rare:* Deafness, lacrimation disorder, oscillopsia, parosmia, ptosis, strabismus, taste loss, uveitis, and visual field defect.

Urogenital System: *Infrequent:* Abnormal ejaculation, hematuria, impotence, menorrhagia, polyuria, and urinary incontinence. *Rare:* Acute kidney failure, anorgasmia, breast abscess, breast neoplasm, creatinine increase, cystitis, dysuria, epididymitis, female lactation, kidney failure, kidney pain, nocturia, urinary retention, and urinary urgency.

6.3 Postmarketing Experience

The following adverse events (not listed above in clinical trials or other sections of the prescribing information) have been identified during postapproval use of LAMICTAL. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and Lymphatic: Agranulocytosis, hemolytic anemia, lymphadenopathy not associated with hypersensitivity disorder.

Gastrointestinal: Esophagitis.

Hepatobiliary Tract and Pancreas: Pancreatitis.

Immunologic: Lupus-like reaction, vasculitis.

Lower Respiratory: Apnea.

Musculoskeletal: Rhabdomyolysis has been observed in patients experiencing hypersensitivity reactions.

Neurology: Exacerbation of Parkinsonian symptoms in patients with pre-existing Parkinson's disease, tics.

Non-site Specific: Progressive immunosuppression.

7 DRUG INTERACTIONS

Significant drug interactions with lamotrigine are summarized in Table 13. Additional details of these drug interaction studies are provided in the Clinical Pharmacology section [*see Clinical Pharmacology (12.3)*].

Table 13. Established and Other Potentially Significant Drug Interactions

Concomitant Drug	Effect on Concentration of Lamotrigine or Concomitant Drug	Clinical Comment
Estrogen-containing oral	↓ lamotrigine	Decreased lamotrigine levels

contraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel	↓ levonorgestrel	approximately 50%. Decrease in levonorgestrel component by 19%.
Carbamazepine (CBZ) and CBZ epoxide	↓ lamotrigine ? CBZ epoxide	Addition of carbamazepine decreases lamotrigine concentration approximately 40%. May increase CBZ epoxide levels.
Phenobarbital/Primidone	↓ lamotrigine	Decreased lamotrigine concentration approximately 40%.
Phenytoin (PHT)	↓ lamotrigine	Decreased lamotrigine concentration approximately 40%.
Rifampin	↓ lamotrigine	Decreased lamotrigine AUC approximately 40%.
Valproate	↑ lamotrigine ? valproate	Increased lamotrigine concentrations slightly more than 2-fold. Decreased valproate concentrations an average of 25% over a 3-week period then stabilized in healthy volunteers; no change in controlled clinical trials in epilepsy patients.

↓ = Decreased (induces lamotrigine glucuronidation).

↑ = Increased (inhibits lamotrigine glucuronidation).

? = Conflicting data.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Teratogenic Effects: Pregnancy Category C. No evidence of teratogenicity was found in mice, rats, or rabbits when lamotrigine was orally administered to pregnant animals during the period of organogenesis at doses up to 1.2, 0.5, and 1.1 times, respectively, on a mg/m² basis, the highest usual human maintenance dose (i.e., 500 mg/day). However, maternal toxicity and secondary fetal toxicity producing reduced fetal weight and/or delayed ossification were seen in mice and rats, but not in rabbits at these doses. Teratology studies were also conducted using bolus intravenous administration of the isethionate salt of lamotrigine in rats and rabbits. In rat dams administered an intravenous dose at 0.6 times the highest usual human maintenance dose, the incidence of intrauterine death without signs of teratogenicity was increased.

A behavioral teratology study was conducted in rats dosed during the period of organogenesis. At day 21 postpartum, offspring of dams receiving 5 mg/kg/day or higher

displayed a significantly longer latent period for open field exploration and a lower frequency of rearing. In a swimming maze test performed on days 39 to 44 postpartum, time to completion was increased in offspring of dams receiving 25 mg/kg/day. These doses represent 0.1 and 0.5 times the clinical dose on a mg/m² basis, respectively.

Lamotrigine did not affect fertility, teratogenesis, or postnatal development when rats were dosed prior to and during mating, and throughout gestation and lactation at doses equivalent to 0.4 times the highest usual human maintenance dose on a mg/m² basis.

When pregnant rats were orally dosed at 0.1, 0.14, or 0.3 times the highest human maintenance dose (on a mg/m² basis) during the latter part of gestation (days 15 to 20), maternal toxicity and fetal death were seen. In dams, food consumption and weight gain were reduced, and the gestation period was slightly prolonged (22.6 vs. 22.0 days in the control group). Stillborn pups were found in all 3 drug-treated groups with the highest number in the high-dose group. Postnatal death was also seen, but only in the 2 highest doses, and occurred between days 1 and 20. Some of these deaths appear to be drug-related and not secondary to the maternal toxicity. A no-observed-effect level (NOEL) could not be determined for this study.

Although lamotrigine was not found to be teratogenic in the above studies, lamotrigine decreases fetal folate concentrations in rats, an effect known to be associated with teratogenesis in animals and humans. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Non-Teratogenic Effects: As with other AEDs, physiological changes during pregnancy may affect lamotrigine concentrations and/or therapeutic effect. There have been reports of decreased lamotrigine concentrations during pregnancy and restoration of pre-partum concentrations after delivery. Dosage adjustments may be necessary to maintain clinical response.

Pregnancy Exposure Registry: To provide information regarding the effects of in utero exposure to LAMICTAL, physicians are advised to recommend that pregnant patients taking LAMICTAL enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll-free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website <http://www.aedpregnancyregistry.org/>.

Physicians are also encouraged to register patients in the Lamotrigine Pregnancy Registry; enrollment in this registry must be done prior to any prenatal diagnostic tests and **before fetal outcome is known. Physicians** can obtain information by calling the Lamotrigine Pregnancy Registry at 1-800-336-2176 (toll-free).

8.2 Labor and Delivery

The effect of LAMICTAL on labor and delivery in humans is unknown.

8.3 Nursing Mothers

Preliminary data indicate that lamotrigine passes into human milk. Because the effects on the infant exposed to lamotrigine by this route are unknown, breastfeeding while taking LAMICTAL is not recommended.

8.4 Pediatric Use

LAMICTAL is indicated for adjunctive therapy in patients ≥ 2 years of age for partial seizures, the generalized seizures of Lennox-Gastaut syndrome, and primary generalized tonic-clonic seizures.

Safety and efficacy of LAMICTAL, used as adjunctive treatment for partial seizures, were not demonstrated in a small randomized, double-blind, placebo-controlled, withdrawal study in very young pediatric patients (1 to 24 months). LAMICTAL was associated with an increased risk for infectious adverse reactions (LAMICTAL 37%, Placebo 5%), and respiratory adverse reactions (LAMICTAL 26%, Placebo 5%). Infectious adverse reactions included bronchiolitis, bronchitis, ear infection, eye infection, otitis externa, pharyngitis, urinary tract infection, and viral infection. Respiratory adverse reactions included nasal congestion, cough, and apnea.

Safety and effectiveness in patients below the age of 18 years with Bipolar Disorder have not been established.

8.5 Geriatric Use

Clinical studies of LAMICTAL for epilepsy and in Bipolar Disorder did not include sufficient numbers of subjects 65 years of age and over to determine whether they respond differently from younger subjects or exhibit a different safety profile than that of younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

8.6 Patients With Hepatic Impairment

Experience in patients with hepatic impairment is limited. Based on a clinical pharmacology study in 24 patients with mild, moderate, and severe liver impairment [*see Clinical Pharmacology (12.3)*], the following general recommendations can be made. No dosage adjustment is needed in patients with mild liver impairment. Initial, escalation, and maintenance doses should generally be reduced by approximately 25% in patients with moderate and severe liver impairment without ascites and 50% in patients with severe liver impairment with ascites. Escalation and maintenance doses may be adjusted according to clinical response [*see Dosage and Administration (2.1)*].

8.7 Patients With Renal Impairment

Lamotrigine is metabolized mainly by glucuronic acid conjugation, with the majority of the metabolites being recovered in the urine. In a small study comparing a single dose of lamotrigine in patients with varying degrees of renal impairment with healthy volunteers, the plasma half-life of lamotrigine was significantly longer in the patients with renal impairment [*see Clinical Pharmacology (12.3)*].

Initial doses of LAMICTAL should be based on patients' AED regimens; reduced maintenance doses may be effective for patients with significant renal impairment. Few patients with severe renal impairment have been evaluated during chronic treatment with LAMICTAL. Because there is inadequate experience in this population, LAMICTAL should be used with caution in these patients [*see Dosage and Administration (2.1)*].

10 OVERDOSAGE

10.1 Human Overdose Experience


Overdoses involving quantities up to 15 g have been reported for LAMICTAL, some of which have been fatal. Overdose has resulted in ataxia, nystagmus, increased seizures, decreased level of consciousness, coma, and intraventricular conduction delay.

10.2 Management of Overdose

There are no specific antidotes for lamotrigine. Following a suspected overdose, hospitalization of the patient is advised. General supportive care is indicated, including frequent monitoring of vital signs and close observation of the patient. If indicated, emesis should be induced; usual precautions should be taken to protect the airway. It should be kept in mind that lamotrigine is rapidly absorbed [*see Clinical Pharmacology (12.3)*]. It is uncertain whether hemodialysis is an effective means of removing lamotrigine from the blood. In 6 renal failure patients, about 20% of the amount of lamotrigine in the body was removed by hemodialysis during a 4-hour session. A Poison Control Center should be contacted for information on the management of overdosage of LAMICTAL.

11 DESCRIPTION

LAMICTAL (lamotrigine), an AED of the phenyltriazine class, is chemically unrelated to existing AEDs. Its chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)-*as*-triazine, its molecular formula is $C_9H_7N_5Cl_2$, and its molecular weight is 256.09. Lamotrigine is a white to pale cream-colored powder and has a pK_a of 5.7. Lamotrigine is very slightly soluble in water (0.17 mg/mL at 25°C) and slightly soluble in 0.1 M HCl (4.1 mg/mL at 25°C). The structural formula is:



LAMICTAL Tablets are supplied for oral administration as 25 mg (white), 100 mg (peach), 150 mg (cream), and 200 mg (blue) tablets. Each tablet contains the labeled amount of lamotrigine and the following inactive ingredients: lactose; magnesium stearate; microcrystalline cellulose; povidone; sodium starch glycolate; FD&C Yellow No. 6 Lake (100 mg tablet only); ferric oxide, yellow (150 mg tablet only); and FD&C Blue No. 2 Lake (200 mg tablet only).

LAMICTAL Chewable Dispersible Tablets are supplied for oral administration. The tablets contain 2 mg (white), 5 mg (white), or 25 mg (white) of lamotrigine and the following inactive ingredients: blackcurrant flavor, calcium carbonate, low-substituted hydroxypropylcellulose, magnesium aluminum silicate, magnesium stearate, povidone, saccharin sodium, and sodium starch glycolate.

LAMICTAL ODT Orally Disintegrating Tablets are supplied for oral administration. The tablets contain 25 mg (white to off-white), 50 mg (white to off-white), 100 mg (white to off-white), or 200 mg (white to off-white) of lamotrigine and the following inactive ingredients: artificial cherry flavor, crospovidone, ethylcellulose, magnesium stearate, mannitol, polyethylene, and sucralose.

LAMICTAL ODT Orally Disintegrating Tablets are formulated using technologies (Microcaps[®] and AdvaTab[®]) designed to mask the bitter taste of lamotrigine and achieve a rapid dissolution profile. Tablet characteristics including flavor, mouth-feel, after-taste, and ease of use were rated as favorable in a study of 108 healthy volunteers.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The precise mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. In animal models designed to detect anticonvulsant activity, lamotrigine was effective in preventing seizure spread in the maximum electroshock (MES) and pentylenetetrazol (scMet) tests, and prevented seizures in the visually and electrically evoked after-discharge (EEAD) tests for antiepileptic activity. Lamotrigine also displayed inhibitory properties in the kindling model in rats both during kindling development and in the fully kindled state. The relevance of these models to human epilepsy, however, is not known.

One proposed mechanism of action of lamotrigine, the relevance of which remains to be established in humans, involves an effect on sodium channels. In vitro pharmacological studies suggest that lamotrigine inhibits voltage-sensitive sodium channels, thereby stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory amino acids (e.g., glutamate and aspartate).

Although the relevance for human use is unknown, the following data characterize the performance of lamotrigine in receptor binding assays. Lamotrigine had a weak inhibitory effect on the serotonin 5-HT₃ receptor (IC₅₀ = 18 μM). It does not exhibit high affinity binding (IC₅₀>100 μM) to the following neurotransmitter receptors: adenosine A₁ and A₂; adrenergic α₁, α₂, and β; dopamine D₁ and D₂; γ-aminobutyric acid (GABA) A and B; histamine H₁; kappa opioid; muscarinic acetylcholine; and serotonin 5-HT₂. Studies have failed to detect an effect of lamotrigine on dihydropyridine-sensitive calcium channels. It had weak effects at sigma opioid receptors (IC₅₀ = 145 μM). Lamotrigine did not inhibit the uptake of norepinephrine, dopamine, or serotonin (IC₅₀>200 μM) when tested in rat synaptosomes and/or human platelets in vitro.

Effect of Lamotrigine on N-Methyl d-Aspartate-Receptor Mediated Activity:

Lamotrigine did not inhibit N-methyl d-aspartate (NMDA)-induced depolarizations in rat cortical

slices or NMDA-induced cyclic GMP formation in immature rat cerebellum, nor did lamotrigine displace compounds that are either competitive or noncompetitive ligands at this glutamate receptor complex (CNQX, CGS, TCHP). The IC_{50} for lamotrigine effects on NMDA-induced currents (in the presence of 3 μ M of glycine) in cultured hippocampal neurons exceeded 100 μ M.

The mechanisms by which lamotrigine exerts its therapeutic action in Bipolar Disorder have not been established.

12.2 Pharmacodynamics

Folate Metabolism: In vitro, lamotrigine inhibited dihydrofolate reductase, the enzyme that catalyzes the reduction of dihydrofolate to tetrahydrofolate. Inhibition of this enzyme may interfere with the biosynthesis of nucleic acids and proteins. When oral daily doses of lamotrigine were given to pregnant rats during organogenesis, fetal, placental, and maternal folate concentrations were reduced. Significantly reduced concentrations of folate are associated with teratogenesis [see *Use in Specific Populations (8.1)*]. Folate concentrations were also reduced in male rats given repeated oral doses of lamotrigine. Reduced concentrations were partially returned to normal when supplemented with folic acid.

Accumulation in Kidneys: Lamotrigine accumulated in the kidney of the male rat, causing chronic progressive nephrosis, necrosis, and mineralization. These findings are attributed to α -2 microglobulin, a species- and sex-specific protein that has not been detected in humans or other animal species.

Melanin Binding: Lamotrigine binds to melanin-containing tissues, e.g., in the eye and pigmented skin. It has been found in the uveal tract up to 52 weeks after a single dose in rodents.

Cardiovascular: In dogs, lamotrigine is extensively metabolized to a 2-N-methyl metabolite. This metabolite causes dose-dependent prolongations of the PR interval, widening of the QRS complex, and, at higher doses, complete AV conduction block. Similar cardiovascular effects are not anticipated in humans because only trace amounts of the 2-N-methyl metabolite (<0.6% of lamotrigine dose) have been found in human urine [see *Clinical Pharmacology (12.3)*]. However, it is conceivable that plasma concentrations of this metabolite could be increased in patients with a reduced capacity to glucuronidate lamotrigine (e.g., in patients with liver disease).

12.3 Pharmacokinetics

The pharmacokinetics of lamotrigine have been studied in patients with epilepsy, healthy young and elderly volunteers, and volunteers with chronic renal failure. Lamotrigine pharmacokinetic parameters for adult and pediatric patients and healthy normal volunteers are summarized in Tables 14 and 16.

Table 14. Mean^a Pharmacokinetic Parameters in Healthy Volunteers and Adult Patients With Epilepsy

Adult Study Population	Number of Subjects	T _{max} : Time of Maximum Plasma Concentration (hr)	t _{1/2} : Elimination Half-life (hr)	Cl/F: Apparent Plasma Clearance (mL/min/kg)
Healthy volunteers taking no other medications:				
Single-dose LAMICTAL	179	2.2 (0.25-12.0)	32.8 (14.0-103.0)	0.44 (0.12-1.10)
Multiple-dose LAMICTAL	36	1.7 (0.5-4.0)	25.4 (11.6-61.6)	0.58 (0.24-1.15)
Healthy volunteers taking valproate:				
Single-dose LAMICTAL	6	1.8 (1.0-4.0)	48.3 (31.5-88.6)	0.30 (0.14-0.42)
Multiple-dose LAMICTAL	18	1.9 (0.5-3.5)	70.3 (41.9-113.5)	0.18 (0.12-0.33)
Patients with epilepsy taking valproate only:				
Single-dose LAMICTAL	4	4.8 (1.8-8.4)	58.8 (30.5-88.8)	0.28 (0.16-0.40)
Patients with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone^b plus valproate:				
Single-dose LAMICTAL	25	3.8 (1.0-10.0)	27.2 (11.2-51.6)	0.53 (0.27-1.04)
Patients with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone:^b				
Single-dose LAMICTAL	24	2.3 (0.5-5.0)	14.4 (6.4-30.4)	1.10 (0.51-2.22)
Multiple-dose LAMICTAL	17	2.0 (0.75-5.93)	12.6 (7.5-23.1)	1.21 (0.66-1.82)

^a The majority of parameter means determined in each study had coefficients of variation between 20% and 40% for half-life and Cl/F and between 30% and 70% for T_{max}. The overall mean values were calculated from individual study means that were weighted based on the

number of volunteers/patients in each study. The numbers in parentheses below each parameter mean represent the range of individual volunteer/patient values across studies.

- ^b Carbamazepine, phenobarbital, phenytoin, and primidone have been shown to increase the apparent clearance of lamotrigine. Estrogen-containing oral contraceptives and other drugs such as rifampin that induce lamotrigine glucuronidation have also been shown to increase the apparent clearance of lamotrigine [*see Drug Interactions (7)*].

Absorption: Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%). The bioavailability is not affected by food. Peak plasma concentrations occur anywhere from 1.4 to 4.8 hours following drug administration. The lamotrigine chewable/dispersible tablets were found to be equivalent, whether they were administered as dispersed in water, chewed and swallowed, or swallowed as whole, to the lamotrigine compressed tablets in terms of rate and extent of absorption. In terms of rate and extent of absorption, lamotrigine orally disintegrating tablets whether disintegrated in the mouth or swallowed whole with water were equivalent to the lamotrigine compressed tablets swallowed with water.

Dose Proportionality: In healthy volunteers not receiving any other medications and given single doses, the plasma concentrations of lamotrigine increased in direct proportion to the dose administered over the range of 50 to 400 mg. In 2 small studies (n = 7 and 8) of patients with epilepsy who were maintained on other AEDs, there also was a linear relationship between dose and lamotrigine plasma concentrations at steady state following doses of 50 to 350 mg twice daily.

Distribution: Estimates of the mean apparent volume of distribution (Vd/F) of lamotrigine following oral administration ranged from 0.9 to 1.3 L/kg. Vd/F is independent of dose and is similar following single and multiple doses in both patients with epilepsy and in healthy volunteers.

Protein Binding: Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy trials). Because lamotrigine is not highly bound to plasma proteins, clinically significant interactions with other drugs through competition for protein binding sites are unlikely. The binding of lamotrigine to plasma proteins did not change in the presence of therapeutic concentrations of phenytoin, phenobarbital, or valproate. Lamotrigine did not displace other AEDs (carbamazepine, phenytoin, phenobarbital) from protein-binding sites.

Metabolism: Lamotrigine is metabolized predominantly by glucuronic acid conjugation; the major metabolite is an inactive 2-N-glucuronide conjugate. After oral administration of 240 mg of ¹⁴C-lamotrigine (15 μCi) to 6 healthy volunteers, 94% was recovered in the urine and 2% was recovered in the feces. The radioactivity in the urine consisted of unchanged lamotrigine

(10%), the 2-N-glucuronide (76%), a 5-N-glucuronide (10%), a 2-N-methyl metabolite (0.14%), and other unidentified minor metabolites (4%).

Enzyme Induction: The effects of lamotrigine on the induction of specific families of mixed-function oxidase isozymes have not been systematically evaluated.

Following multiple administrations (150 mg twice daily) to normal volunteers taking no other medications, lamotrigine induced its own metabolism, resulting in a 25% decrease in $t_{1/2}$ and a 37% increase in Cl/F at steady state compared with values obtained in the same volunteers following a single dose. Evidence gathered from other sources suggests that self-induction by lamotrigine may not occur when lamotrigine is given as adjunctive therapy in patients receiving enzyme-inducing drugs such as carbamazepine, phenytoin, phenobarbital, primidone, or drugs such as rifampin that induce lamotrigine glucuronidation [see *Drug Interactions (7)*].

Elimination: The elimination half-life and apparent clearance of lamotrigine following administration of LAMICTAL to adult patients with epilepsy and healthy volunteers is summarized in Table 14. Half-life and apparent oral clearance vary depending on concomitant AEDs.

Drug Interactions: The apparent clearance of lamotrigine is affected by the coadministration of certain medications [see *Warnings and Precautions (5.9, 5.13), Drug Interactions (7)*].

The net effects of drug interactions with LAMICTAL are summarized in Tables 13 and 15, followed by details of the drug interaction studies below.

Table 15. Summary of Drug Interactions With LAMICTAL

Drug	Drug Plasma Concentration With Adjunctive LAMICTAL ^a	Lamotrigine Plasma Concentration With Adjunctive Drugs ^b
Oral contraceptives (e.g., ethinylestradiol/levonorgestrel) ^c	↔ ^d	↓
Bupropion	Not assessed	↔
Carbamazepine (CBZ)	↔	↓
CBZ epoxide ^e	?	
Felbamate	Not assessed	↔
Gabapentin	Not assessed	↔
Levetiracetam	↔	↔
Lithium	↔	Not assessed
Olanzapine	↔	↔ ^f
Oxcarbazepine	↔	↔
10-monohydroxy oxcarbazepine metabolite ^g	↔	
Phenobarbital/primidone	↔	↓

Phenytoin (PHT)	↔	↓
Pregabalin	↔	↔
Rifampin	Not assessed	↓
Topiramate	↔ ^h	↔
Valproate	↓	↑
Valproate + PHT and/or CBZ	Not assessed	↔
Zonisamide	Not assessed	↔

- ^a From adjunctive clinical trials and volunteer studies.
- ^b Net effects were estimated by comparing the mean clearance values obtained in adjunctive clinical trials and volunteer studies.
- ^c The effect of other hormonal contraceptive preparations or hormone replacement therapy on the pharmacokinetics of lamotrigine has not been systematically evaluated in clinical trials, although the effect may be similar to that seen with the ethinylestradiol/levonorgestrel combinations.
- ^d Modest decrease in levonorgestrel.
- ^e Not administered, but an active metabolite of carbamazepine.
- ^f Slight decrease, not expected to be clinically relevant.
- ^g Not administered, but an active metabolite of oxcarbazepine.
- ^h Slight increase, not expected to be clinically relevant.

↔ = No significant effect.

? = Conflicting data.

Estrogen-Containing Oral Contraceptives: In 16 female volunteers, an oral contraceptive preparation containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel increased the apparent clearance of lamotrigine (300 mg/day) by approximately 2-fold with mean decreases in AUC of 52% and in C_{max} of 39%. In this study, trough serum lamotrigine concentrations gradually increased and were approximately 2-fold higher on average at the end of the week of the inactive hormone preparation compared with trough lamotrigine concentrations at the end of the active hormone cycle.

Gradual transient increases in lamotrigine plasma levels (approximate 2-fold increase) occurred during the week of inactive hormone preparation (“pill-free” week) for women not also taking a drug that increased the clearance of lamotrigine (carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin that induce lamotrigine glucuronidation [see *Drug Interactions (7)*]). The increase in lamotrigine plasma levels will be greater if the dose of LAMICTAL is increased in the few days before or during the “pill-free” week. Increases in lamotrigine plasma levels could result in dose-dependent adverse reactions.

In the same study, coadministration of LAMICTAL (300 mg/day) in 16 female volunteers did not affect the pharmacokinetics of the ethinylestradiol component of the oral contraceptive preparation. There were mean decreases in the AUC and C_{max} of the levonorgestrel

component of 19% and 12%, respectively. Measurement of serum progesterone indicated that there was no hormonal evidence of ovulation in any of the 16 volunteers, although measurement of serum FSH, LH, and estradiol indicated that there was some loss of suppression of the hypothalamic-pituitary-ovarian axis.

The effects of doses of LAMICTAL other than 300 mg/day have not been systematically evaluated in controlled clinical trials.

The clinical significance of the observed hormonal changes on ovulatory activity is unknown. However, the possibility of decreased contraceptive efficacy in some patients cannot be excluded. Therefore, patients should be instructed to promptly report changes in their menstrual pattern (e.g., break-through bleeding).

Dosage adjustments may be necessary for women receiving estrogen-containing oral contraceptive preparations [*see Dosage and Administration (2.1)*].

Other Hormonal Contraceptives or Hormone Replacement Therapy: The effect of other hormonal contraceptive preparations or hormone replacement therapy on the pharmacokinetics of lamotrigine has not been systematically evaluated. It has been reported that ethinylestradiol, not progestogens, increased the clearance of lamotrigine up to 2-fold, and the progestin-only pills had no effect on lamotrigine plasma levels. Therefore, adjustments to the dosage of LAMICTAL in the presence of progestogens alone will likely not be needed.

Bupropion: The pharmacokinetics of a 100-mg single dose of LAMICTAL in healthy volunteers (n = 12) were not changed by coadministration of bupropion sustained-release formulation (150 mg twice daily) starting 11 days before LAMICTAL.

Carbamazepine: LAMICTAL has no appreciable effect on steady-state carbamazepine plasma concentration. Limited clinical data suggest there is a higher incidence of dizziness, diplopia, ataxia, and blurred vision in patients receiving carbamazepine with lamotrigine than in patients receiving other AEDs with lamotrigine [*see Adverse Reactions (6.1)*]. The mechanism of this interaction is unclear. The effect of lamotrigine on plasma concentrations of carbamazepine-epoxide is unclear. In a small subset of patients (n = 7) studied in a placebo-controlled trial, lamotrigine had no effect on carbamazepine-epoxide plasma concentrations, but in a small, uncontrolled study (n = 9), carbamazepine-epoxide levels increased.

The addition of carbamazepine decreases lamotrigine steady-state concentrations by approximately 40%.

Felbamate: In a study of 21 healthy volunteers, coadministration of felbamate (1,200 mg twice daily) with lamotrigine (100 mg twice daily for 10 days) appeared to have no clinically relevant effects on the pharmacokinetics of lamotrigine.

Folate Inhibitors: Lamotrigine is a weak inhibitor of dihydrofolate reductase. Prescribers should be aware of this action when prescribing other medications that inhibit folate metabolism.

Gabapentin: Based on a retrospective analysis of plasma levels in 34 patients who received lamotrigine both with and without gabapentin, gabapentin does not appear to change the apparent clearance of lamotrigine.

Levetiracetam: Potential drug interactions between levetiracetam and lamotrigine were assessed by evaluating serum concentrations of both agents during placebo-controlled clinical trials. These data indicate that lamotrigine does not influence the pharmacokinetics of levetiracetam and that levetiracetam does not influence the pharmacokinetics of lamotrigine.

Lithium: The pharmacokinetics of lithium were not altered in healthy subjects (n = 20) by coadministration of lamotrigine (100 mg/day) for 6 days.

Olanzapine: The AUC and C_{max} of olanzapine were similar following the addition of olanzapine (15 mg once daily) to lamotrigine (200 mg once daily) in healthy male volunteers (n = 16) compared with the AUC and C_{max} in healthy male volunteers receiving olanzapine alone (n = 16).

In the same study, the AUC and C_{max} of lamotrigine were reduced on average by 24% and 20%, respectively, following the addition of olanzapine to lamotrigine in healthy male volunteers compared with those receiving lamotrigine alone. This reduction in lamotrigine plasma concentrations is not expected to be clinically relevant.

Oxcarbazepine: The AUC and C_{max} of oxcarbazepine and its active 10-monohydroxy oxcarbazepine metabolite were not significantly different following the addition of oxcarbazepine (600 mg twice daily) to lamotrigine (200 mg once daily) in healthy male volunteers (n = 13) compared with healthy male volunteers receiving oxcarbazepine alone (n = 13).

In the same study, the AUC and C_{max} of lamotrigine were similar following the addition of oxcarbazepine (600 mg twice daily) to LAMICTAL in healthy male volunteers compared with those receiving LAMICTAL alone. Limited clinical data suggest a higher incidence of headache, dizziness, nausea, and somnolence with coadministration of lamotrigine and oxcarbazepine compared with lamotrigine alone or oxcarbazepine alone.

Phenobarbital, Primidone: The addition of phenobarbital or primidone decreases lamotrigine steady-state concentrations by approximately 40%.

Phenytoin: Lamotrigine has no appreciable effect on steady-state phenytoin plasma concentrations in patients with epilepsy. The addition of phenytoin decreases lamotrigine steady-state concentrations by approximately 40%.

Pregabalin: Steady-state trough plasma concentrations of lamotrigine were not affected by concomitant pregabalin (200 mg 3 times daily) administration. There are no pharmacokinetic interactions between lamotrigine and pregabalin.

Rifampin: In 10 male volunteers, rifampin (600 mg/day for 5 days) significantly increased the apparent clearance of a single 25-mg dose of lamotrigine by approximately 2-fold (AUC decreased by approximately 40%).

Topiramate: Topiramate resulted in no change in plasma concentrations of lamotrigine. Administration of lamotrigine resulted in a 15% increase in topiramate concentrations.

Valproate: When lamotrigine was administered to healthy volunteers (n = 18) receiving valproate, the trough steady-state valproate plasma concentrations decreased by an average of

25% over a 3-week period, and then stabilized. However, adding lamotrigine to the existing therapy did not cause a change in valproate plasma concentrations in either adult or pediatric patients in controlled clinical trials.

The addition of valproate increased lamotrigine steady-state concentrations in normal volunteers by slightly more than 2-fold. In one study, maximal inhibition of lamotrigine clearance was reached at valproate doses between 250 and 500 mg/day and did not increase as the valproate dose was further increased.

Zonisamide: In a study of 18 patients with epilepsy, coadministration of zonisamide (200 to 400 mg/day) with lamotrigine (150 to 500 mg/day for 35 days) had no significant effect on the pharmacokinetics of lamotrigine.

Known Inducers or Inhibitors of Glucuronidation: Drugs other than those listed above have not been systematically evaluated in combination with lamotrigine. Since lamotrigine is metabolized predominately by glucuronic acid conjugation, drugs that are known to induce or inhibit glucuronidation may affect the apparent clearance of lamotrigine and doses of lamotrigine may require adjustment based on clinical response.

Other: Results of in vitro experiments suggest that clearance of lamotrigine is unlikely to be reduced by concomitant administration of amitriptyline, clonazepam, clozapine, fluoxetine, haloperidol, lorazepam, phenelzine, risperidone, sertraline, or trazodone.

Results of in vitro experiments suggest that lamotrigine does not reduce the clearance of drugs eliminated predominantly by CYP2D6.

Special Populations: Patients With Renal Impairment: Twelve volunteers with chronic renal failure (mean creatinine clearance: 13 mL/min; range: 6 to 23) and another 6 individuals undergoing hemodialysis were each given a single 100-mg dose of lamotrigine. The mean plasma half-lives determined in the study were 42.9 hours (chronic renal failure), 13.0 hours (during hemodialysis), and 57.4 hours (between hemodialysis) compared with 26.2 hours in healthy volunteers. On average, approximately 20% (range: 5.6 to 35.1) of the amount of lamotrigine present in the body was eliminated by hemodialysis during a 4-hour session [*see Dosage and Administration (2.1)*].

Hepatic Disease: The pharmacokinetics of lamotrigine following a single 100-mg dose of lamotrigine were evaluated in 24 subjects with mild, moderate, and severe hepatic impairment (Child-Pugh Classification system) and compared with 12 subjects without hepatic impairment. The patients with severe hepatic impairment were without ascites (n = 2) or with ascites (n = 5). The mean apparent clearances of lamotrigine in patients with mild (n = 12), moderate (n = 5), severe without ascites (n = 2), and severe with ascites (n = 5) liver impairment were 0.30 ± 0.09 , 0.24 ± 0.1 , 0.21 ± 0.04 , and 0.15 ± 0.09 mL/min/kg, respectively, as compared with 0.37 ± 0.1 mL/min/kg in the healthy controls. Mean half-lives of lamotrigine in patients with mild, moderate, severe without ascites, and severe with ascites hepatic impairment were 46 ± 20 , 72 ± 44 , 67 ± 11 , and 100 ± 48 hours, respectively, as compared with 33 ± 7 hours in healthy controls [*see Dosage and Administration (2.1)*].

Age: Pediatric Patients: The pharmacokinetics of lamotrigine following a single 2-mg/kg dose were evaluated in 2 studies of pediatric patients (n = 29 for patients 10 months to 5.9 years of age and n = 26 for patients 5 to 11 years of age). Forty-three patients received concomitant therapy with other AEDs and 12 patients received lamotrigine as monotherapy. Lamotrigine pharmacokinetic parameters for pediatric patients are summarized in Table 16.

Population pharmacokinetic analyses involving patients 2 to 18 years of age demonstrated that lamotrigine clearance was influenced predominantly by total body weight and concurrent AED therapy. The oral clearance of lamotrigine was higher, on a body weight basis, in pediatric patients than in adults. Weight-normalized lamotrigine clearance was higher in those subjects weighing less than 30 kg, compared with those weighing greater than 30 kg. Accordingly, patients weighing less than 30 kg may need an increase of as much as 50% in maintenance doses, based on clinical response, as compared with subjects weighing more than 30 kg being administered the same AEDs [see *Dosage and Administration (2.2)*]. These analyses also revealed that, after accounting for body weight, lamotrigine clearance was not significantly influenced by age. Thus, the same weight-adjusted doses should be administered to children irrespective of differences in age. Concomitant AEDs which influence lamotrigine clearance in adults were found to have similar effects in children.

Table 16. Mean Pharmacokinetic Parameters in Pediatric Patients With Epilepsy

Pediatric Study Population	Number of Subjects	T _{max} (hr)	t _{1/2} (hr)	Cl/F (mL/min/kg)
Ages 10 months-5.3 years				
Patients taking carbamazepine, phenytoin, phenobarbital, or primidone ^a	10	3.0 (1.0-5.9)	7.7 (5.7-11.4)	3.62 (2.44-5.28)
Patients taking AEDs with no known effect on the apparent clearance of lamotrigine	7	5.2 (2.9-6.1)	19.0 (12.9-27.1)	1.2 (0.75-2.42)
Patients taking valproate only	8	2.9 (1.0-6.0)	44.9 (29.5-52.5)	0.47 (0.23-0.77)
Ages 5-11 years				
Patients taking carbamazepine, phenytoin, phenobarbital, or primidone ^a	7	1.6 (1.0-3.0)	7.0 (3.8-9.8)	2.54 (1.35-5.58)
Patients taking carbamazepine, phenytoin, phenobarbital, or primidone ^a plus valproate	8	3.3 (1.0-6.4)	19.1 (7.0-31.2)	0.89 (0.39-1.93)
Patients taking valproate only ^b	3	4.5 (3.0-6.0)	65.8 (50.7-73.7)	0.24 (0.21-0.26)

Ages 13-18 years				
Patients taking carbamazepine, phenytoin, phenobarbital, or primidone ^a	11	c	c	1.3
Patients taking carbamazepine, phenytoin, phenobarbital, or primidone ^a plus valproate	8	c	c	0.5
Patients taking valproate only	4	c	c	0.3

^a Carbamazepine, phenobarbital, phenytoin, and primidone have been shown to increase the apparent clearance of lamotrigine. Estrogen-containing oral contraceptives and rifampin have also been shown to increase the apparent clearance of lamotrigine [see *Drug Interactions (7)*].

^b Two subjects were included in the calculation for mean T_{max}

^c Parameter not estimated.

Elderly: The pharmacokinetics of lamotrigine following a single 150-mg dose of LAMICTAL were evaluated in 12 elderly volunteers between the ages of 65 and 76 years (mean creatinine clearance = 61 mL/min, range: 33 to 108 mL/min). The mean half-life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).

Gender: The clearance of lamotrigine is not affected by gender. However, during dose escalation of LAMICTAL in one clinical trial in patients with epilepsy on a stable dose of valproate (n = 77), mean trough lamotrigine concentrations, unadjusted for weight, were 24% to 45% higher (0.3 to 1.7 mcg/mL) in females than in males.

Race: The apparent oral clearance of lamotrigine was 25% lower in non-Caucasians than Caucasians.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No evidence of carcinogenicity was seen in 1 mouse study or 2 rat studies following oral administration of lamotrigine for up to 2 years at maximum tolerated doses (30 mg/kg/day for mice and 10 to 15 mg/kg/day for rats, doses that are equivalent to 90 mg/m² and 60 to 90 mg/m², respectively). Steady-state plasma concentrations ranged from 1 to 4 mcg/mL in the mouse study and 1 to 10 mcg/mL in the rat study. Plasma concentrations associated with the recommended human doses of 300 to 500 mg/day are generally in the range of 2 to 5 mcg/mL, but concentrations as high as 19 mcg/mL have been recorded.

Lamotrigine was not mutagenic in the presence or absence of metabolic activation when tested in 2 gene mutation assays (the Ames test and the in vitro mammalian mouse lymphoma assay). In 2 cytogenetic assays (the in vitro human lymphocyte assay and the in vivo rat bone

marrow assay), lamotrigine did not increase the incidence of structural or numerical chromosomal abnormalities.

No evidence of impairment of fertility was detected in rats given oral doses of lamotrigine up to 2.4 times the highest usual human maintenance dose of 8.33 mg/kg/day or 0.4 times the human dose on a mg/m² basis. The effect of lamotrigine on human fertility is unknown.

14 CLINICAL STUDIES

14.1 Epilepsy

Monotherapy With LAMICTAL in Adults With Partial Seizures Already Receiving Treatment With Carbamazepine, Phenytoin, Phenobarbital, or Primidone as the Single AED: The effectiveness of monotherapy with LAMICTAL was established in a multicenter, double-blind clinical trial enrolling 156 adult outpatients with partial seizures. The patients experienced at least 4 simple partial, complex partial, and/or secondarily generalized seizures during each of 2 consecutive 4-week periods while receiving carbamazepine or phenytoin monotherapy during baseline. LAMICTAL (target dose of 500 mg/day) or valproate (1,000 mg/day) was added to either carbamazepine or phenytoin monotherapy over a 4-week period. Patients were then converted to monotherapy with LAMICTAL or valproate during the next 4 weeks, then continued on monotherapy for an additional 12-week period.

Study endpoints were completion of all weeks of study treatment or meeting an escape criterion. Criteria for escape relative to baseline were: (1) doubling of average monthly seizure count, (2) doubling of highest consecutive 2-day seizure frequency, (3) emergence of a new seizure type (defined as a seizure that did not occur during the 8-week baseline) that is more severe than seizure types that occur during study treatment, or (4) clinically significant prolongation of generalized tonic-clonic (GTC) seizures. The primary efficacy variable was the proportion of patients in each treatment group who met escape criteria.

The percentages of patients who met escape criteria were 42% (32/76) in the group receiving LAMICTAL and 69% (55/80) in the valproate group. The difference in the percentage of patients meeting escape criteria was statistically significant ($p = 0.0012$) in favor of LAMICTAL. No differences in efficacy based on age, sex, or race were detected.

Patients in the control group were intentionally treated with a relatively low dose of valproate; as such, the sole objective of this study was to demonstrate the effectiveness and safety of monotherapy with LAMICTAL, and cannot be interpreted to imply the superiority of LAMICTAL to an adequate dose of valproate.

Adjunctive Therapy With LAMICTAL in Adults With Partial Seizures: The effectiveness of LAMICTAL as adjunctive therapy (added to other AEDs) was established in 3 multicenter, placebo-controlled, double-blind clinical trials in 355 adults with refractory partial seizures. The patients had a history of at least 4 partial seizures per month in spite of receiving one or more AEDs at therapeutic concentrations and, in 2 of the studies, were observed on their established AED regimen during baselines that varied between 8 to 12 weeks. In the third, patients were not observed in a prospective baseline. In patients continuing to have at least 4

seizures per month during the baseline, LAMICTAL or placebo was then added to the existing therapy. In all 3 studies, change from baseline in seizure frequency was the primary measure of effectiveness. The results given below are for all partial seizures in the intent-to-treat population (all patients who received at least one dose of treatment) in each study, unless otherwise indicated. The median seizure frequency at baseline was 3 per week while the mean at baseline was 6.6 per week for all patients enrolled in efficacy studies.

One study (n = 216) was a double-blind, placebo-controlled, parallel trial consisting of a 24-week treatment period. Patients could not be on more than 2 other anticonvulsants and valproate was not allowed. Patients were randomized to receive placebo, a target dose of 300 mg/day of LAMICTAL, or a target dose of 500 mg/day of LAMICTAL. The median reductions in the frequency of all partial seizures relative to baseline were 8% in patients receiving placebo, 20% in patients receiving 300 mg/day of LAMICTAL, and 36% in patients receiving 500 mg/day of LAMICTAL. The seizure frequency reduction was statistically significant in the 500-mg/day group compared with the placebo group, but not in the 300-mg/day group.

A second study (n = 98) was a double-blind, placebo-controlled, randomized, crossover trial consisting of two 14-week treatment periods (the last 2 weeks of which consisted of dose tapering) separated by a 4-week washout period. Patients could not be on more than 2 other anticonvulsants and valproate was not allowed. The target dose of LAMICTAL was 400 mg/day. When the first 12 weeks of the treatment periods were analyzed, the median change in seizure frequency was a 25% reduction on LAMICTAL compared with placebo ($p < 0.001$).

The third study (n = 41) was a double-blind, placebo-controlled, crossover trial consisting of two 12-week treatment periods separated by a 4-week washout period. Patients could not be on more than 2 other anticonvulsants. Thirteen patients were on concomitant valproate; these patients received 150 mg/day of LAMICTAL. The 28 other patients had a target dose of 300 mg/day of LAMICTAL. The median change in seizure frequency was a 26% reduction on LAMICTAL compared with placebo ($p < 0.01$).

No differences in efficacy based on age, sex, or race, as measured by change in seizure frequency, were detected.

Adjunctive Therapy With LAMICTAL in Pediatric Patients With Partial Seizures:
The effectiveness of LAMICTAL as adjunctive therapy in pediatric patients with partial seizures was established in a multicenter, double-blind, placebo-controlled trial in 199 patients 2 to 16 years of age (n = 98 on LAMICTAL, n = 101 on placebo). Following an 8-week baseline phase, patients were randomized to 18 weeks of treatment with LAMICTAL or placebo added to their current AED regimen of up to 2 drugs. Patients were dosed based on body weight and valproate use. Target doses were designed to approximate 5 mg/kg/day for patients taking valproate (maximum dose: 250 mg/day) and 15 mg/kg/day for the patients not taking valproate (maximum dose: 750 mg/day). The primary efficacy endpoint was percentage change from baseline in all partial seizures. For the intent-to-treat population, the median reduction of all partial seizures

was 36% in patients treated with LAMICTAL and 7% on placebo, a difference that was statistically significant ($p < 0.01$).

Adjunctive Therapy With LAMICTAL in Pediatric and Adult Patients With Lennox-Gastaut Syndrome: The effectiveness of LAMICTAL as adjunctive therapy in patients with Lennox-Gastaut syndrome was established in a multicenter, double-blind, placebo-controlled trial in 169 patients 3 to 25 years of age ($n = 79$ on LAMICTAL, $n = 90$ on placebo). Following a 4-week single-blind, placebo phase, patients were randomized to 16 weeks of treatment with LAMICTAL or placebo added to their current AED regimen of up to 3 drugs. Patients were dosed on a fixed-dose regimen based on body weight and valproate use. Target doses were designed to approximate 5 mg/kg/day for patients taking valproate (maximum dose: 200 mg/day) and 15 mg/kg/day for patients not taking valproate (maximum dose: 400 mg/day). The primary efficacy endpoint was percentage change from baseline in major motor seizures (atonic, tonic, major myoclonic, and tonic-clonic seizures). For the intent-to-treat population, the median reduction of major motor seizures was 32% in patients treated with LAMICTAL and 9% on placebo, a difference that was statistically significant ($p < 0.05$). Drop attacks were significantly reduced by LAMICTAL (34%) compared with placebo (9%), as were tonic-clonic seizures (36% reduction versus 10% increase for LAMICTAL and placebo, respectively).

Adjunctive Therapy With LAMICTAL in Pediatric and Adult Patients With Primary Generalized Tonic-Clonic Seizures: The effectiveness of LAMICTAL as adjunctive therapy in patients with primary generalized tonic-clonic seizures was established in a multicenter, double-blind, placebo-controlled trial in 117 pediatric and adult patients ≥ 2 years ($n = 58$ on LAMICTAL, $n = 59$ on placebo). Patients with at least 3 primary generalized tonic-clonic seizures during an 8-week baseline phase were randomized to 19 to 24 weeks of treatment with LAMICTAL or placebo added to their current AED regimen of up to 2 drugs. Patients were dosed on a fixed-dose regimen, with target doses ranging from 3 mg/kg/day to 12 mg/kg/day for pediatric patients and from 200 mg/day to 400 mg/day for adult patients based on concomitant AED.

The primary efficacy endpoint was percentage change from baseline in primary generalized tonic-clonic seizures. For the intent-to-treat population, the median percent reduction of primary generalized tonic-clonic seizures was 66% in patients treated with LAMICTAL and 34% on placebo, a difference that was statistically significant ($p = 0.006$).

14.2 Bipolar Disorder

The effectiveness of LAMICTAL in the maintenance treatment of Bipolar I Disorder was established in 2 multicenter, double-blind, placebo-controlled studies in adult patients who met DSM-IV criteria for Bipolar I Disorder. Study 1 enrolled patients with a current or recent (within 60 days) depressive episode as defined by DSM-IV and Study 2 included patients with a current or recent (within 60 days) episode of mania or hypomania as defined by DSM-IV. Both studies included a cohort of patients (30% of 404 patients in Study 1 and 28% of 171 patients in Study 2) with rapid cycling Bipolar Disorder (4 to 6 episodes per year).

In both studies, patients were titrated to a target dose of 200 mg of LAMICTAL, as add-on therapy or as monotherapy, with gradual withdrawal of any psychotropic medications during an 8- to 16-week open-label period. Overall 81% of 1,305 patients participating in the open-label period were receiving 1 or more other psychotropic medications, including benzodiazepines, selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics (including olanzapine), valproate, or lithium, during titration of LAMICTAL. Patients with a CGI-severity score of 3 or less maintained for at least 4 continuous weeks, including at least the final week on monotherapy with LAMICTAL, were randomized to a placebo-controlled, double-blind treatment period for up to 18 months. The primary endpoint was TIME (time to intervention for a mood episode or one that was emerging, time to discontinuation for either an adverse event that was judged to be related to Bipolar Disorder, or for lack of efficacy). The mood episode could be depression, mania, hypomania, or a mixed episode.

In Study 1, patients received double-blind monotherapy with LAMICTAL 50 mg/day (n = 50), LAMICTAL 200 mg/day (n = 124), LAMICTAL 400 mg/day (n = 47), or placebo (n = 121). LAMICTAL (200- and 400-mg/day treatment groups combined) was superior to placebo in delaying the time to occurrence of a mood episode. Separate analyses of the 200- and 400-mg/day dose groups revealed no added benefit from the higher dose.

In Study 2, patients received double-blind monotherapy with LAMICTAL (100 to 400 mg/day, n = 59), or placebo (n = 70). LAMICTAL was superior to placebo in delaying time to occurrence of a mood episode. The mean dose of LAMICTAL was about 211 mg/day.

Although these studies were not designed to separately evaluate time to the occurrence of depression or mania, a combined analysis for the studies revealed a statistically significant benefit for LAMICTAL over placebo in delaying the time to occurrence of both depression and mania, although the finding was more robust for depression.

16 HOW SUPPLIED/STORAGE AND HANDLING

LAMICTAL (lamotrigine) Tablets

25 mg, white, scored, shield-shaped tablets debossed with “LAMICTAL” and “25”, bottles of 100 (NDC 0173-0633-02).

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature] in a dry place.

100 mg, peach, scored, shield-shaped tablets debossed with “LAMICTAL” and “100”, bottles of 100 (NDC 0173-0642-55).

150 mg, cream, scored, shield-shaped tablets debossed with “LAMICTAL” and “150”, bottles of 60 (NDC 0173-0643-60).

200 mg, blue, scored, shield-shaped tablets debossed with “LAMICTAL” and “200”, bottles of 60 (NDC 0173-0644-60).

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature] in a dry place and protect from light.

LAMICTAL (lamotrigine) Starter Kit for Patients Taking Valproate (Blue Kit)

25 mg, white, scored, shield-shaped tablets debossed with “LAMICTAL” and “25”, blisterpack of 35 tablets (NDC 0173-0633-10).

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature] in a dry place.

LAMICTAL (lamotrigine) Starter Kit for Patients Taking Carbamazepine, Phenytoin, Phenobarbital, or Primidone and Not Taking Valproate (Green Kit)

25 mg, white, scored, shield-shaped tablets debossed with “LAMICTAL” and “25” and 100 mg, peach, scored, shield-shaped tablets debossed with “LAMICTAL” and “100”, blisterpack of 98 tablets (84/25-mg tablets and 14/100-mg tablets) (NDC 0173-0817-28).

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature] in a dry place and protect from light.

LAMICTAL (lamotrigine) Starter Kit for Patients Not Taking Carbamazepine, Phenytoin, Phenobarbital, Primidone, or Valproate (Orange Kit)

25 mg, white, scored, shield-shaped tablets debossed with “LAMICTAL” and “25” and 100 mg, peach, scored, shield-shaped tablets debossed with “LAMICTAL” and “100”, blisterpack of 49 tablets (42/25-mg tablets and 7/100-mg tablets) (NDC 0173-0594-02).

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature] in a dry place and protect from light.

LAMICTAL (lamotrigine) Chewable Dispersible Tablets

2 mg, white to off-white, round tablets debossed with “LTG” over “2”, bottles of 30 (NDC 0173-0699-00). ORDER DIRECTLY FROM GlaxoSmithKline 1-800-334-4153.

5 mg, white to off-white, caplet-shaped tablets debossed with “GX CL2”, bottles of 100 (NDC 0173-0526-00).

25 mg, white, super elliptical-shaped tablets debossed with “GX CL5”, bottles of 100 (NDC 0173-0527-00).

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature] in a dry place.

LAMICTAL ODT (lamotrigine) Orally Disintegrating Tablets

25 mg, white to off-white, round, flat-faced, radius edge, tablets debossed with “LMT” on one side and “25” on the other, Maintenance Packs of 30 (NDC 0173-0772-02).

50 mg, white to off-white, round, flat-faced, radius edge, tablets debossed with “LMT” on one side and “50” on the other, Maintenance Packs of 30 (NDC 0173-0774-02).

100 mg, white to off-white, round, flat-faced, radius edge, tablets debossed with “LAMICTAL” on one side and “100” on the other, Maintenance Packs of 30 (NDC 0173-0776-02).

200 mg, white to off-white, round, flat-faced, radius edge, tablets debossed with “LAMICTAL” on one side and “200” on the other, Maintenance Packs of 30 (NDC 0173-0777-02).

Store between 20°C to 25°C (68°F to 77°F); with excursions permitted between 15°C and 30°C (59°F and 86°F).

LAMICTAL ODT (lamotrigine) Patient Titration Kit for Patients Taking Valproate (Blue ODT Kit)

25 mg, white to off-white, round, flat-faced, radius edge, tablets debossed with “LMT” on one side and “25” on the other, and 50 mg, white to off-white, round, flat-faced, radius edge, tablets debossed with “LMT” on one side and “50” on the other, blisterpack of 28 tablets (21/25-mg tablets and 7/50-mg tablets) (NDC 0173-0779-00).

LAMICTAL ODT (lamotrigine) Patient Titration Kit for Patients Taking Carbamazepine, Phenytoin, Phenobarbital, or Primidone and Not Taking Valproate (Green ODT Kit)

50 mg, white to off-white, round, flat-faced, radius edge, tablets debossed with “LMT” on one side and “50” on the other, and 100 mg, white to off-white, round, flat-faced, radius edge, tablets debossed with “LAMICTAL” on one side and “100” on the other, blisterpack of 56 tablets (42/50-mg tablets and 14/100-mg tablets) (NDC 0173-0780-00).

LAMICTAL ODT (lamotrigine) Patient Titration Kit for Patients Not Taking Carbamazepine, Phenytoin, Phenobarbital, Primidone, or Valproate (Orange ODT Kit)

25 mg, white to off-white, round, flat-faced, radius edge, tablets debossed with “LMT” on one side and “25” on the other, 50 mg, white to off-white, round, flat-faced, radius edge, tablets debossed with “LMT” on one side and “50” on the other, and 100 mg, white to off-white, round, flat-faced, radius edge, tablets debossed with “LAMICTAL” on one side and “100” on the other, blisterpack of 35 (14/25-mg tablets, 14/50-mg tablets, and 7/100-mg tablets) (NDC 0173-0778-00).

Store between 20°C to 25°C (68°F to 77°F); with excursions permitted between 15°C and 30°C (59°F and 86°F).

Blisterpacks: If the product is dispensed in a blisterpack, the patient should be advised to examine the blisterpack before use and not use if blisters are torn, broken, or missing.

17 PATIENT COUNSELING INFORMATION

See Medication Guide that accompanies the product.

17.1 Rash

Prior to initiation of treatment with LAMICTAL, the patient should be instructed that a rash or other signs or symptoms of hypersensitivity (e.g., fever, lymphadenopathy) may herald a serious medical event and that the patient should report any such occurrence to a physician immediately.

17.2 Suicidal Thinking and Behavior

Patients, their caregivers, and families should be counseled that AEDs, including LAMICTAL, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

17.3 Worsening of Seizures

Patients should be advised to notify their physician if worsening of seizure control occurs.

17.4 CNS Adverse Effects

Patients should be advised that LAMICTAL may cause dizziness, somnolence, and other symptoms and signs of central nervous system (CNS) depression. Accordingly, they should be advised neither to drive a car nor to operate other complex machinery until they have gained sufficient experience on LAMICTAL to gauge whether or not it adversely affects their mental and/or motor performance.

17.5 Blood Dyscrasias and/or Acute Multiorgan Failure

Patients should be advised of the possibility of blood dyscrasias and/or acute multiorgan failure and to contact their physician immediately if they experience any signs or symptoms of these conditions [*see Warnings and Precautions (5.3, 5.4)*].

17.6 Pregnancy

Patients should be advised to notify their physicians if they become pregnant or intend to become pregnant during therapy. Patients should be advised to notify their physicians if they intend to breastfeed or are breastfeeding an infant.

Patients should also be encouraged to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll-free number 1-888-233-2334 [*see Use in Specific Populations (8.1)*].

17.7 Oral Contraceptive Use

Women should be advised to notify their physician if they plan to start or stop use of oral contraceptives or other female hormonal preparations. Starting estrogen-containing oral contraceptives may significantly decrease lamotrigine plasma levels and stopping estrogen-containing oral contraceptives (including the “pill-free” week) may significantly increase lamotrigine plasma levels [*see Warnings and Precautions (5.9), Clinical Pharmacology (12.3)*]. Women should also be advised to promptly notify their physician if they experience adverse reactions or changes in menstrual pattern (e.g., break-through bleeding) while receiving LAMICTAL in combination with these medications.

17.8 Discontinuing LAMICTAL

Patients should be advised to notify their physician if they stop taking LAMICTAL for any reason and not to resume LAMICTAL without consulting their physician.

17.9 Aseptic Meningitis

Patients should be advised that LAMICTAL may cause aseptic meningitis. Patients should be advised to notify their physician immediately if they develop signs and symptoms of meningitis such as headache, fever, nausea, vomiting, stiff neck, rash, abnormal sensitivity to light, myalgia, chills, confusion, or drowsiness while taking LAMICTAL.

17.10 Potential Medication Errors

Medication errors involving LAMICTAL have occurred. In particular the names LAMICTAL or lamotrigine can be confused with the names of other commonly used medications. Medication errors may also occur between the different formulations of LAMICTAL. To reduce the potential of medication errors, write and say LAMICTAL clearly. Depictions of the LAMICTAL Tablets, Chewable Dispersible Tablets, and Orally Disintegrating Tablets can be found in the Medication Guide that accompanies the product to highlight the distinctive markings, colors, and shapes that serve to identify the different presentations of the drug and thus may help reduce the risk of medication errors. **To avoid a medication error of using the wrong drug or formulation, patients should be strongly advised to visually inspect their tablets to verify that they are LAMICTAL, as well as the correct formulation of LAMICTAL, each time they fill their prescription** [see *Dosage Forms and Strengths (3.1, 3.2, 3.3), How Supplied/Storage and Handling (16)*].



GlaxoSmithKline
Research Triangle Park, NC 27709

LAMICTAL Tablets and Chewable Dispersible Tablets are manufactured by
DSM Pharmaceuticals, Inc., Greenville, NC 27834 or
GlaxoSmithKline, Research Triangle Park, NC 27709

LAMICTAL Orally Disintegrating Tablets are manufactured by
Eurand, Inc., Vandalia, OH 45377

LAMICTAL is a registered trademark of GlaxoSmithKline.

Microcaps and AdvaTab are registered trademarks of Eurand, Inc.

©Year, GlaxoSmithKline. All rights reserved.

Month Year
LMT:PI

MEDICATION GUIDE

LAMICTAL[®] (la-MIK-tal) (lamotrigine)

Tablets and Chewable Dispersible Tablets

LAMICTAL[®] ODT[™] (lamotrigine) Orally Disintegrating Tablets

Read this Medication Guide before you start taking LAMICTAL and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment. If you have questions about LAMICTAL, ask your healthcare provider or pharmacist.

What is the most important information I should know about LAMICTAL?

1. LAMICTAL may cause a serious skin rash that may cause you to be hospitalized or even cause death.

There is no way to tell if a mild rash will become more serious. A serious skin rash can happen at any time during your treatment with LAMICTAL, but is more likely to happen within the first 2 to 8 weeks of treatment. Children between 2 to 16 years of age have a higher chance of getting this serious skin rash while taking LAMICTAL.

The risk of getting a serious skin rash is higher if you:

- take LAMICTAL while taking valproate [DEPAKENE[®] (valproic acid) or DEPAKOTE[®] (divalproex sodium)]
- take a higher starting dose of LAMICTAL than yo^ur healthcare provider prescri^bed
- increase your dose of LAMICTAL faster than prescribed.

Call your healthcare provider right away if you have any of the following:

- a skin rash
- blistering or peeling of your skin
- hives
- painful sores in your mouth or around your eyes

These symptoms may be the first signs of a serious skin reaction. A healthcare provider should examine you to decide if you should continue taking LAMICTAL.

2. Other serious reactions, including serious blood problems or liver problems.

LAMICTAL can also cause other types of allergic reactions or serious problems that may affect organs and other parts of your body like your liver or blood cells. You may or may not

have a rash with these types of reactions. Call your healthcare provider right away if you have any of these symptoms:

- fever
- frequent infections
- severe muscle pain
- swelling of your face, eyes, lips, or tongue
- swollen lymph glands
- unusual bruising or bleeding
- weakness, fatigue
- yellowing of your skin or the white part of your eyes

3. Like other antiepileptic drugs, LAMICTAL may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.

Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:

- thoughts about suicide or dying
- attempt to commit suicide
- new or worse depression
- new or worse anxiety
- feeling agitated or restless
- panic attacks
- trouble sleeping (insomnia)
- new or worse irritability
- acting aggressive, being angry, or violent
- acting on dangerous impulses
- an extreme increase in activity and talking (mania)
- other unusual changes in behavior or mood

Do not stop LAMICTAL without first talking to a healthcare provider.

- Stopping LAMICTAL suddenly can cause serious problems.
- Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.

How can I watch for early symptoms of suicidal thoughts and actions?

- Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.
- Keep all follow-up visits with your healthcare provider as scheduled.
- Call your healthcare provider between visits as needed, especially if you are worried about symptoms.

4. LAMICTAL may rarely cause aseptic meningitis, a serious inflammation of the protective membrane that covers the brain and spinal cord.

Call your healthcare provider right away if you have any of the following symptoms:

- headache
- fever
- nausea
- vomiting
- stiff neck
- rash
- unusual sensitivity to light
- muscle pains
- chills
- confusion
- drowsiness

Meningitis has many causes other than LAMICTAL, which your doctor would check for if you developed meningitis while taking LAMICTAL.

LAMICTAL can have other serious side effects. For more information ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effect that bothers you. Be sure to read the section below entitled “What are the possible side effects of LAMICTAL?”





5. Patients prescribed LAMICTAL have sometimes been given the wrong medicine because many medicines have names similar to LAMICTAL, so always check that you receive LAMICTAL.

Taking the wrong medication can cause serious health problems. When your healthcare provider gives you a prescription for LAMICTAL:

- Make sure you can read it clearly.
- Talk to your pharmacist to check that you are given the correct medicine.
- Each time you fill your prescription, check the tablets you receive against the pictures of the tablets below.




These pictures show the distinct wording, colors, and shapes of the tablets that help to identify the right strength of LAMICTAL Tablets, Chewable Dispersible Tablets, and Orally Disintegrating Tablets. Immediately call your pharmacist if you receive a LAMICTAL tablet that does not look like one of the tablets shown below, as you may have received the wrong medication.

LAMICTAL (lamotrigine) Tablets





 25 mg, white Imprinted with	 100 mg, peach	 150 mg, cream	 200 mg, blue
--	---	---	--

LAMICTAL 25	Imprinted with LAMICTAL 100	Imprinted with LAMICTAL 150	Imprinted with LAMICTAL 200
--------------------	--	--	--

LAMICTAL (lamotrigine) Chewable Dispersible Tablets

 2 mg, white Imprinted with LTG 2	 5 mg, white Imprinted with GX CL2	 25 mg, white Imprinted with GX CL5
--	---	--

LAMICTAL ODT (lamotrigine) Orally Disintegrating Tablets

 25 mg, white to off-white Imprinted with LMT on one side 25 on the other	 50 mg, white to off-white Imprinted with LMT on one side 50 on the other	 100 mg, white to off-white Imprinted with LAMICTAL on one side 100 on the other	 200 mg, white to off-white Imprinted with LAMICTAL on one side 200 on the other
--	--	---	---

What is LAMICTAL?

LAMICTAL is a prescription medicine used:

1. together with other medicines to treat certain types of seizures (partial seizures, primary generalized tonic-clonic seizures, generalized seizures of Lennox-Gastaut syndrome) in people 2 years or older.
2. alone when changing from other medicines used to treat partial seizures in people 16 years or older.
3. for the long-term treatment of Bipolar I Disorder to lengthen the time between mood episodes in people 18 years or older who have been treated for mood episodes with other medicine.

It is not known if LAMICTAL is safe or effective in children or teenagers under the age of 18 with mood disorders such as bipolar disorder or depression.

It is not known if LAMICTAL is safe or effective when used alone as the first treatment of seizures in adults.

Who should not take LAMICTAL?

You should not take LAMICTAL if you have had an allergic reaction to lamotrigine or to any of the inactive ingredients in LAMICTAL. See the end of this leaflet for a complete list of ingredients in LAMICTAL.

What should I tell my healthcare provider before taking LAMICTAL?

Before taking LAMICTAL, tell your healthcare provider about all of your medical conditions, including if you:

- have had a rash or allergic reaction to another antiseizure medicine.
- have or have had depression, mood problems, or suicidal thoughts or behavior.
- have had aseptic meningitis after taking LAMICTAL or LAMICTAL XR (lamotrigine).
- are taking oral contraceptives (birth control pills) or other female hormonal medicines. Do not start or stop taking birth control pills or other female hormonal medicine until you have talked with your healthcare provider. Tell your healthcare provider if you have any changes in your menstrual pattern such as breakthrough bleeding. Stopping these medicines may cause side effects (such as dizziness, lack of coordination, or double vision). Starting these medicines may lessen how well LAMICTAL works.
- are pregnant or plan to become pregnant. It is not known if LAMICTAL will harm your unborn baby. If you become pregnant while taking LAMICTAL, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling 1-888-233-2334. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy.
- are breastfeeding. LAMICTAL can pass into your breast milk. You and your healthcare provider should decide if you should take LAMICTAL or breastfeed. Breastfeeding while taking LAMICTAL is not recommended.

Tell your healthcare provider about all the medicines you take or if you are planning to take a new medicine, including prescription and non-prescription medicines, vitamins, and herbal supplements. If you use LAMICTAL with certain other medicines, they can affect each other, causing side effects.

How should I take LAMICTAL?

- Take LAMICTAL exactly as prescribed.
- Your healthcare provider may change your dose. Do not change your dose without talking to your healthcare provider.
- Do not stop taking LAMICTAL without talking to your healthcare provider. Stopping LAMICTAL suddenly may cause serious problems. For example, if you have epilepsy and you stop taking LAMICTAL suddenly, you may get seizures that do not stop. Talk with your healthcare provider about how to stop LAMICTAL slowly.
- If you miss a dose of LAMICTAL, take it as soon as you remember. If it is almost time for

your next dose, just skip the missed dose. Take the next dose at your regular time. **Do not take two doses at the same time.**

- You may not feel the full effect of LAMICTAL for several weeks.
- If you have epilepsy, tell your healthcare provider if your seizures get worse or if you have any new types of seizures.
- Swallow LAMICTAL tablets whole.
- If you have trouble swallowing LAMICTAL tablets, tell your healthcare provider because there may be another form of LAMICTAL you can take.
- LAMICTAL ODT should be placed on the tongue and moved around the mouth. The tablet will rapidly disintegrate, can be swallowed with or without water, and can be taken with or without food.
- LAMICTAL Chewable Dispersible tablets may be swallowed whole, chewed, or mixed in water or diluted fruit juice. If the tablets are chewed, drink a small amount of water or diluted fruit juice to help in swallowing. To break up LAMICTAL Chewable Dispersible tablets, add the tablets to a small amount of liquid (1 teaspoon, or enough to cover the medicine) in a glass or spoon. Wait at least 1 minute or until the tablets are completely broken up, mix the solution together and take the whole amount right away.
- If you receive LAMICTAL in a blisterpack, examine the blisterpack before use. Do not use if blisters are torn, broken, or missing.

What should I avoid while taking LAMICTAL?

Do not drive a car or operate complex, hazardous machinery until you know how LAMICTAL affects you.

What are possible side effects of LAMICTAL?

- See “What is the most important information I should know about LAMICTAL?”

Common side effects of LAMICTAL include:

• dizziness	• tremor
• headache	• rash
• blurred or double vision	• fever
• lack of coordination	• abdominal pain
• sleepiness	• back pain
• nausea, vomiting	• tiredness
• insomnia	• dry mouth

Tell your healthcare provider about any side effect that bothers you or that does not go away.

These are not all the possible side effects of LAMICTAL. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store LAMICTAL?

- Store LAMICTAL at room temperature between 68°F to 77°F (20°C to 25°C).
- **Keep LAMICTAL and all medicines out of the reach of children.**

General information about LAMICTAL

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use LAMICTAL for a condition for which it was not prescribed. Do not give LAMICTAL to other people, even if they have the same symptoms you have. It may harm them.

This Medication Guide summarizes the most important information about LAMICTAL. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about LAMICTAL that is written for healthcare professionals.

For more information, go to www.lamictal.com or call 1-888-825-5249.

What are the ingredients in LAMICTAL?

LAMICTAL Tablets

Active ingredient: lamotrigine.

Inactive ingredients: lactose; magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate, FD&C Yellow No. 6 Lake (100 mg tablet only), ferric oxide, yellow (150 mg tablet only), and FD&C Blue No. 2 Lake (200 mg tablet only).

LAMICTAL Chewable Dispersible Tablets

Active ingredient: lamotrigine.

Inactive ingredients: blackcurrant flavor, calcium carbonate, low-substituted hydroxypropylcellulose, magnesium aluminum silicate, magnesium stearate, povidone, saccharin sodium, and sodium starch glycolate.

LAMICTAL ODT Orally Disintegrating Tablets

Active ingredient: lamotrigine.

Inactive ingredients: artificial cherry flavor, crospovidone, ethylcellulose, magnesium stearate, mannitol, polyethylene, and sucralose.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

LAMICTAL is a registered trademark of GlaxoSmithKline.

DEPAKENE and DEPAKOTE are registered trademarks of Abbott Laboratories.



GlaxoSmithKline
Research Triangle Park, NC 27709

LAMICTAL Tablets and Chewable Dispersible Tablets are manufactured by
DSM Pharmaceuticals, Inc.,
Greenville, NC 27834 or
GlaxoSmithKline
Research Triangle Park, NC 27709

LAMICTAL Orally Disintegrating Tablets are manufactured by
Eurand, Inc., Vandalia, OH 45377

©2011, GlaxoSmithKline. All rights reserved.

Revised November 2011
LMT:xMG

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use LAMICTAL XR safely and effectively. See full prescribing information for LAMICTAL XR.

LAMICTAL XR (lamotrigine) Extended-Release Tablets
Initial U.S. Approval: 1994

WARNING: SERIOUS SKIN RASHES

See full prescribing information for complete boxed warning.

Cases of life-threatening serious rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis, and/or rash-related death have been caused by lamotrigine. The rate of serious rash is greater in pediatric patients than in adults. Additional factors that may increase the risk of rash include (5.1):

- coadministration with valproate
- exceeding recommended initial dose of LAMICTAL XR
- exceeding recommended dose escalation for LAMICTAL XR.

Benign rashes are also caused by lamotrigine; however, it is not possible to predict which rashes will prove to be serious or life threatening. LAMICTAL XR should be discontinued at the first sign of rash, unless the rash is clearly not drug related. (5.1)

RECENT MAJOR CHANGES

Indications and Usage, Monotherapy (1.2) April 2011
Dosage and Administration, Conversion from Adjunctive Therapy to Monotherapy (2.3) April 2011
Warnings and Precautions, Aseptic Meningitis (5.6) October 2010

INDICATIONS AND USAGE

LAMICTAL XR is an antiepileptic drug (AED) indicated for:

- adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial onset seizures with or without secondary generalization in patients ≥ 13 years of age. (1.1)
- conversion to monotherapy in patients ≥ 13 years of age with partial seizures who are receiving treatment with a single AED. (1.2)
- Limitation of use: Safety and effectiveness in patients less than 13 years of age have not been established. (1.3)

DOSAGE AND ADMINISTRATION

- Do not exceed the recommended initial dosage and subsequent dose escalation. (2.1)
- Initiation of adjunctive therapy and conversion to monotherapy requires slow titration dependent on concomitant AEDs; the prescriber must refer to the appropriate algorithm in Dosage and Administration (2.2, 2.3)
 - Adjunct therapy target therapeutic dose range is 200 to 600 mg daily and is dependent on concomitant AEDs. (2.2)
 - Conversion to monotherapy: Target therapeutic dosage range is 250 to 300 mg daily. (2.3)
- Conversion from immediate-release lamotrigine to LAMICTAL XR: The initial dose of LAMICTAL XR should match the total daily dose of the immediate-release lamotrigine. Patients should be closely monitored for seizure control after conversion. (2.4)
- Do not restart LAMICTAL XR in patients who discontinued due to rash unless the potential benefits clearly outweigh the risks. (2.1, 5.1)
- Adjustments to maintenance doses are likely in patients starting or stopping estrogen-containing oral contraceptives. (2.1, 5.8)
- Discontinuation: Taper over a period of at least 2 weeks (approximately 50% dose reduction per week). (2.1, 5.9)

DOSAGE FORMS AND STRENGTHS
Extended-Release Tablets: 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg. (3.1, 16)

CONTRAINDICATIONS
Hypersensitivity to the drug or its ingredients. (Boxed Warning, 4)

WARNINGS AND PRECAUTIONS

- Life-threatening serious rash and/or rash-related death: Discontinue at the first sign of rash, unless the rash is clearly not drug related. (Boxed Warning, 5.1)
- Fatal or life-threatening hypersensitivity reaction: Monitor for early signs of hypersensitivity (e.g., fever, lymphadenopathy), which may present without rash; if signs present, patient should be evaluated immediately. Discontinue LAMICTAL XR if alternate etiology is not found. (5.2)
- Acute multiorgan failure has resulted (some cases fatal). Monitor for hypersensitivity signs with multiple organ dysfunction. (5.3)
- Blood dyscrasias (e.g., neutropenia, thrombocytopenia, pancytopenia): May occur, either with or without an associated hypersensitivity syndrome. Monitor for signs of anemia, unexpected infection, or bleeding. (5.4)
- Suicidal behavior and ideation: Monitor for suicidal thoughts or behaviors. (5.5)
- Aseptic meningitis: Monitor for signs of meningitis. (5.6)
- Medication errors due to product name confusion: Strongly advise patients to visually inspect tablets to verify the received drug is correct. (3.2, 5.7, 16, 17.10)

ADVERSE REACTIONS

- Most common adverse reactions with use as adjunctive therapy (treatment difference between LAMICTAL XR and placebo $\geq 4\%$) are dizziness, tremor/intention tremor, vomiting, and diplopia. (6.1)
- Most common adverse reactions with use as monotherapy were similar to those seen with previous studies conducted with immediate-release lamotrigine and LAMICTAL XR. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Valproate increases lamotrigine concentrations more than 2-fold. (7, 12.3)
- Carbamazepine, phenytoin, phenobarbital, and primidone decrease lamotrigine concentrations by approximately 40%. (7, 12.3)
- Estrogen-containing oral contraceptives and rifampin also decrease lamotrigine concentrations by approximately 50%. (7, 12.3)

USE IN SPECIFIC POPULATIONS

- Pregnancy: Based on animal data may cause fetal harm. Pregnancy registry available. (8.1)
- Hepatic impairment: Dosage adjustments required in patients with moderate and severe liver impairment. (2.1, 8.6)
- Renal impairment: Reduced maintenance doses may be effective for patients with significant renal impairment. (2.1, 8.7)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised:

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: SERIOUS SKIN RASHES

1 INDICATIONS AND USAGE

- 1.1 Adjunctive Therapy
- 1.2 Monotherapy
- 1.3 Limitation of Use

2 DOSAGE AND ADMINISTRATION

- 2.1 General Dosing Considerations
- 2.2 Adjunctive Therapy for Primary Generalized Tonic-Clonic and Partial Onset Seizures
- 2.3 Conversion From Adjunctive Therapy to Monotherapy

2.4 Conversion From Immediate-Release Lamotrigine Tablets to LAMICTAL XR

3 DOSAGE FORMS AND STRENGTHS

- 3.1 Extended-Release Tablets
- 3.2 Potential Medication Errors

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Serious Skin Rashes
- 5.2 Hypersensitivity Reactions
- 5.3 Acute Multiorgan Failure
- 5.4 Blood Dyscrasias
- 5.5 Suicidal Behavior and Ideation
- 5.6 Aseptic Meningitis
- 5.7 Potential Medication Errors

- 5.8 Concomitant Use With Oral Contraceptives
- 5.9 Withdrawal Seizures
- 5.10 Status Epilepticus
- 5.11 Sudden Unexplained Death in Epilepsy
- 5.12 Addition of LAMICTAL XR to a Multidrug Regimen That Includes Valproate
- 5.13 Binding in the Eye and Other Melanin-Containing Tissues
- 5.14 Laboratory Tests
- 6 ADVERSE REACTIONS**
- 6.1 Clinical Trial Experience With LAMICTAL XR for Treatment of Primary Generalized Tonic-Clonic and Partial Onset Seizures
- 6.2 Other Adverse Reactions Observed During the Clinical Development of Immediate-Release Lamotrigine
- 6.3 Postmarketing Experience With Immediate-Release Lamotrigine
- 7 DRUG INTERACTIONS**
- 8 USE IN SPECIFIC POPULATIONS**
- 8.1 Pregnancy
- 8.2 Labor and Delivery
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Patients With Hepatic Impairment
- 8.7 Patients With Renal Impairment
- 10 OVERDOSAGE**
- 10.1 Human Overdose Experience
- 10.2 Management of Overdose
- 11 DESCRIPTION**
- 12 CLINICAL PHARMACOLOGY**
- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics
- 13 NONCLINICAL TOXICOLOGY**
- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 14 CLINICAL STUDIES**
- 14.1 Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures
- 14.2 Adjunctive Therapy for Partial Onset Seizures
- 14.3 Conversion to Monotherapy for Partial Onset Seizures
- 15 REFERENCES**
- 16 HOW SUPPLIED/STORAGE AND HANDLING**
- 17 PATIENT COUNSELING INFORMATION**
- 17.1 Rash
- 17.2 Suicidal Thinking and Behavior
- 17.3 Worsening of Seizures
- 17.4 Central Nervous System Adverse Effects
- 17.5 Blood Dyscrasias and/or Acute Multiorgan Failure
- 17.6 Pregnancy
- 17.7 Oral Contraceptive Use
- 17.8 Discontinuing LAMICTAL XR
- 17.9 Aseptic Meningitis
- 17.10 Potential Medication Errors

*Sections or subsections omitted from the full prescribing information are not listed.

1

2 **FULL PRESCRIBING INFORMATION**

3 **WARNING: SERIOUS SKIN RASHES**

4 **LAMICTAL® XR™ can cause serious rashes requiring hospitalization and**
5 **discontinuation of treatment. The incidence of these rashes, which have included Stevens-**
6 **Johnson syndrome, is approximately 0.8% (8 per 1,000) in pediatric patients (aged 2 to 16**
7 **years) receiving immediate-release lamotrigine as adjunctive therapy for epilepsy and**
8 **0.3% (3 per 1,000) in adults on adjunctive therapy for epilepsy. In a prospectively followed**
9 **cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking adjunctive**
10 **immediate-release lamotrigine, there was 1 rash-related death. LAMICTAL XR is not**
11 **approved for patients less than 13 years of age. In worldwide postmarketing experience,**
12 **rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in**
13 **adult and pediatric patients, but their numbers are too few to permit a precise estimate of**
14 **the rate.**

15 **The risk of serious rash caused by treatment with LAMICTAL XR is not expected**
16 **to differ from that with immediate-release lamotrigine. However, the relatively limited**
17 **treatment experience with LAMICTAL XR makes it difficult to characterize the frequency**
18 **and risk of serious rashes caused by treatment with LAMICTAL XR.**

19 **Other than age, there are as yet no factors identified that are known to predict the**
20 **risk of occurrence or the severity of rash caused by LAMICTAL XR. There are**
21 **suggestions, yet to be proven, that the risk of rash may also be increased by (1)**
22 **coadministration of LAMICTAL XR with valproate (includes valproic acid and divalproex**
23 **sodium), (2) exceeding the recommended initial dose of LAMICTAL XR, or (3) exceeding**
24 **the recommended dose escalation for LAMICTAL XR. However, cases have occurred in**
25 **the absence of these factors.**

26 **Nearly all cases of life-threatening rashes caused by immediate-release lamotrigine**
27 **have occurred within 2 to 8 weeks of treatment initiation. However, isolated cases have**
28 **occurred after prolonged treatment (e.g., 6 months). Accordingly, duration of therapy**
29 **cannot be relied upon as means to predict the potential risk heralded by the first**
30 **appearance of a rash.**

31 **Although benign rashes are also caused by LAMICTAL XR, it is not possible to**
32 **predict reliably which rashes will prove to be serious or life threatening. Accordingly,**
33 **LAMICTAL XR should ordinarily be discontinued at the first sign of rash, unless the rash**
34 **is clearly not drug related. Discontinuation of treatment may not prevent a rash from**
35 **becoming life threatening or permanently disabling or disfiguring [see *Warnings and***
36 ***Precautions (5.1)*].**

37 **1 INDICATIONS AND USAGE**

38 **1.1 Adjunctive Therapy**

39 LAMICTAL XR is indicated as adjunctive therapy for primary generalized tonic-clonic
40 (PGTC) seizures and partial onset seizures with or without secondary generalization in patients
41 ≥ 13 years of age.

42 **1.2 Monotherapy**

43 LAMICTAL XR is indicated for conversion to monotherapy in patients ≥ 13 years of age
44 with partial seizures who are receiving treatment with a single antiepileptic drug (AED).

45 Safety and effectiveness of LAMICTAL XR have not been established (1) as initial
46 monotherapy or (2) for simultaneous conversion to monotherapy from two or more concomitant
47 AEDs.

48 **1.3 Limitation of Use**

49 Safety and effectiveness of LAMICTAL XR for use in patients less than 13 years of age
50 have not been established.

51 **2 DOSAGE AND ADMINISTRATION**

52 LAMICTAL XR Extended-Release Tablets are taken once daily, with or without food.
53 Tablets must be swallowed whole and must not be chewed, crushed, or divided.

54 **2.1 General Dosing Considerations**

55 Rash: There are suggestions, yet to be proven, that the risk of severe, potentially life-
56 threatening rash may be increased by (1) coadministration of LAMICTAL XR with valproate,
57 (2) exceeding the recommended initial dose of LAMICTAL XR, or (3) exceeding the
58 recommended dose escalation for LAMICTAL XR. However, cases have occurred in the
59 absence of these factors [see *Boxed Warning*]. Therefore, it is important that the dosing
60 recommendations be followed closely.

61 The risk of nonserious rash may be increased when the recommended initial dose and/or
62 the rate of dose escalation for LAMICTAL XR is exceeded and in patients with a history of
63 allergy or rash to other AEDs.

64 LAMICTAL XR Patient Titration Kits provide LAMICTAL XR at doses consistent with
65 the recommended titration schedule for the first 5 weeks of treatment, based upon concomitant
66 medications for patients with partial onset seizures, and are intended to help reduce the potential
67 for rash. The use of LAMICTAL XR Patient Titration Kits is recommended for appropriate
68 patients who are starting or restarting LAMICTAL XR [see *How Supplied/Storage and Handling*
69 (16)].

70 It is recommended that LAMICTAL XR not be restarted in patients who discontinued
71 due to rash associated with prior treatment with lamotrigine, unless the potential benefits clearly
72 outweigh the risks. If the decision is made to restart a patient who has discontinued LAMICTAL
73 XR, the need to restart with the initial dosing recommendations should be assessed. The greater
74 the interval of time since the previous dose, the greater consideration should be given to
75 restarting with the initial dosing recommendations. If a patient has discontinued lamotrigine for a

76 period of more than 5 half-lives, it is recommended that initial dosing recommendations and
77 guidelines be followed. The half-life of lamotrigine is affected by other concomitant medications
78 [*see Clinical Pharmacology (12.3)*].

79 **LAMICTAL XR Added to Drugs Known to Induce or Inhibit Glucuronidation:** Drugs
80 other than those listed in the Clinical Pharmacology section [*see Clinical Pharmacology (12.3)*]
81 have not been systematically evaluated in combination with lamotrigine. Because lamotrigine is
82 metabolized predominantly by glucuronic acid conjugation, drugs that are known to induce or
83 inhibit glucuronidation may affect the apparent clearance of lamotrigine and doses of
84 LAMICTAL XR may require adjustment based on clinical response.

85 **Target Plasma Levels:** A therapeutic plasma concentration range has not been
86 established for lamotrigine. Dosing of LAMICTAL XR should be based on therapeutic response
87 [*see Clinical Pharmacology (12.3)*].

88 **Women Taking Estrogen-Containing Oral Contraceptives: Starting LAMICTAL**
89 **XR in Women Taking Estrogen-Containing Oral Contraceptives:** Although estrogen-
90 containing oral contraceptives have been shown to increase the clearance of lamotrigine [*see*
91 *Clinical Pharmacology (12.3)*], no adjustments to the recommended dose-escalation guidelines
92 for LAMICTAL XR should be necessary solely based on the use of estrogen-containing oral
93 contraceptives. Therefore, dose escalation should follow the recommended guidelines for
94 initiating adjunctive therapy with LAMICTAL XR based on the concomitant AED or other
95 concomitant medications (see Table 1). See below for adjustments to maintenance doses of
96 LAMICTAL XR in women taking estrogen-containing oral contraceptives.

97 ***Adjustments to the Maintenance Dose of LAMICTAL XR in Women Taking***
98 ***Estrogen-Containing Oral Contraceptives:***

99 (1) ***Taking Estrogen-Containing Oral Contraceptives:*** For women not taking
100 carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin that induce
101 lamotrigine glucuronidation [*see Drug Interactions (7), Clinical Pharmacology (12.3)*], the
102 maintenance dose of LAMICTAL XR will in most cases need to be increased by as much as 2-
103 fold over the recommended target maintenance dose in order to maintain a consistent lamotrigine
104 plasma level [*see Clinical Pharmacology (12.3)*].

105 (2) ***Starting Estrogen-Containing Oral Contraceptives:*** In women taking a
106 stable dose of LAMICTAL XR and not taking carbamazepine, phenytoin, phenobarbital,
107 primidone, or other drugs such as rifampin that induce lamotrigine glucuronidation [*see Drug*
108 *Interactions (7), Clinical Pharmacology (12.3)*], the maintenance dose will in most cases need to
109 be increased by as much as 2-fold in order to maintain a consistent lamotrigine plasma level. The
110 dose increases should begin at the same time that the oral contraceptive is introduced and
111 continue, based on clinical response, no more rapidly than 50 to 100 mg/day every week. Dose
112 increases should not exceed the recommended rate (see Table 1) unless lamotrigine plasma
113 levels or clinical response support larger increases. Gradual transient increases in lamotrigine
114 plasma levels may occur during the week of inactive hormonal preparation (pill-free week), and
115 these increases will be greater if dose increases are made in the days before or during the week of

116 inactive hormonal preparation. Increased lamotrigine plasma levels could result in additional
117 adverse reactions, such as dizziness, ataxia, and diplopia. If adverse reactions attributable to
118 LAMICTAL XR consistently occur during the pill-free week, dose adjustments to the overall
119 maintenance dose may be necessary. Dose adjustments limited to the pill-free week are not
120 recommended. For women taking LAMICTAL XR in addition to carbamazepine, phenytoin,
121 phenobarbital, primidone, or other drugs such as rifampin that induce lamotrigine
122 glucuronidation [see *Drug Interactions (7), Clinical Pharmacology (12.3)*], no adjustment to the
123 dose of LAMICTAL XR should be necessary.

124 **(3) Stopping Estrogen-Containing Oral Contraceptives:** For women not
125 taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin that
126 induce lamotrigine glucuronidation [see *Drug Interactions (7), Clinical Pharmacology (12.3)*],
127 the maintenance dose of LAMICTAL XR will in most cases need to be decreased by as much as
128 50% in order to maintain a consistent lamotrigine plasma level. The decrease in dose of
129 LAMICTAL XR should not exceed 25% of the total daily dose per week over a 2-week period,
130 unless clinical response or lamotrigine plasma levels indicate otherwise [see *Clinical*
131 *Pharmacology (12.3)*]. For women taking LAMICTAL XR in addition to carbamazepine,
132 phenytoin, phenobarbital, primidone, or other drugs such as rifampin that induce lamotrigine
133 glucuronidation [see *Drug Interactions (7), Clinical Pharmacology (12.3)*], no adjustment to the
134 dose of LAMICTAL XR should be necessary.

135 **Women and Other Hormonal Contraceptive Preparations or Hormone**
136 **Replacement Therapy:** The effect of other hormonal contraceptive preparations or hormone
137 replacement therapy on the pharmacokinetics of lamotrigine has not been systematically
138 evaluated. It has been reported that ethinylestradiol, not progestogens, increased the clearance of
139 lamotrigine up to 2-fold, and the progestin-only pills had no effect on lamotrigine plasma levels.
140 Therefore, adjustments to the dosage of LAMICTAL XR in the presence of progestogens alone
141 will likely not be needed.

142 **Patients With Hepatic Impairment:** Experience in patients with hepatic impairment is
143 limited. Based on a clinical pharmacology study in 24 patients with mild, moderate, and severe
144 liver impairment [see *Use in Specific Populations (8.6), Clinical Pharmacology (12.3)*], the
145 following general recommendations can be made. No dosage adjustment is needed in patients
146 with mild liver impairment. Initial, escalation, and maintenance doses should generally be
147 reduced by approximately 25% in patients with moderate and severe liver impairment without
148 ascites and 50% in patients with severe liver impairment with ascites. Escalation and
149 maintenance doses may be adjusted according to clinical response.

150 **Patients With Renal Impairment:** Initial doses of LAMICTAL XR should be based on
151 patients' concomitant medications (see Table 1); reduced maintenance doses may be effective for
152 patients with significant renal impairment [see *Use in Specific Populations (8.7), Clinical*
153 *Pharmacology (12.3)*]. Few patients with severe renal impairment have been evaluated during
154 chronic treatment with immediate-release lamotrigine. Because there is inadequate experience in
155 this population, LAMICTAL XR should be used with caution in these patients.

156 **Discontinuation Strategy:** For patients receiving LAMICTAL XR in combination with
 157 other AEDs, a re-evaluation of all AEDs in the regimen should be considered if a change in
 158 seizure control or an appearance or worsening of adverse reactions is observed.

159 If a decision is made to discontinue therapy with LAMICTAL XR, a step-wise reduction
 160 of dose over at least 2 weeks (approximately 50% per week) is recommended unless safety
 161 concerns require a more rapid withdrawal [*see Warnings and Precautions (5.9)*].

162 Discontinuing carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such
 163 as rifampin that induce lamotrigine glucuronidation should prolong the half-life of lamotrigine;
 164 discontinuing valproate should shorten the half-life of lamotrigine.

165 **2.2 Adjunctive Therapy for Primary Generalized Tonic-Clonic and Partial Onset**
 166 **Seizures**

167 This section provides specific dosing recommendations for patients ≥ 13 years of age.
 168 Specific dosing recommendations are provided depending upon concomitant AED or other
 169 concomitant medications.

170

171 **Table 1. Escalation Regimen for LAMICTAL XR in Patients ≥ 13 Years of Age**

	For Patients TAKING Valproate ^a	For Patients NOT TAKING Carbamazepine, Phenytoin, Phenobarbital, Primidone, ^b or Valproate ^a	For Patients TAKING Carbamazepine, Phenytoin, Phenobarbital, or Primidone ^b and NOT TAKING Valproate ^a
Weeks 1 and 2	25 mg every <i>other</i> day	25 mg every day	50 mg every day
Weeks 3 and 4	25 mg every day	50 mg every day	100 mg every day
Week 5	50 mg every day	100 mg every day	200 mg every day
Week 6	100 mg every day	150 mg every day	300 mg every day
Week 7	150 mg every day	200 mg every day	400 mg every day
Maintenance range (week 8 and onward)	200 to 250 mg every day ^c	300 to 400 mg every day ^c	400 to 600 mg every day ^c

172 ^a Valproate has been shown to inhibit glucuronidation and decrease the apparent clearance of
 173 lamotrigine [*see Drug Interactions (7), Clinical Pharmacology (12.3)*].

174 ^b These drugs induce lamotrigine glucuronidation and increase clearance [*see Drug Interactions (7),*
 175 *Clinical Pharmacology (12.3)*]. Other drugs which have similar effects include estrogen-
 176 containing oral contraceptives [*see Drug Interactions (7), Clinical Pharmacology (12.3)*]. Dosing
 177 recommendations for oral contraceptives can be found in General Dosing Considerations [*see*
 178 *Dosage and Administration (2.1)*]. Patients on rifampin, or other drugs that induce lamotrigine
 179 glucuronidation and increase clearance, should follow the same dosing titration/maintenance
 180 regimen as that used with anticonvulsants that have this effect.

181 ^c Dose increases at week 8 or later should not exceed 100 mg daily at weekly intervals.

182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211

2.3 Conversion From Adjunctive Therapy to Monotherapy

The goal of the transition regimen is to attempt to maintain seizure control while mitigating the risk of serious rash associated with the rapid titration of LAMICTAL XR.

The recommended maintenance dosage range of LAMICTAL XR as monotherapy is 250 to 300 mg given once daily.

The recommended initial dose and subsequent dose escalations for LAMICTAL XR should not be exceeded [see *Boxed Warning*].

Conversion From Adjunctive Therapy With Carbamazepine, Phenytoin, Phenobarbital, or Primidone to Monotherapy With LAMICTAL XR: After achieving a dosage of 500 mg/day of LAMICTAL XR using the guidelines in Table 1, the concomitant enzyme-inducing AED should be withdrawn by 20% decrements each week over a 4-week period. Two weeks after completion of withdrawal of the enzyme-inducing AED, the dosage of LAMICTAL XR may be decreased no faster than 100 mg/day each week to achieve the monotherapy maintenance dosage range of 250 to 300 mg/day.

The regimen for the withdrawal of the concomitant AED is based on experience gained in the controlled monotherapy clinical trial using immediate-release lamotrigine.

Conversion From Adjunctive Therapy With Valproate to Monotherapy With LAMICTAL XR: The conversion regimen involves the 4 steps outlined in Table 2.

Table 2. Conversion From Adjunctive Therapy With Valproate to Monotherapy With LAMICTAL XR in Patients ≥ 13 Years of Age With Epilepsy

	LAMICTAL XR	Valproate
Step 1	Achieve a dosage of 150 mg/day according to guidelines in Table 1.	Maintain established stable dose.
Step 2	Maintain at 150 mg/day.	Decrease dosage by decrements no greater than 500 mg/day/week to 500 mg/day and then maintain for 1 week.
Step 3	Increase to 200 mg/day.	Simultaneously decrease to 250 mg/day and maintain for 1 week.
Step 4	Increase to 250 or 300 mg/day.	Discontinue.

Conversion From Adjunctive Therapy With Antiepileptic Drugs Other Than Carbamazepine, Phenytoin, Phenobarbital, Primidone, or Valproate to Monotherapy With LAMICTAL XR: After achieving a dosage of 250 to 300 mg/day of LAMICTAL XR using the guidelines in Table 1, the concomitant AED should be withdrawn by 20% decrements each week over a 4-week period. No adjustment to the monotherapy dose of LAMICTAL XR is needed.

2.4 Conversion From Immediate-Release Lamotrigine Tablets to LAMICTAL XR

212 Patients may be converted directly from immediate-release lamotrigine to LAMICTAL
213 XR Extended-Release Tablets. The initial dose of LAMICTAL XR should match the total daily
214 dose of immediate-release lamotrigine. However, some subjects on concomitant enzyme-
215 inducing agents may have lower plasma levels of lamotrigine on conversion and should be
216 monitored [see *Clinical Pharmacology (12.3)*].

217 Following conversion to LAMICTAL XR, all patients (but especially those on drugs that
218 induce lamotrigine glucuronidation) should be closely monitored for seizure control [see *Drug*
219 *Interactions (7)*]. Depending on the therapeutic response after conversion, the total daily dose
220 may need to be adjusted within the recommended dosing instructions (Table 1).

221 **3 DOSAGE FORMS AND STRENGTHS**

222 **3.1 Extended-Release Tablets**

223 25 mg, yellow with white center, round, biconvex, film-coated tablets printed with
224 “LAMICTAL” and “XR 25.”

225 50 mg, green with white center, round, biconvex, film-coated tablets printed with
226 “LAMICTAL” and “XR 50.”

227 100 mg, orange with white center, round, biconvex, film-coated tablets printed with
228 “LAMICTAL” and “XR 100.”

229 200 mg, blue with white center, round, biconvex, film-coated tablets printed with
230 “LAMICTAL” and “XR 200.”

231 250 mg, purple with white center, caplet-shaped, film-coated tablets printed with
232 “LAMICTAL” and “XR 250.”

233 300 mg, gray with white center, caplet-shaped, film-coated tablets printed with
234 “LAMICTAL” and “XR 300.”

235 **3.2 Potential Medication Errors**

236 Patients should be strongly advised to visually inspect their tablets to verify that they are
237 receiving LAMICTAL XR, as opposed to other medications, and that they are receiving the
238 correct formulation of lamotrigine each time they fill their prescription. Depictions of the
239 LAMICTAL XR tablets can be found in the Medication Guide.

240 **4 CONTRAINDICATIONS**

241 LAMICTAL XR is contraindicated in patients who have demonstrated hypersensitivity
242 (e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its
243 ingredients [see *Boxed Warning, Warnings and Precautions (5.1, 5.2)*].

244 **5 WARNINGS AND PRECAUTIONS**

245 **5.1 Serious Skin Rashes**

246 The risk of serious rash caused by treatment with LAMICTAL XR is not expected to
247 differ from that with immediate-release lamotrigine [see *Boxed Warning*]. However, the
248 relatively limited treatment experience with LAMICTAL XR makes it difficult to characterize
249 the frequency and risk of serious rashes caused by treatment with LAMICTAL XR.

250 Pediatric Population: The incidence of serious rash associated with hospitalization and
251 discontinuation of immediate-release lamotrigine in a prospectively followed cohort of pediatric
252 patients (aged 2 to 16 years) with epilepsy receiving adjunctive therapy with immediate-release
253 lamotrigine was approximately 0.8% (16 of 1,983). When 14 of these cases were reviewed by 3
254 expert dermatologists, there was considerable disagreement as to their proper classification. To
255 illustrate, one dermatologist considered none of the cases to be Stevens-Johnson syndrome;
256 another assigned 7 of the 14 to this diagnosis. There was 1 rash-related death in this 1,983-
257 patient cohort. Additionally, there have been rare cases of toxic epidermal necrolysis with and
258 without permanent sequelae and/or death in US and foreign postmarketing experience.

259 There is evidence that the inclusion of valproate in a multidrug regimen increases the risk
260 of serious, potentially life-threatening rash in pediatric patients. In pediatric patients who used
261 valproate concomitantly, 1.2% (6 of 482) experienced a serious rash compared with 0.6% (6 of
262 952) patients not taking valproate.

263 LAMICTAL XR is not approved in patients less than 13 years of age.

264 Adult Population: Serious rash associated with hospitalization and discontinuation of
265 immediate-release lamotrigine occurred in 0.3% (11 of 3,348) of adult patients who received
266 immediate-release lamotrigine in premarketing clinical trials of epilepsy. In worldwide
267 postmarketing experience, rare cases of rash-related death have been reported, but their numbers
268 are too few to permit a precise estimate of the rate.

269 Among the rashes leading to hospitalization were Stevens-Johnson syndrome, toxic
270 epidermal necrolysis, angioedema, and a rash associated with a variable number of the following
271 systemic manifestations: fever, lymphadenopathy, facial swelling, and hematologic and
272 hepatologic abnormalities.

273 There is evidence that the inclusion of valproate in a multidrug regimen increases the risk
274 of serious, potentially life-threatening rash in adults. Specifically, of 584 patients administered
275 immediate-release lamotrigine with valproate in epilepsy clinical trials, 6 (1%) were hospitalized
276 in association with rash; in contrast, 4 (0.16%) of 2,398 clinical trial patients and volunteers
277 administered immediate-release lamotrigine in the absence of valproate were hospitalized.

278 Patients With History of Allergy or Rash to Other Antiepileptic Drugs: The risk of
279 nonserious rash may be increased when the recommended initial dose and/or the rate of dose
280 escalation for LAMICTAL XR is exceeded and in patients with a history of allergy or rash to
281 other AEDs.

282 **5.2 Hypersensitivity Reactions**

283 Hypersensitivity reactions, some fatal or life threatening, have also occurred. Some of
284 these reactions have included clinical features of multiorgan failure/dysfunction, including
285 hepatic abnormalities and evidence of disseminated intravascular coagulation. It is important to
286 note that early manifestations of hypersensitivity (e.g., fever, lymphadenopathy) may be present
287 even though a rash is not evident. If such signs or symptoms are present, the patient should be
288 evaluated immediately. LAMICTAL XR should be discontinued if an alternative etiology for the
289 signs or symptoms cannot be established.

290 **Prior to initiation of treatment with LAMICTAL XR, the patient should be**
291 **instructed that a rash or other signs or symptoms of hypersensitivity (e.g., fever,**
292 **lymphadenopathy) may herald a serious medical event and that the patient should report**
293 **any such occurrence to a physician immediately.**

294 **5.3 Acute Multiorgan Failure**

295 Multiorgan failure, which in some cases has been fatal or irreversible, has been observed
296 in patients receiving immediate-release lamotrigine. Fatalities associated with multiorgan failure
297 and various degrees of hepatic failure have been reported in 2 of 3,796 adult patients and 4 of
298 2,435 pediatric patients who received immediate-release lamotrigine in epilepsy clinical trials.
299 Rare fatalities from multiorgan failure have been reported in compassionate plea and
300 postmarketing use. The majority of these deaths occurred in association with other serious
301 medical events, including status epilepticus and overwhelming sepsis, and hantavirus, making it
302 difficult to identify the initial cause.

303 Additionally, 3 patients (a 45-year-old woman, a 3.5-year-old boy, and an 11-year-old
304 girl) developed multiorgan dysfunction and disseminated intravascular coagulation 9 to 14 days
305 after immediate-release lamotrigine was added to their AED regimens. Rash and elevated
306 transaminases were also present in all patients and rhabdomyolysis was noted in 2 patients. Both
307 pediatric patients were receiving concomitant therapy with valproate, while the adult patient was
308 being treated with carbamazepine and clonazepam. All patients subsequently recovered with
309 supportive care after treatment with immediate-release lamotrigine was discontinued.

310 **5.4 Blood Dyscrasias**

311 There have been reports of blood dyscrasias with immediate-release lamotrigine that may
312 or may not be associated with the hypersensitivity syndrome. These have included neutropenia,
313 leukopenia, anemia, thrombocytopenia, pancytopenia, and, rarely, aplastic anemia and pure red
314 cell aplasia.

315 **5.5 Suicidal Behavior and Ideation**

316 AEDs, including LAMICTAL XR, increase the risk of suicidal thoughts or behavior in
317 patients taking these drugs for any indication. Patients treated with any AED for any indication
318 should be monitored for the emergence or worsening of depression, suicidal thoughts or
319 behavior, and/or any unusual changes in mood or behavior.

320 Pooled analyses of 199 placebo-controlled clinical trials (monotherapy and adjunctive
321 therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had
322 approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or
323 behavior compared to patients randomized to placebo. In these trials, which had a median
324 treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among
325 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated
326 patients, representing an increase of approximately 1 case of suicidal thinking or behavior for
327 every 530 patients treated. There were 4 suicides in drug-treated patients in the trials and none in
328 placebo-treated patients, but the number of events is too small to allow any conclusion about
329 drug effect on suicide.

330 The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1
331 week after starting treatment with AEDs and persisted for the duration of treatment assessed.
332 Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal
333 thoughts or behavior beyond 24 weeks could not be assessed.

334 The risk of suicidal thoughts or behavior was generally consistent among drugs in the
335 data analyzed. The finding of increased risk with AEDs of varying mechanism of action and
336 across a range of indications suggests that the risk applies to all AEDs used for any indication.
337 The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed.

338 Table 3 shows absolute and relative risk by indication for all evaluated AEDs.
339

340 **Table 3. Risk by Indication for Antiepileptic Drugs in the Pooled Analysis**

Indication	Placebo Patients With Events per 1,000 Patients	Drug Patients With Events per 1,000 Patients	Relative Risk: Incidence of Events in Drug Patients/ Incidence in Placebo Patients	Risk Difference: Additional Drug Patients With Events per 1,000 Patients
Epilepsy	1.0	3.4	3.5	2.4
Psychiatric	5.7	8.5	1.5	2.9
Other	1.0	1.8	1.9	0.9
Total	2.4	4.3	1.8	1.9

341
342 The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy
343 than in clinical trials for psychiatric or other conditions, but the absolute risk differences were
344 similar for the epilepsy and psychiatric indications.

345 Anyone considering prescribing LAMICTAL XR or any other AED must balance the risk
346 of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other
347 illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality
348 and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior
349 emerge during treatment, the prescriber needs to consider whether the emergence of these
350 symptoms in any given patient may be related to the illness being treated.

351 Patients, their caregivers, and families should be informed that AEDs increase the risk of
352 suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or
353 worsening of the signs and symptoms of depression; any unusual changes in mood or behavior;
354 or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of
355 concern should be reported immediately to healthcare providers.

356 **5.6 Aseptic Meningitis**

357 Therapy with lamotrigine increases the risk of developing aseptic meningitis. Because of
358 the potential for serious outcomes of untreated meningitis due to other causes, patients should
359 also be evaluated for other causes of meningitis and treated as appropriate.

360 Postmarketing cases of aseptic meningitis have been reported in pediatric and adult
361 patients taking lamotrigine for various indications. Symptoms upon presentation have included
362 headache, fever, nausea, vomiting, and nuchal rigidity. Rash, photophobia, myalgia, chills,
363 altered consciousness, and somnolence were also noted in some cases. Symptoms have been
364 reported to occur within 1 day to one and a half months following the initiation of treatment. In
365 most cases, symptoms were reported to resolve after discontinuation of lamotrigine. Re-exposure
366 resulted in a rapid return of symptoms (from within 30 minutes to 1 day following re-initiation of
367 treatment) that were frequently more severe. Some of the patients treated with LAMICTAL who
368 developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus or other
369 autoimmune diseases.

370 Cerebrospinal fluid (CSF) analyzed at the time of clinical presentation in reported cases
371 was characterized by a mild to moderate pleocytosis, normal glucose levels, and mild to
372 moderate increase in protein. CSF white blood cell count differentials showed a predominance of
373 neutrophils in a majority of the cases, although a predominance of lymphocytes was reported in
374 approximately one third of the cases. Some patients also had new onset of signs and symptoms
375 of involvement of other organs (predominantly hepatic and renal involvement), which may
376 suggest that in these cases the aseptic meningitis observed was part of a hypersensitivity reaction
377 [*see Warnings and Precautions (5.2)*].

378 **5.7 Potential Medication Errors**

379 Medication errors involving LAMICTAL have occurred. In particular, the names
380 LAMICTAL or lamotrigine can be confused with the names of other commonly used
381 medications. Medication errors may also occur between the different formulations of
382 LAMICTAL. To reduce the potential of medication errors, write and say LAMICTAL XR
383 clearly. Depictions of the LAMICTAL XR Extended-Release Tablets can be found in the
384 Medication Guide. Each LAMICTAL XR tablet has a distinct color and white center, and is
385 printed with "LAMICTAL XR" and the tablet strength. These distinctive features serve to
386 identify the different presentations of the drug and thus may help reduce the risk of medication
387 errors. LAMICTAL XR is supplied in round, unit-of-use bottles with orange caps containing 30
388 tablets. The label on the bottle includes a depiction of the tablets that further communicates to
389 patients and pharmacists that the medication is LAMICTAL XR and the specific tablet strength
390 included in the bottle. The unit-of-use bottle with a distinctive orange cap and distinctive bottle
391 label features serves to identify the different presentations of the drug and thus may help to
392 reduce the risk of medication errors. To avoid the medication error of using the wrong drug or
393 formulation, patients should be strongly advised to visually inspect their tablets to verify that
394 they are LAMICTAL XR each time they fill their prescription.

395 **5.8 Concomitant Use With Oral Contraceptives**

396 Some estrogen-containing oral contraceptives have been shown to decrease serum
397 concentrations of lamotrigine [*see Clinical Pharmacology (12.3)*]. **Dosage adjustments will be**
398 **necessary in most patients who start or stop estrogen-containing oral contraceptives while**
399 **taking LAMICTAL XR** [*see Dosage and Administration (2.1)*]. During the week of inactive

400 hormone preparation (pill-free week) of oral contraceptive therapy, plasma lamotrigine levels are
401 expected to rise, as much as doubling at the end of the week. Adverse reactions consistent with
402 elevated levels of lamotrigine, such as dizziness, ataxia, and diplopia, could occur.

403 **5.9 Withdrawal Seizures**

404 As with other AEDs, LAMICTAL XR should not be abruptly discontinued. In patients
405 with epilepsy there is a possibility of increasing seizure frequency. Unless safety concerns
406 require a more rapid withdrawal, the dose of LAMICTAL XR should be tapered over a period of
407 at least 2 weeks (approximately 50% reduction per week) [*see Dosage and Administration*
408 (2.1)].

409 **5.10 Status Epilepticus**

410 Valid estimates of the incidence of treatment-emergent status epilepticus among patients
411 treated with immediate-release lamotrigine are difficult to obtain because reporters participating
412 in clinical trials did not all employ identical rules for identifying cases. At a minimum, 7 of 2,343
413 adult patients had episodes that could unequivocally be described as status epilepticus. In
414 addition, a number of reports of variably defined episodes of seizure exacerbation (e.g., seizure
415 clusters, seizure flurries) were made.

416 **5.11 Sudden Unexplained Death in Epilepsy**

417 During the premarketing development of immediate-release lamotrigine, 20 sudden and
418 unexplained deaths were recorded among a cohort of 4,700 patients with epilepsy (5,747 patient-
419 years of exposure).

420 Some of these could represent seizure-related deaths in which the seizure was not
421 observed, e.g., at night. This represents an incidence of 0.0035 deaths per patient-year. Although
422 this rate exceeds that expected in a healthy population matched for age and sex, it is within the
423 range of estimates for the incidence of sudden unexplained death in patients with epilepsy not
424 receiving lamotrigine (ranging from 0.0005 for the general population of patients with epilepsy,
425 to 0.004 for a recently studied clinical trial population similar to that in the clinical development
426 program for immediate-release lamotrigine, to 0.005 for patients with refractory epilepsy).
427 Consequently, whether these figures are reassuring or suggest concern depends on the
428 comparability of the populations reported upon to the cohort receiving immediate-release
429 lamotrigine and the accuracy of the estimates provided. Probably most reassuring is the
430 similarity of estimated sudden unexplained death in epilepsy (SUDEP) rates in patients receiving
431 immediate-release lamotrigine and those receiving other AEDs, chemically unrelated to each
432 other, that underwent clinical testing in similar populations. Importantly, that drug is chemically
433 unrelated to lamotrigine. This evidence suggests, although it certainly does not prove, that the
434 high SUDEP rates reflect population rates, not a drug effect.

435 **5.12 Addition of LAMICTAL XR to a Multidrug Regimen That Includes Valproate**

436 Because valproate reduces the clearance of lamotrigine, the dosage of lamotrigine in the
437 presence of valproate is less than half of that required in its absence [*see Dosage and*
438 *Administration (2.1, 2.2), Drug Interactions (7)*].

439 **5.13 Binding in the Eye and Other Melanin-Containing Tissues**

440 Because lamotrigine binds to melanin, it could accumulate in melanin-rich tissues over
441 time. This raises the possibility that lamotrigine may cause toxicity in these tissues after
442 extended use. Although ophthalmological testing was performed in one controlled clinical trial,
443 the testing was inadequate to exclude subtle effects or injury occurring after long-term exposure.
444 Moreover, the capacity of available tests to detect potentially adverse consequences, if any, of
445 lamotrigine binding to melanin is unknown [see *Clinical Pharmacology (12.2)*].

446 Accordingly, although there are no specific recommendations for periodic
447 ophthalmological monitoring, prescribers should be aware of the possibility of long-term
448 ophthalmologic effects.

449 **5.14 Laboratory Tests**

450 Plasma Concentrations of Lamotrigine: The value of monitoring plasma
451 concentrations of lamotrigine in patients treated with LAMICTAL XR has not been established.
452 Because of the possible pharmacokinetic interactions between lamotrigine and other drugs,
453 including AEDs (see Table 6), monitoring of the plasma levels of lamotrigine and concomitant
454 drugs may be indicated, particularly during dosage adjustments. In general, clinical judgment
455 should be exercised regarding monitoring of plasma levels of lamotrigine and other drugs and
456 whether or not dosage adjustments are necessary.

457 Effect on Leukocytes: Treatment with LAMICTAL XR caused an increased incidence
458 of subnormal (below the reference range) values in some hematology analytes (e.g., total white
459 blood cells, monocytes). The treatment effect (LAMICTAL XR % - Placebo %) incidence of
460 subnormal counts was 3% for total white blood cells and 4% for monocytes.

461 **6 ADVERSE REACTIONS**

462 The following adverse reactions are described in more detail in the *Warnings and*
463 *Precautions* section of the label:

- 464 • Serious skin rashes [see *Warnings and Precautions (5.1)*]
- 465 • Hypersensitivity reactions [see *Warnings and Precautions (5.2)*]
- 466 • Acute multiorgan failure [see *Warnings and Precautions (5.3)*]
- 467 • Blood dyscrasias [see *Warnings and Precautions (5.4)*]
- 468 • Suicidal behavior and ideation [see *Warnings and Precautions (5.5)*]
- 469 • Aseptic meningitis [see *Warnings and Precautions (5.6)*]
- 470 • Withdrawal seizures [see *Warnings and Precautions (5.9)*]
- 471 • Status epilepticus [see *Warnings and Precautions (5.10)*]
- 472 • Sudden unexplained death in epilepsy [see *Warnings and Precautions (5.11)*]

473 **6.1 Clinical Trial Experience With LAMICTAL XR for Treatment of Primary** 474 **Generalized Tonic-Clonic and Partial Onset Seizures**

475 Most Common Adverse Reactions in Clinical Studies: *Adjunctive Therapy in*
476 *Patients With Epilepsy:* Because clinical trials are conducted under widely varying conditions,
477 adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with
478 rates in the clinical trials of another drug and may not reflect the rates observed in practice.

479 LAMICTAL XR has been evaluated for safety in patients ≥ 13 years of age with PGTC
 480 and partial onset seizures. The most commonly observed adverse reactions in these 2 double-
 481 blind, placebo-controlled trials of adjunctive therapy with LAMICTAL XR were, in order of
 482 decreasing incidence (treatment difference between LAMICTAL XR and placebo $\geq 4\%$):
 483 dizziness, tremor/intention tremor, vomiting, and diplopia.

484 In these 2 trials, adverse reactions led to withdrawal of 4 (2%) patients in the group
 485 receiving placebo and 10 (5%) patients in the group receiving LAMICTAL XR. Dizziness was
 486 the most common reason for withdrawal in the group receiving LAMICTAL XR (5 patients
 487 [3%]). The next most common adverse reactions leading to withdrawal in 2 patients each (1%)
 488 were rash, headache, nausea, and nystagmus.

489 Table 4 displays the incidence of adverse reactions in these two 19-week, double-blind,
 490 placebo-controlled studies of patients with PGTC and partial onset seizures.

491

492 **Table 4. Adverse Reaction Incidence in Double-Blind, Placebo-Controlled Adjunctive**
 493 **Trials of Patients With Epilepsy (Adverse Reactions $\geq 2\%$ of Patients Treated With**
 494 **LAMICTAL XR and Numerically More Frequent Than in the Placebo Group)**

Body System/Adverse Reaction	LAMICTAL XR (n = 190) %	Placebo (n = 195) %
Ear and labyrinth disorders		
Vertigo	3	<1
Eye disorders		
Diplopia	5	<1
Vision blurred	3	2
Gastrointestinal disorders		
Nausea	7	4
Vomiting	6	3
Diarrhea	5	3
Constipation	2	<1
Dry mouth	2	1
General disorders and administration site conditions		
Asthenia and fatigue	6	4
Infections and infestations		
Sinusitis	2	1
Metabolic and nutritional disorders		
Anorexia	3	2
Musculoskeletal and connective tissue disorder		
Myalgia	2	0

Nervous system		
Dizziness	14	6
Tremor and intention tremor	6	1
Somnolence	5	3
Cerebellar coordination and balance disorder	3	0
Nystagmus	2	<1
Psychiatric disorders		
Depression	3	<1
Anxiety	3	0
Respiratory, thoracic, and mediastinal disorders		
Pharyngolaryngeal pain	3	2
Vascular disorder		
Hot flush	2	0

495 Note: In these trials the incidence of nonserious rash was 2% for LAMICTAL XR and 3% for
 496 placebo. In clinical trials evaluating immediate-release lamotrigine, the rate of serious rash was
 497 0.3% in adults on adjunctive therapy for epilepsy [see *Boxed Warning*].
 498

499 Adverse reactions were also analyzed to assess the incidence of the onset of an event in
 500 the titration period, and in the maintenance period, and if adverse reactions occurring in the
 501 titration phase persisted in the maintenance phase.

502 The incidence for many adverse reactions caused by treatment with LAMICTAL XR was
 503 increased relative to placebo (i.e., treatment difference between LAMICTAL XR and placebo
 504 $\geq 2\%$) in either the titration or maintenance phases of the study. During the titration phase, an
 505 increased incidence (shown in descending order of % treatment difference) was observed for
 506 diarrhea, nausea, vomiting, somnolence, vertigo, myalgia, hot flush, and anxiety. During the
 507 maintenance phase, an increased incidence was observed for dizziness, tremor, and diplopia.
 508 Some adverse reactions developing in the titration phase were notable for persisting (>7 days)
 509 into the maintenance phase. These “persistent” adverse reactions included somnolence and
 510 dizziness.

511 There were inadequate data to evaluate the effect of dose and/or concentration on the
 512 incidence of adverse reactions because, although patients were randomized to different target
 513 doses based upon concomitant AED, the plasma exposure was expected to be generally similar
 514 among all patients receiving different doses. However, in a randomized, parallel study
 515 comparing placebo and 300 and 500 mg/day of immediate-release lamotrigine, the incidence of
 516 the most common adverse reactions ($\geq 5\%$) such as ataxia, blurred vision, diplopia, and dizziness
 517 were dose related. Less common adverse reactions (<5%) were not assessed for dose-response
 518 relationships.

519 *Monotherapy in Patients With Epilepsy:* Adverse reactions observed in this study
 520 were generally similar to those observed and attributed to drug in adjunctive and monotherapy
 521 immediate-release lamotrigine and adjunctive LAMICTAL XR placebo-controlled studies. Only

522 2 adverse events, nasopharyngitis and upper respiratory tract infection, were observed at a rate of
523 $\geq 3\%$ and not reported at a similar rate in previous studies. Because this study did not include a
524 placebo control group, causality could not be established [*see Clinical Studies (14.3)*].

525 **6.2 Other Adverse Reactions Observed During the Clinical Development of** 526 **Immediate-Release Lamotrigine**

527 All reported reactions are included except those already listed in the previous tables or
528 elsewhere in the labeling, those too general to be informative, and those not reasonably
529 associated with the use of the drug.

530 Adjunctive Therapy in Adults With Epilepsy: In addition to the adverse reactions
531 reported above from the development of LAMICTAL XR, the following adverse reactions with
532 an uncertain relationship to lamotrigine were reported during the clinical development of
533 immediate-release lamotrigine for treatment of epilepsy in adults. These reactions occurred in
534 $\geq 2\%$ of patients receiving immediate-release lamotrigine and more frequently than in the placebo
535 group.

536 *Body as a Whole:* Headache, flu syndrome, fever, neck pain.

537 *Musculoskeletal:* Arthralgia.

538 *Nervous:* Insomnia, convulsion, irritability, speech disorder, concentration
539 disturbance.

540 *Respiratory:* Pharyngitis, cough increased.

541 *Skin and Appendages:* Rash, pruritus.

542 *Urogenital (female patients only):* Vaginitis, amenorrhea, dysmenorrhea.

543 Monotherapy in Adults With Epilepsy: In addition to the adverse reactions reported
544 above from the development of LAMICTAL XR, the following adverse reactions with an
545 uncertain relationship to lamotrigine were reported during the clinical development of
546 immediate-release lamotrigine for treatment of epilepsy in adults. These reactions occurred in
547 $>2\%$ of patients receiving immediate-release lamotrigine and more frequently than in the placebo
548 group.

549 *Body as a Whole:* Chest pain.

550 *Digestive:* Rectal hemorrhage, peptic ulcer.

551 *Metabolic and Nutritional:* Weight decrease, peripheral edema.

552 *Nervous:* Hypesthesia, libido increase, decreased reflexes.

553 *Respiratory:* Epistaxis, dyspnea.

554 *Skin and Appendages:* Contact dermatitis, dry skin, sweating.

555 *Special Senses:* Vision abnormality.

556 *Urogenital (female patients only):* Dysmenorrhea.

557 Other Clinical Trial Experience: Immediate-release lamotrigine has been administered
558 to 6,694 individuals for whom complete adverse reaction data was captured during all clinical
559 trials, only some of which were placebo controlled.

560 Adverse reactions are further classified within body system categories and enumerated in
561 order of decreasing frequency using the following definitions: *frequent* adverse reactions are

562 defined as those occurring in at least 1/100 patients; *infrequent* adverse reactions are those
563 occurring in 1/100 to 1/1,000 patients; *rare* adverse reactions are those occurring in fewer than
564 1/1,000 patients.

565 *Cardiovascular System: Infrequent:* Hypertension, palpitations, postural
566 hypotension, syncope, tachycardia, vasodilation.

567 *Dermatological: Infrequent:* Acne, alopecia, hirsutism, maculopapular rash, urticaria.
568 *Rare:* Leukoderma, multiforme erythema, petechial rash, pustular rash.

569 *Digestive System: Infrequent:* Dysphagia, liver function tests abnormal, mouth
570 ulceration. *Rare:* Gastrointestinal hemorrhage, hemorrhagic colitis, hepatitis, melena and
571 stomach ulcer.

572 *Endocrine System: Rare:* Goiter, hypothyroidism.

573 *Hematologic and Lymphatic System: Infrequent:* Ecchymosis, leukopenia. *Rare:*
574 Anemia, eosinophilia, fibrin decrease, fibrinogen decrease, iron deficiency anemia, leukocytosis,
575 lymphocytosis, macrocytic anemia, petechia, thrombocytopenia.

576 *Metabolic and Nutritional Disorders: Infrequent:* Aspartate transaminase increased.
577 *Rare:* Alcohol intolerance, alkaline phosphatase increase, alanine transaminase increase,
578 bilirubinemia, gamma glutamyl transpeptidase increase, hyperglycemia.

579 *Musculoskeletal System: Rare:* Muscle atrophy, pathological fracture, tendinous
580 contracture.

581 *Nervous System: Frequent:* Confusion. *Infrequent:* Akathisia, apathy, aphasia,
582 depersonalization, dysarthria, dyskinesia, euphoria, hallucinations, hostility, hyperkinesia,
583 hypertonia, libido decreased, memory decrease, mind racing, movement disorder, myoclonus,
584 panic attack, paranoid reaction, personality disorder, psychosis, stupor. *Rare:* Choreoathetosis,
585 delirium, delusions, dysphoria, dystonia, extrapyramidal syndrome, hemiplegia, hyperalgesia,
586 hyperesthesia, hypokinesia, hypotonia, manic depression reaction, neuralgia, paralysis,
587 peripheral neuritis.

588 *Respiratory System: Rare:* Hiccup, hyperventilation.

589 *Special Senses: Frequent:* Amblyopia. *Infrequent:* Abnormality of
590 accommodation, conjunctivitis, dry eyes, ear pain, photophobia, taste perversion, tinnitus. *Rare:*
591 Deafness, lacrimation disorder, oscillopsia, parosmia, ptosis, strabismus, taste loss, uveitis, visual
592 field defect.

593 *Urogenital System: Infrequent:* Abnormal ejaculation, hematuria, impotence,
594 menorrhagia, polyuria, urinary incontinence. *Rare:* Acute kidney failure, breast neoplasm,
595 creatinine increase, female lactation, kidney failure, kidney pain, nocturia, urinary retention,
596 urinary urgency.

597 **6.3 Postmarketing Experience With Immediate-Release Lamotrigine**

598 The following adverse events (not listed above in clinical trials or other sections of the
599 prescribing information) have been identified during postapproval use of immediate-release
600 lamotrigine. Because these events are reported voluntarily from a population of uncertain size, it

601 is not always possible to reliably estimate their frequency or establish a causal relationship to
 602 drug exposure.

603 Blood and Lymphatic: Agranulocytosis, hemolytic anemia, lymphadenopathy not
 604 associated with hypersensitivity disorder.

605 Gastrointestinal: Esophagitis.

606 Hepatobiliary Tract and Pancreas: Pancreatitis.

607 Immunologic: Lupus-like reaction, vasculitis.

608 Lower Respiratory: Apnea.

609 Musculoskeletal: Rhabdomyolysis has been observed in patients experiencing
 610 hypersensitivity reactions.

611 Neurology: Exacerbation of Parkinsonian symptoms in patients with pre-existing
 612 Parkinson's disease, tics.

613 Non-site Specific: Progressive immunosuppression.

614 **7 DRUG INTERACTIONS**

615 Significant drug interactions with lamotrigine are summarized in Table 5. Additional
 616 details of these drug interaction studies, which were conducted using immediate-release
 617 lamotrigine, are provided in the Clinical Pharmacology section [*see Clinical Pharmacology*
 618 (*12.3*)].

619

620 **Table 5. Established and Other Potentially Significant Drug Interactions**

Concomitant Drug	Effect on Concentration of Lamotrigine or Concomitant Drug	Clinical Comment
Estrogen-containing oral contraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel	↓ lamotrigine ↓ levonorgestrel	Decreased lamotrigine levels approximately 50%. Decrease in levonorgestrel component by 19%.
Carbamazepine and carbamazepine epoxide	↓ lamotrigine ? CBZ epoxide	Addition of carbamazepine decreases lamotrigine concentration approximately 40%. May increase carbamazepine epoxide levels.
Phenobarbital/Primidone	↓ lamotrigine	Decreased lamotrigine concentration approximately 40%.
Phenytoin	↓ lamotrigine	Decreased lamotrigine concentration approximately 40%.

Rifampin	↓ lamotrigine	Decreased lamotrigine AUC approximately 40%.
Valproate	↑ lamotrigine ? valproate	Increased lamotrigine concentrations slightly more than 2-fold. Decreased valproate concentrations an average of 25% over a 3-week period then stabilized in healthy volunteers; no change in controlled clinical trials in epilepsy patients.

621 ↓ = Decreased (induces lamotrigine glucuronidation).

622 ↑ = Increased (inhibits lamotrigine glucuronidation).

623 ? = Conflicting data.

624 **8 USE IN SPECIFIC POPULATIONS**

625 **8.1 Pregnancy**

626 As with other AEDs, physiological changes during pregnancy may affect lamotrigine
 627 concentrations and/or therapeutic effect. There have been reports of decreased lamotrigine
 628 concentrations during pregnancy and restoration of pre-partum concentrations after delivery.
 629 Dosage adjustments may be necessary to maintain clinical response.

630 Pregnancy Category C.

631 There are no adequate and well-controlled studies in pregnant women. In animal studies,
 632 lamotrigine was developmentally toxic at doses lower than those administered clinically.
 633 LAMICTAL XR should be used during pregnancy only if the potential benefit justifies the
 634 potential risk to the fetus.

635 When lamotrigine was administered to pregnant mice, rats, or rabbits during the period of
 636 organogenesis (oral doses of up to 125, 25, and 30 mg/kg, respectively), reduced fetal body
 637 weight and increased incidences of fetal skeletal variations were seen in mice and rats at doses
 638 that were also maternally toxic. The no-effect doses for embryo-fetal developmental toxicity in
 639 mice, rats, and rabbits (75, 6.25, and 30 mg/kg, respectively) are similar to (mice and rabbits) or
 640 less than the human dose of 400 mg/day on a body surface area (mg/m²) basis.

641 In a study in which pregnant rats were administered lamotrigine (oral doses of 5 or 25
 642 mg/kg) during the period of organogenesis and offspring were evaluated postnatally, behavioral
 643 abnormalities were observed in exposed offspring at both doses. The lowest effect dose for
 644 developmental neurotoxicity in rats is less than the human dose of 400 mg/day on a mg/m² basis.
 645 Maternal toxicity was observed at the higher dose tested.

646 When pregnant rats were administered lamotrigine (oral doses of 5, 10, or 20 mg/kg)
 647 during the latter part of gestation, increased offspring mortality (including stillbirths) was seen at
 648 all doses. The lowest effect dose for peri/postnatal developmental toxicity in rats is less than the
 649 human dose of 400 mg/day on a mg/m² basis. Maternal toxicity was observed at the two highest
 650 doses tested.

651 Lamotrigine decreases fetal folate concentrations in rat, an effect known to be associated
652 with adverse pregnancy outcomes in animals and humans.

653 **Pregnancy Registry:** To provide information regarding the effects of in utero exposure
654 to LAMICTAL XR, physicians are advised to recommend that pregnant patients taking
655 LAMICTAL XR enroll in the North American Antiepileptic Drug (NAAED) Pregnancy
656 Registry. This can be done by calling the toll-free number 1-888-233-2334, and must be done by
657 patients themselves. Information on the registry can also be found at the website
658 <http://www.aedpregnancyregistry.org>.

659 **8.2 Labor and Delivery**

660 The effect of LAMICTAL XR on labor and delivery in humans is unknown.

661 **8.3 Nursing Mothers**

662 Preliminary data indicate that lamotrigine is excreted in human milk. Caution should be
663 exercised when LAMICTAL XR is administered to a nursing woman.

664 **8.4 Pediatric Use**

665 LAMICTAL XR is indicated as adjunctive therapy for PGTC and partial onset seizures
666 with or without secondary generalization in patients ≥ 13 years of age. Safety and effectiveness of
667 LAMICTAL XR for any use in patients less than 13 years of age have not been established.

668 Immediate-release lamotrigine is indicated for adjunctive therapy in patients ≥ 2 years of
669 age for partial seizures, the generalized seizures of Lennox-Gastaut syndrome, and PGTC
670 seizures.

671 Safety and efficacy of immediate-release lamotrigine, used as adjunctive treatment for
672 partial seizures, were not demonstrated in a small, randomized, double-blind, placebo-controlled
673 withdrawal study in very young pediatric patients (aged 1 to 24 months). Immediate-release
674 lamotrigine was associated with an increased risk for infectious adverse reactions (lamotrigine
675 37%, placebo 5%), and respiratory adverse reactions (lamotrigine 26%, placebo 5%). Infectious
676 adverse reactions included bronchiolitis, bronchitis, ear infection, eye infection, otitis externa,
677 pharyngitis, urinary tract infection, and viral infection. Respiratory adverse reactions included
678 nasal congestion, cough, and apnea.

679 In a juvenile animal study in which lamotrigine (oral doses of 5, 15, or 30 mg/kg) was
680 administered to young rats (postnatal days 7-62), decreased viability and growth were seen at the
681 highest dose tested and long-term behavioral abnormalities (decreased locomotor activity,
682 increased reactivity, and learning deficits in animals tested as adults) were observed at the two
683 highest doses. The no-effect dose for adverse effects on neurobehavioral development is less
684 than the human dose of 400 mg/day on a mg/m^2 basis.

685 **8.5 Geriatric Use**

686 Clinical studies of LAMICTAL XR for epilepsy did not include sufficient numbers of
687 subjects aged 65 years and over to determine whether they respond differently from younger
688 subjects or exhibit a different safety profile than that of younger patients. In general, dose
689 selection for an elderly patient should be cautious, usually starting at the low end of the dosing

690 range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of
691 concomitant disease or other drug therapy.

692 **8.6 Patients With Hepatic Impairment**

693 Experience in patients with hepatic impairment is limited. Based on a clinical
694 pharmacology study with immediate-release lamotrigine in 24 patients with mild, moderate, and
695 severe liver impairment [*see Clinical Pharmacology (12.3)*], the following general
696 recommendations can be made. No dosage adjustment is needed in patients with mild liver
697 impairment. Initial, escalation, and maintenance doses should generally be reduced by
698 approximately 25% in patients with moderate and severe liver impairment without ascites and
699 50% in patients with severe liver impairment with ascites. Escalation and maintenance doses
700 may be adjusted according to clinical response [*see Dosage and Administration (2.1)*].

701 **8.7 Patients With Renal Impairment**

702 Lamotrigine is metabolized mainly by glucuronic acid conjugation, with the majority of
703 the metabolites being recovered in the urine. In a small study comparing a single dose of
704 immediate-release lamotrigine in patients with varying degrees of renal impairment with healthy
705 volunteers, the plasma half-life of lamotrigine was approximately twice as long in the patients
706 with significant renal impairment [*see Clinical Pharmacology (12.3)*].

707 Initial doses of LAMICTAL XR should be based on patients' AED regimens; reduced
708 maintenance doses may be effective for patients with significant renal impairment. Few patients
709 with severe renal impairment have been evaluated during chronic treatment with lamotrigine.
710 Because there is inadequate experience in this population, LAMICTAL XR should be used with
711 caution in these patients [*see Dosage and Administration (2.1)*].

712 **10 OVERDOSAGE**

713 **10.1 Human Overdose Experience**

714 Overdoses involving quantities up to 15 g have been reported for immediate-release
715 lamotrigine, some of which have been fatal. Overdose has resulted in ataxia, nystagmus,
716 increased seizures, decreased level of consciousness, coma, and intraventricular conduction
717 delay.


718 **10.2 Management of Overdose**

719 There are no specific antidotes for lamotrigine. Following a suspected overdose,
720 hospitalization of the patient is advised. General supportive care is indicated, including frequent
721 monitoring of vital signs and close observation of the patient. If indicated, emesis should be
722 induced; usual precautions should be taken to protect the airway. It is uncertain whether
723 hemodialysis is an effective means of removing lamotrigine from the blood. In 6 renal failure
724 patients, about 20% of the amount of lamotrigine in the body was removed by hemodialysis
725 during a 4-hour session. A Poison Control Center should be contacted for information on the
726 management of overdosage of LAMICTAL XR.

727 **11 DESCRIPTION**

728 LAMICTAL XR (lamotrigine), an AED of the phenyltriazine class, is chemically
729 unrelated to existing AEDs. Its chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)-*as*-triazine,
730 its molecular formula is C₉H₇N₅Cl₂, and its molecular weight is 256.09. Lamotrigine is a white to
731 pale cream-colored powder and has a pK_a of 5.7. Lamotrigine is very slightly soluble in water
732 (0.17 mg/mL at 25°C) and slightly soluble in 0.1 M HCl (4.1 mg/mL at 25°C). The structural
733 formula is:

734



735

736

737 LAMICTAL XR Extended-Release Tablets are supplied for oral administration as 25-mg
738 (yellow with white center), 50-mg (green with white center), 100-mg (orange with white center),
739 200-mg (blue with white center), 250-mg (purple with white center), and 300-mg (gray with
740 white center) tablets. Each tablet contains the labeled amount of lamotrigine and the following
741 inactive ingredients: glycerol monostearate, hypromellose, lactose monohydrate; magnesium
742 stearate; methacrylic acid copolymer dispersion, polyethylene glycol 400, polysorbate 80, silicon
743 dioxide (25- and 50-mg tablets only), titanium dioxide, triethyl citrate, carmine (250-mg tablet
744 only), iron oxide black (50-, 250-, and 300-mg tablets only), iron oxide yellow (25-, 50-, 100-mg
745 tablets only), iron oxide red (100-mg tablet only), FD&C Blue No. 2 Aluminum Lake (200- and
746 250-mg tablets only). Tablets are printed with edible black ink.

747 LAMICTAL XR Extended-Release Tablets contain a modified-release eroding
748 formulation as the core. The tablets are coated with a clear enteric coat and have an aperture
749 drilled through the coats on both faces of the tablet (DiffCORE™) to enable a controlled release
750 of drug in the acidic environment of the stomach. The combination of this and the modified-
751 release core are designed to control the dissolution rate of lamotrigine over a period of
752 approximately 12 to 15 hours, leading to a gradual increase in serum lamotrigine levels.

753 **12 CLINICAL PHARMACOLOGY**

754 **12.1 Mechanism of Action**

755 The precise mechanism(s) by which lamotrigine exerts its anticonvulsant action is
756 unknown. In animal models designed to detect anticonvulsant activity, lamotrigine was effective
757 in preventing seizure spread in the maximum electroshock and pentylenetetrazol tests, and
758 prevented seizures in the visually and electrically evoked after-discharge tests for antiepileptic
759 activity. Lamotrigine also displayed inhibitory properties in a kindling model in rats both during
760 kindling development and in the fully kindled state. The relevance of these models to human
761 epilepsy, however, is not known.

762 One proposed mechanism of action of lamotrigine, the relevance of which remains to be
763 established in humans, involves an effect on sodium channels. In vitro pharmacological studies
764 suggest that lamotrigine inhibits voltage-sensitive sodium channels, thereby stabilizing neuronal
765 membranes and consequently modulating presynaptic transmitter release of excitatory amino
766 acids (e.g., glutamate and aspartate).

767 Effect of Lamotrigine on N-Methyl d-Aspartate-Receptor Mediated Activity:

768 Lamotrigine did not inhibit N-methyl d-aspartate (NMDA)-induced depolarizations in rat cortical
769 slices or NMDA-induced cyclic GMP formation in immature rat cerebellum, nor did lamotrigine
770 displace compounds that are either competitive or noncompetitive ligands at this glutamate
771 receptor complex (CNQX, CGS, TCHP). The IC₅₀ for lamotrigine effects on NMDA-induced
772 currents (in the presence of 3 μM of glycine) in cultured hippocampal neurons exceeded
773 100 μM.

774 **12.2 Pharmacodynamics**

775 Folate Metabolism: In vitro, lamotrigine inhibited dihydrofolate reductase, the enzyme
776 that catalyzes the reduction of dihydrofolate to tetrahydrofolate. Inhibition of this enzyme may
777 interfere with the biosynthesis of nucleic acids and proteins. When oral daily doses of
778 lamotrigine were given to pregnant rats during organogenesis, fetal, placental, and maternal
779 folate concentrations were reduced. Significantly reduced concentrations of folate are associated
780 with teratogenesis [see *Use in Specific Populations (8.1)*]. Folate concentrations were also
781 reduced in male rats given repeated oral doses of lamotrigine. Reduced concentrations were
782 partially returned to normal when supplemented with folic acid.

783 Cardiovascular: In dogs, lamotrigine is extensively metabolized to a 2-N-methyl
784 metabolite. This metabolite causes dose-dependent prolongation of the PR interval, widening of
785 the QRS complex, and, at higher doses, complete AV conduction block. Similar cardiovascular
786 effects are not anticipated in humans because only trace amounts of the 2-N-methyl metabolite
787 (<0.6% of lamotrigine dose) have been found in human urine [see *Clinical Pharmacology*
788 (12.3)]. However, it is conceivable that plasma concentrations of this metabolite could be
789 increased in patients with a reduced capacity to glucuronidate lamotrigine (e.g., in patients with
790 liver disease, patients taking concomitant medications that inhibit glucuronidation).

791 **12.3 Pharmacokinetics**

792 In comparison to immediate-release lamotrigine, the plasma lamotrigine levels following
793 administration of LAMICTAL XR are not associated with any significant changes in trough
794 plasma concentrations, and are characterized by lower peaks, longer time to peaks, and lower
795 peak-to-trough fluctuation, as described in detail below.

796 Absorption: Lamotrigine is absorbed after oral administration with negligible first-pass
797 metabolism. The bioavailability of lamotrigine is not affected by food.

798 In an open-label, crossover study of 44 subjects with epilepsy receiving concomitant
799 AEDs, the steady-state pharmacokinetics of lamotrigine were compared following administration
800 of equivalent total doses of LAMICTAL XR given once daily with those of lamotrigine
801 immediate-release given twice daily. In this study, the median time to peak concentration (T_{max})

802 following administration of LAMICTAL XR was 4 to 6 hours in patients taking carbamazepine,
803 phenytoin, phenobarbital, or primidone; 9 to 11 hours in patients taking valproate; and 6 to 10
804 hours in patients taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone,
805 or valproate. In comparison, the median T_{max} following administration of immediate-release
806 lamotrigine was between 1 and 1.5 hours.

807 The steady-state trough concentrations for extended-release lamotrigine were similar to
808 or higher than those of immediate-release lamotrigine depending on concomitant AED (Table 6).
809 A mean reduction in the lamotrigine C_{max} by 11% to 29% was observed for LAMICTAL XR
810 compared to immediate-release lamotrigine, resulting in a decrease in the peak-to-trough
811 fluctuation in serum lamotrigine concentrations. However, in some subjects receiving enzyme-
812 inducing AEDs, a reduction in C_{max} of 44% to 77% was observed. The degree of fluctuation was
813 reduced by 17% in patients taking enzyme-inducing AEDs; 34% in patients taking valproate; and
814 37% in patients taking AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or
815 valproate. LAMICTAL XR and immediate-release lamotrigine regimens were similar with
816 respect to area under the curve (AUC, a measure of the extent of bioavailability) for patients
817 receiving AEDs other than those known to induce the metabolism of lamotrigine. The relative
818 bioavailability of extended-release lamotrigine was approximately 21% lower than immediate-
819 release lamotrigine in subjects receiving enzyme-inducing AEDs. However, a reduction in
820 exposure of up to 70% was observed in some subjects in this group when they switched to
821 LAMICTAL XR. Therefore, doses may need to be adjusted in some subjects based on
822 therapeutic response.

823

824 **Table 6. Steady-State Bioavailability of LAMICTAL XR Relative to Immediate-Release**
825 **Lamotrigine at Equivalent Daily Doses (Ratio of Extended-Release to Immediate-Release**
826 **90% CI)**

Concomitant Antiepileptic Drug	AUC _(0-24ss)	C_{max}	C_{min}
Enzyme-inducing antiepileptic drugs ^a	0.79 (0.69, 0.90)	0.71 (0.61, 0.82)	0.99 (0.89, 1.09)
Valproate	0.94 (0.81, 1.08)	0.88 (0.75, 1.03)	0.99 (0.88, 1.10)
Antiepileptic drugs other than enzyme-inducing antiepileptic drugs ^a or valproate	1.00 (0.88, 1.14)	0.89 (0.78, 1.03)	1.14 (1.03, 1.25)

827 ^a Enzyme-inducing antiepileptic drugs include carbamazepine, phenytoin, phenobarbital, and
828 primidone.

829

830 **Dose Proportionality:** In healthy volunteers not receiving any other medications and
831 given LAMICTAL XR once daily, the systemic exposure to lamotrigine increased in direct
832 proportion to the dose administered over the range of 50 to 200 mg. At doses between 25 and
833 50 mg, the increase was less than dose proportional, with a 2-fold increase in dose resulting in an
834 approximately 1.6-fold increase in systemic exposure.

835 **Distribution:** Estimates of the mean apparent volume of distribution (Vd/F) of
836 lamotrigine following oral administration ranged from 0.9 to 1.3 L/kg. Vd/F is independent of
837 dose and is similar following single and multiple doses in both patients with epilepsy and in
838 healthy volunteers.

839 **Protein Binding:** Data from in vitro studies indicate that lamotrigine is approximately
840 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL
841 (10 mcg/mL is 4 to 6 times the trough plasma concentration observed in the controlled efficacy
842 trials). Because lamotrigine is not highly bound to plasma proteins, clinically significant
843 interactions with other drugs through competition for protein binding sites are unlikely. The
844 binding of lamotrigine to plasma proteins did not change in the presence of therapeutic
845 concentrations of phenytoin, phenobarbital, or valproate. Lamotrigine did not displace other
846 AEDs (carbamazepine, phenytoin, phenobarbital) from protein-binding sites.

847 **Metabolism:** Lamotrigine is metabolized predominantly by glucuronic acid conjugation;
848 the major metabolite is an inactive 2-N-glucuronide conjugate. After oral administration of
849 240 mg of ¹⁴C-lamotrigine (15 µCi) to 6 healthy volunteers, 94% was recovered in the urine and
850 2% was recovered in the feces. The radioactivity in the urine consisted of unchanged lamotrigine
851 (10%), the 2-N-glucuronide (76%), a 5-N-glucuronide (10%), a 2-N-methyl metabolite (0.14%),
852 and other unidentified minor metabolites (4%).

853 **Enzyme Induction:** The effects of lamotrigine on the induction of specific families of
854 mixed-function oxidase isozymes have not been systematically evaluated.

855 Following multiple administrations (150 mg twice daily) to normal volunteers taking no
856 other medications, lamotrigine induced its own metabolism, resulting in a 25% decrease in t_{1/2} and
857 a 37% increase in CL/F at steady state compared with values obtained in the same volunteers
858 following a single dose. Evidence gathered from other sources suggests that self-induction by
859 lamotrigine may not occur when lamotrigine is given as adjunctive therapy in patients receiving
860 enzyme-inducing drugs such as carbamazepine, phenytoin, phenobarbital, primidone, or other
861 drugs such as rifampin that induce lamotrigine glucuronidation [*see Drug Interactions (7)*].

862 **Elimination:** The elimination half-life and apparent clearance of lamotrigine following
863 oral administration of immediate-release lamotrigine to adult patients with epilepsy and healthy
864 volunteers is summarized in Table 7. Half-life and apparent clearance vary depending on
865 concomitant AEDs.

866 Since the half-life of lamotrigine following administration of single doses of immediate-
867 release lamotrigine is comparable to that observed following administration of LAMICTAL XR,
868 similar changes in the half-life of lamotrigine would be expected for LAMICTAL XR.
869

870 **Table 7. Mean^a Pharmacokinetic Parameters of Immediate-Release Lamotrigine in**
 871 **Healthy Volunteers and Adult Patients With Epilepsy**

Adult Study Population	Number of Subjects	t _{1/2} : Elimination Half-life (hr)	CL/F: Apparent Plasma Clearance (mL/min/kg)
Healthy volunteers taking no other medications:			
Single-dose lamotrigine	179	32.8 (14.0-103.0)	0.44 (0.12-1.10)
Multiple-dose lamotrigine	36	25.4 (11.6-61.6)	0.58 (0.24-1.15)
Healthy volunteers taking valproate:			
Single-dose lamotrigine	6	48.3 (31.5-88.6)	0.30 (0.14-0.42)
Multiple-dose lamotrigine	18	70.3 (41.9-113.5)	0.18 (0.12-0.33)
Patients with epilepsy taking valproate only:			
Single-dose lamotrigine	4	58.8 (30.5-88.8)	0.28 (0.16-0.40)
Patients with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone^b plus valproate:			
Single-dose lamotrigine	25	27.2 (11.2-51.6)	0.53 (0.27-1.04)
Patients with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone:^b			
Single-dose lamotrigine	24	14.4 (6.4-30.4)	1.10 (0.51-2.22)
Multiple-dose lamotrigine	17	12.6 (7.5-23.1)	1.21 (0.66-1.82)

872 ^a The majority of parameter means determined in each study had coefficients of variation
 873 between 20% and 40% for half-life and CL/F and between 30% and 70% for T_{max}. The
 874 overall mean values were calculated from individual study means that were weighted based
 875 on the number of volunteers/patients in each study. The numbers in parentheses below each
 876 parameter mean represent the range of individual volunteer/patient values across studies.

877 ^b Carbamazepine, phenobarbital, phenytoin, and primidone have been shown to increase the
 878 apparent clearance of lamotrigine. Estrogen-containing oral contraceptives and other drugs
 879 such as rifampin that induce lamotrigine glucuronidation have also been shown to increase
 880 the apparent clearance of lamotrigine [see Drug Interactions (7)].

881
 882 **Drug Interactions:** The apparent clearance of lamotrigine is affected by the
 883 coadministration of certain medications [see Warnings and Precautions (5.8, 5.12), Drug
 884 Interactions (7)].

885 The net effects of drug interactions with lamotrigine are summarized in Table 8. Details
 886 of the drug interaction studies, which were done using immediate-release lamotrigine, are
 887 provided in Table 8.

888
 889

Table 8. Summary of Drug Interactions With Lamotrigine

Drug	Drug Plasma Concentration With Adjunctive Lamotrigine ^a	Lamotrigine Plasma Concentration With Adjunctive Drugs ^b
Oral contraceptives (e.g., ethinylestradiol/levonorgestrel ^c)	↔ ^d	↓
Bupropion	Not assessed	↔
Carbamazepine	↔	↓
Carbamazepine epoxide ^e	?	
Felbamate	Not assessed	↔
Gabapentin	Not assessed	↔
Levetiracetam	↔	↔
Lithium	↔	Not assessed
Olanzapine	↔	↔ ^f
Oxcarbazepine	↔	↔
10-monohydroxy oxcarbazepine metabolite ^g	↔	
Phenobarbital/primidone	↔	↓
Phenytoin	↔	↓
Pregabalin	↔	↔
Rifampin	Not assessed	↓
Topiramate	↔ ^h	↔
Valproate	↓	↑
Valproate + phenytoin and/or carbamazepine	Not assessed	↔
Zonisamide	Not assessed	↔

890 ^a From adjunctive clinical trials and volunteer studies.

- 891 ^b Net effects were estimated by comparing the mean clearance values obtained in adjunctive
892 clinical trials and volunteer studies.
- 893 ^c The effect of other hormonal contraceptive preparations or hormone replacement therapy on
894 the pharmacokinetics of lamotrigine has not been systematically evaluated in clinical trials,
895 although the effect may be similar to that seen with the ethinylestradiol/levonorgestrel
896 combinations.
- 897 ^d Modest decrease in levonorgestrel.
- 898 ^e Not administered, but an active metabolite of carbamazepine.
- 899 ^f Slight decrease, not expected to be clinically relevant.
- 900 ^g Not administered, but an active metabolite of oxcarbazepine.
- 901 ^h Slight increase, not expected to be clinically relevant.
- 902 ↔ = No significant effect.
- 903 ? = Conflicting data.
- 904

905 Estrogen-Containing Oral Contraceptives: In 16 female volunteers, an oral
906 contraceptive preparation containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel
907 increased the apparent clearance of lamotrigine (300 mg/day) by approximately 2-fold with mean
908 decreases in AUC of 52% and in C_{max} of 39%. In this study, trough serum lamotrigine
909 concentrations gradually increased and were approximately 2-fold higher on average at the end
910 of the week of the inactive hormone preparation compared with trough lamotrigine
911 concentrations at the end of the active hormone cycle.

912 Gradual transient increases in lamotrigine plasma levels (approximate 2-fold increase)
913 occurred during the week of inactive hormone preparation (pill-free week) for women not also
914 taking a drug that increased the clearance of lamotrigine (carbamazepine, phenytoin,
915 phenobarbital, primidone, or other drugs such as rifampin that induce lamotrigine
916 glucuronidation) [see *Drug Interactions (7)*]. The increase in lamotrigine plasma levels will be
917 greater if the dose of LAMICTAL XR is increased in the few days before or during the pill-free
918 week. Increases in lamotrigine plasma levels could result in dose-dependent adverse reactions.

919 In the same study, coadministration of lamotrigine (300 mg/day) in 16 female volunteers
920 did not affect the pharmacokinetics of the ethinylestradiol component of the oral contraceptive
921 preparation. There were mean decreases in the AUC and C_{max} of the levonorgestrel component of
922 19% and 12%, respectively. Measurement of serum progesterone indicated that there was no
923 hormonal evidence of ovulation in any of the 16 volunteers, although measurement of serum
924 FSH, LH, and estradiol indicated that there was some loss of suppression of the hypothalamic-
925 pituitary-ovarian axis.

926 The effects of doses of lamotrigine other than 300 mg/day have not been systematically
927 evaluated in controlled clinical trials.

928 The clinical significance of the observed hormonal changes on ovulatory activity is
929 unknown. However, the possibility of decreased contraceptive efficacy in some patients cannot

930 be excluded. Therefore, patients should be instructed to promptly report changes in their
931 menstrual pattern (e.g., break-through bleeding).

932 Dosage adjustments may be necessary for women receiving estrogen-containing oral
933 contraceptive preparations [see *Dosage and Administration (2.1)*].

934 **Other Hormonal Contraceptives or Hormone Replacement Therapy:** The effect of
935 other hormonal contraceptive preparations or hormone replacement therapy on the
936 pharmacokinetics of lamotrigine has not been systematically evaluated. It has been reported that
937 ethinylestradiol, not progestogens, increased the clearance of lamotrigine up to 2-fold, and the
938 progestin-only pills had no effect on lamotrigine plasma levels. Therefore, adjustments to the
939 dosage of LAMICTAL XR in the presence of progestogens alone will likely not be needed.

940 **Bupropion:** The pharmacokinetics of a 100-mg single dose of lamotrigine in healthy
941 volunteers (n = 12) were not changed by coadministration of bupropion sustained-release
942 formulation (150 mg twice daily) starting 11 days before lamotrigine.

943 **Carbamazepine:** Lamotrigine has no appreciable effect on steady-state carbamazepine
944 plasma concentration. Limited clinical data suggest there is a higher incidence of dizziness,
945 diplopia, ataxia, and blurred vision in patients receiving carbamazepine with lamotrigine than in
946 patients receiving other AEDs with lamotrigine [see *Adverse Reactions (6.1)*]. The mechanism
947 of this interaction is unclear. The effect of lamotrigine on plasma concentrations of
948 carbamazepine-epoxide is unclear. In a small subset of patients (n = 7) studied in a placebo-
949 controlled trial, lamotrigine had no effect on carbamazepine-epoxide plasma concentrations, but
950 in a small, uncontrolled study (n = 9), carbamazepine-epoxide levels increased.

951 The addition of carbamazepine decreases lamotrigine steady-state concentrations by
952 approximately 40%.

953 **Esomeprazole:** In a study of 30 subjects, coadministration of LAMICTAL XR with
954 esomeprazole resulted in no significant change in lamotrigine levels and a small decrease in T_{max} .
955 The levels of gastric pH were not altered compared with pre-lamotrigine dosing.

956 **Felbamate:** In a study of 21 healthy volunteers, coadministration of felbamate (1,200 mg
957 twice daily) with lamotrigine (100 mg twice daily for 10 days) appeared to have no clinically
958 relevant effects on the pharmacokinetics of lamotrigine.

959 **Folate Inhibitors:** Lamotrigine is a weak inhibitor of dihydrofolate reductase. Prescribers
960 should be aware of this action when prescribing other medications that inhibit folate metabolism.

961 **Gabapentin:** Based on a retrospective analysis of plasma levels in 34 patients who
962 received lamotrigine both with and without gabapentin, gabapentin does not appear to change the
963 apparent clearance of lamotrigine.

964 **Levetiracetam:** Potential drug interactions between levetiracetam and lamotrigine were
965 assessed by evaluating serum concentrations of both agents during placebo-controlled clinical
966 trials. These data indicate that lamotrigine does not influence the pharmacokinetics of
967 levetiracetam and that levetiracetam does not influence the pharmacokinetics of lamotrigine.

968 **Lithium:** The pharmacokinetics of lithium were not altered in healthy subjects (n = 20) by
969 coadministration of lamotrigine (100 mg/day) for 6 days.

970 Olanzapine: The AUC and C_{\max} of olanzapine were similar following the addition of
971 olanzapine (15 mg once daily) to lamotrigine (200 mg once daily) in healthy male volunteers (n
972 = 16) compared with the AUC and C_{\max} in healthy male volunteers receiving olanzapine alone (n
973 = 16).

974 In the same study, the AUC and C_{\max} of lamotrigine were reduced on average by 24%
975 and 20%, respectively, following the addition of olanzapine to lamotrigine in healthy male
976 volunteers compared with those receiving lamotrigine alone. This reduction in lamotrigine
977 plasma concentrations is not expected to be clinically relevant.

978 Oxcarbazepine: The AUC and C_{\max} of oxcarbazepine and its active 10-monohydroxy
979 oxcarbazepine metabolite were not significantly different following the addition of
980 oxcarbazepine (600 mg twice daily) to lamotrigine (200 mg once daily) in healthy male
981 volunteers (n = 13) compared with healthy male volunteers receiving oxcarbazepine alone
982 (n = 13).

983 In the same study, the AUC and C_{\max} of lamotrigine were similar following the addition
984 of oxcarbazepine (600 mg twice daily) to lamotrigine in healthy male volunteers compared with
985 those receiving lamotrigine alone. Limited clinical data suggest a higher incidence of headache,
986 dizziness, nausea, and somnolence with coadministration of lamotrigine and oxcarbazepine
987 compared with lamotrigine alone or oxcarbazepine alone.

988 Phenobarbital, Primidone: The addition of phenobarbital or primidone decreases
989 lamotrigine steady-state concentrations by approximately 40%.

990 Phenytoin: Lamotrigine has no appreciable effect on steady-state phenytoin plasma
991 concentrations in patients with epilepsy. The addition of phenytoin decreases lamotrigine steady-
992 state concentrations by approximately 40%.

993 Pregabalin: Steady-state trough plasma concentrations of lamotrigine were not affected
994 by concomitant pregabalin (200 mg 3 times daily) administration. There are no pharmacokinetic
995 interactions between lamotrigine and pregabalin.

996 Rifampin: In 10 male volunteers, rifampin (600 mg/day for 5 days) significantly
997 increased the apparent clearance of a single 25-mg dose of lamotrigine by approximately 2-fold
998 (AUC decreased by approximately 40%).

999 Topiramate: Topiramate resulted in no change in plasma concentrations of lamotrigine.
1000 Administration of lamotrigine resulted in a 15% increase in topiramate concentrations.

1001 Valproate: When lamotrigine was administered to healthy volunteers (n = 18) receiving
1002 valproate, the trough steady-state valproate plasma concentrations decreased by an average of
1003 25% over a 3-week period, and then stabilized. However, adding lamotrigine to the existing
1004 therapy did not cause a change in valproate plasma concentrations in either adult or pediatric
1005 patients in controlled clinical trials.

1006 The addition of valproate increased lamotrigine steady-state concentrations in normal
1007 volunteers by slightly more than 2-fold. In one study, maximal inhibition of lamotrigine
1008 clearance was reached at valproate doses between 250 and 500 mg/day and did not increase as
1009 the valproate dose was further increased.

1010 **Zonisamide:** In a study of 18 patients with epilepsy, coadministration of zonisamide
1011 (200 to 400 mg/day) with lamotrigine (150 to 500 mg/day for 35 days) had no significant effect
1012 on the pharmacokinetics of lamotrigine.

1013 **Known Inducers or Inhibitors of Glucuronidation:** Drugs other than those listed above
1014 have not been systematically evaluated in combination with lamotrigine. Since lamotrigine is
1015 metabolized predominately by glucuronic acid conjugation, drugs that are known to induce or
1016 inhibit glucuronidation may affect the apparent clearance of lamotrigine, and doses of
1017 LAMICTAL XR may require adjustment based on clinical response.

1018 **Other:** Results of in vitro experiments suggest that clearance of lamotrigine is unlikely to
1019 be reduced by concomitant administration of amitriptyline, clonazepam, clozapine, fluoxetine,
1020 haloperidol, lorazepam, phenelzine, risperidone, sertraline, or trazodone.

1021 Results of in vitro experiments suggest that lamotrigine does not reduce the clearance of
1022 drugs eliminated predominantly by CYP2D6.

1023 **Special Populations: Patients With Renal Impairment:** Twelve volunteers with
1024 chronic renal failure (mean creatinine clearance: 13 mL/min, range: 6 to 23) and another 6
1025 individuals undergoing hemodialysis were each given a single 100-mg dose of immediate-release
1026 lamotrigine. The mean plasma half-lives determined in the study were 42.9 hours (chronic renal
1027 failure), 13.0 hours (during hemodialysis), and 57.4 hours (between hemodialysis) compared
1028 with 26.2 hours in healthy volunteers. On average, approximately 20% (range: 5.6 to 35.1) of the
1029 amount of lamotrigine present in the body was eliminated by hemodialysis during a 4-hour
1030 session [*see Dosage and Administration (2.1)*].

1031 **Hepatic Disease:** The pharmacokinetics of lamotrigine following a single 100-mg
1032 dose of immediate-release lamotrigine were evaluated in 24 subjects with mild, moderate, and
1033 severe hepatic impairment (Child-Pugh Classification system) and compared with 12 subjects
1034 without hepatic impairment. The patients with severe hepatic impairment were without ascites
1035 (n = 2) or with ascites (n = 5). The mean apparent clearances of lamotrigine in patients with mild
1036 (n = 12), moderate (n = 5), severe without ascites (n = 2), and severe with ascites (n = 5) liver
1037 impairment were 0.30 ± 0.09 , 0.24 ± 0.1 , 0.21 ± 0.04 , and 0.15 ± 0.09 mL/min/kg, respectively,
1038 as compared with 0.37 ± 0.1 mL/min/kg in the healthy controls. Mean half-lives of lamotrigine
1039 in patients with mild, moderate, severe without ascites, and severe with ascites hepatic
1040 impairment were 46 ± 20 , 72 ± 44 , 67 ± 11 , and 100 ± 48 hours, respectively, as compared with
1041 33 ± 7 hours in healthy controls [*see Dosage and Administration (2.1)*].

1042 **Elderly:** The pharmacokinetics of lamotrigine following a single 150-mg dose of
1043 immediate-release lamotrigine were evaluated in 12 elderly volunteers between the ages of 65
1044 and 76 years (mean creatinine clearance: 61 mL/min, range: 33 to 108 mL/min). The mean half-
1045 life of lamotrigine in these subjects was 31.2 hours (range: 24.5 to 43.4 hours), and the mean
1046 clearance was 0.40 mL/min/kg (range: 0.26 to 0.48 mL/min/kg).

1047 **Gender:** The clearance of lamotrigine is not affected by gender. However, during
1048 dose escalation of immediate-release lamotrigine in one clinical trial in patients with epilepsy on

1049 a stable dose of valproate (n = 77), mean trough lamotrigine concentrations, unadjusted for
1050 weight, were 24% to 45% higher (0.3 to 1.7 mcg/mL) in females than in males.

1051 *Race:* The apparent oral clearance of lamotrigine was 25% lower in non-Caucasians
1052 than Caucasians.

1053 *Pediatric Patients:* Safety and effectiveness of LAMICTAL XR for use in patients
1054 less than 13 years of age have not been established.

1055 **13 NONCLINICAL TOXICOLOGY**

1056 **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

1057 No evidence of carcinogenicity was seen in mouse or rat following oral administration of
1058 lamotrigine for up to 2 years at doses up to 30 mg/kg/day and 10 to 15 mg/kg/day in mouse and
1059 rat, respectively. The highest doses tested are less than the human dose of 400 mg/day on a body
1060 surface area (mg/m²) basis.

1061 Lamotrigine was negative in *in vitro* gene mutation (Ames and mouse lymphoma *tk*)
1062 assays and in clastogenicity (*in vitro* human lymphocyte and *in vivo* rat bone marrow) assays.

1063 No evidence of impaired fertility was detected in rats given oral doses of lamotrigine up
1064 to 20 mg/kg/day. The highest dose tested is less than the human dose of 400 mg/day on a mg/m²
1065 basis.

1066 **14 CLINICAL STUDIES**

1067 **14.1 Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures**

1068 The effectiveness of LAMICTAL XR as adjunctive therapy was established in PGTC
1069 seizures in a 19-week, international, multicenter, double-blind, randomized, placebo-controlled
1070 study in 143 patients 13 years of age and older (n = 70 on LAMICTAL XR and n = 73 on
1071 placebo). Patients with at least 3 PGTC seizures during an 8-week baseline phase were
1072 randomized to 19 weeks of treatment with LAMICTAL XR or placebo added to their current
1073 AED regimen of up to 2 drugs. Patients were dosed on a fixed-dose regimen, with target doses
1074 ranging from 200 to 500 mg/day of LAMICTAL XR based on concomitant AED(s) (target dose
1075 = 200 mg for valproate, 300 mg for AEDs not altering plasma lamotrigine levels, and 500 mg for
1076 enzyme-inducing AEDs).


1077 The primary efficacy endpoint was percent change from baseline in PGTC seizure
1078 frequency during the double-blind treatment phase. For the intent-to-treat population, the median
1079 percent reduction in PGTC seizure frequency was 75% in patients treated with LAMICTAL XR
1080 and 32% in patients treated with placebo, a difference that was statistically significant, defined as
1081 a 2-sided *P* value ≤ 0.05 .

1082 Figure 1 presents the percentage of patients (X-axis) with a percent reduction in PGTC
1083 seizure frequency (responder rate) from baseline through the entire treatment period at least as
1084 great as that represented on the Y-axis. A positive value on the Y-axis indicates an improvement
1085 from baseline (i.e., a decrease in seizure frequency), while a negative value indicates a worsening
1086 from baseline (i.e., an increase in seizure frequency). Thus, in a display of this type, a curve for
1087 an effective treatment is shifted to the left of the curve for placebo. The proportion of patients

1088 achieving any particular level of reduction in PGTC seizure frequency was consistently higher
1089 for the group treated with LAMICTAL XR compared with the placebo group. For example, 70%
1090 of patients randomized to LAMICTAL XR experienced a 50% or greater reduction in PGTC
1091 seizure frequency, compared with 32% of patients randomized to placebo. Patients with an
1092 increase in seizure frequency >100% are represented on the Y-axis as equal to or greater than
1093 -100%.

1094
1095
1096

Figure 1. Proportion of Patients by Responder Rate for LAMICTAL XR and Placebo Group (Primary Generalized Tonic-Clonic Seizures Study)



1097

1098 **14.2 Adjunctive Therapy for Partial Onset Seizures**

1099 The effectiveness of immediate-release lamotrigine as adjunctive therapy was initially
1100 established in 3 pivotal, multicenter, placebo-controlled, double-blind clinical trials in 355 adults
1101 with refractory partial onset seizures.

1102 The effectiveness of LAMICTAL XR as adjunctive therapy in partial onset seizures, with
1103 or without secondary generalization, was established in a 19-week, multicenter, double-blind,
1104 placebo-controlled trial in 236 patients 13 years of age and older (approximately 93% of patients
1105 were aged 16 to 65 years). Approximately 36% were from the U.S. and approximately 64% were
1106 from other countries including Argentina, Brazil, Chile, Germany, India, Korea, Russian
1107 Federation, and Ukraine. Patients with at least 8 partial onset seizures during an 8-week
1108 prospective baseline phase (or 4-week prospective baseline coupled with a 4-week historical


1109 baseline documented with seizure diary data) were randomized to treatment with
1110 LAMICTAL XR (n = 116) or placebo (n = 120) added to their current regimen of 1 or 2 AEDs.
1111 Approximately half of the patients were taking 2 concomitant AEDs at baseline. Target doses
1112 ranged from 200 to 500 mg/day of LAMICTAL XR based on concomitant AED (target dose =
1113 200 mg for valproate, 300 mg for AEDs not altering plasma lamotrigine, and 500 mg for
1114 enzyme-inducing AEDs). The median partial seizure frequency per week at baseline was 2.3 for
1115 LAMICTAL XR and 2.1 for placebo.

1116 The primary endpoint was the median percent change from baseline in partial onset
1117 seizure frequency during the entire double-blind treatment phase. The median percent reductions
1118 in weekly partial onset seizures were 47% in patients treated with LAMICTAL XR and 25% on
1119 placebo, a difference that was statistically significant, defined as a 2-sided *P* value ≤ 0.05 .

1120 Figure 2 presents the percentage of patients (X-axis) with a percent reduction in partial
1121 seizure frequency (responder rate) from baseline through the entire treatment period at least as
1122 great as that represented on the Y-axis. The proportion of patients achieving any particular level
1123 of reduction in partial seizure frequency was consistently higher for the group treated with
1124 LAMICTAL XR compared with the placebo group. For example, 44% of patients randomized to
1125 LAMICTAL XR experienced a 50% or greater reduction in partial seizure frequency compared
1126 with 21% of patients randomized to placebo.

1127

1128 **Figure 2. Proportion of Patients by Responder Rate for LAMICTAL XR and Placebo**
1129 **Group (Partial Onset Seizure Study)**



1130
1131

1132 **14.3 Conversion to Monotherapy for Partial Onset Seizures**

1133 The effectiveness of LAMICTAL XR as monotherapy for partial onset seizures was
1134 established in a historical-control trial in 223 adults with partial seizures. The historical control
1135 methodology is described in a publication by French, et al. [see References (15)]. Briefly, in this
1136 study, patients were randomized to ultimately receive either LAMICTAL XR 300 mg or 250 mg
1137 once a day, and their responses were compared to those of a historical control group. The
1138 historical control consisted of a pooled analysis of the control groups from 8 studies of similar
1139 design, which utilized a subtherapeutic dose of an AED as a comparator. Statistical superiority to
1140 the historical control was considered to be demonstrated if the upper 95% confidence interval for
1141 the proportion of patients meeting escape criteria in patients receiving LAMICTAL XR remained
1142 below the lower 95% prediction interval of 65.3% derived from the historical control data.

1143 In this study, patients ≥ 13 years of age experienced at least 4 partial seizures during an 8-
1144 week baseline period with at least 2 seizures occurring during each of 2 consecutive 4-week
1145 periods while receiving valproate or a non-enzyme-inducing AED. LAMICTAL XR was added
1146 to either valproate or a non-enzyme-inducing AED over a 6- to 7-week period followed by the
1147 gradual withdrawal of the background AED. Patients were then continued on monotherapy with
1148 LAMICTAL XR for 12 weeks. The escape criteria were one or more of the following:

1149 (1) doubling of average monthly seizure count during any 28 consecutive days, (2) doubling of
1150 highest consecutive 2-day seizure frequency during the entire treatment phase, (3) emergence of
1151 a new seizure type compared to baseline (4) clinically significant prolongation of generalized
1152 tonic-clonic seizures or worsening of seizure considered by the investigator to require
1153 intervention. These criteria were similar to those in the 8 controlled trials from which the
1154 historical control group was constituted.

1155 The upper 95% confidence limits of the proportion of subjects meeting escape criteria
1156 (40.2% at 300 mg/day and 44.5% at 250 mg/day) were below the threshold of 65.3% derived
1157 from the historical control data.

1158 Although the study population was not fully comparable to the historical controlled
1159 population and the study was not fully blinded, numerous sensitivity analyses supported the
1160 primary results. Efficacy was further supported by the established effectiveness of the
1161 immediate-release formulation as monotherapy.

1162 **15 REFERENCES**

1163 1. French JA, Wang S, Warnock B, Temkin N. Historical control monotherapy design in the
1164 treatment of epilepsy. *Epilepsia*. 2010; 51(10):1936-1943.

1165 **16 HOW SUPPLIED/STORAGE AND HANDLING**

1166 **LAMICTAL XR (lamotrigine) Extended-Release Tablets**

1167 25 mg, yellow with a white center, round, biconvex, film-coated tablets printed on one
1168 face in black ink with "LAMICTAL" and "XR 25", unit-of-use bottles of 30 with orange caps
1169 (NDC 0173-0754-00).

1170 50 mg, green with a white center, round, biconvex, film-coated tablets printed on one
1171 face in black ink with "LAMICTAL" and "XR 50", unit-of-use bottles of 30 with orange caps
1172 (NDC 0173-0755-00).

1173 100 mg, orange with a white center, round, biconvex, film-coated tablets printed on one
1174 face in black ink with "LAMICTAL" and "XR 100", unit-of-use bottles of 30 with orange caps
1175 (NDC 0173-0756-00).

1176 200 mg, blue with a white center, round, biconvex, film-coated tablets printed on one
1177 face in black ink with "LAMICTAL" and "XR 200", unit-of-use bottles of 30 with orange caps
1178 (NDC 0173-0757-00).

1179 250 mg, purple with a white center, caplet-shaped, film-coated tablets printed on one face
1180 in black ink with "LAMICTAL" and "XR 250", unit-of-use bottles of 30 with orange caps (NDC
1181 0173-0781-00).

1182 300 mg, gray with a white center, caplet-shaped, film-coated tablets printed on one face
1183 in black ink with "LAMICTAL" and "XR 300", unit-of-use bottles of 30 with orange caps (NDC
1184 0173-0761-00).

1185 **LAMICTAL XR (lamotrigine) Patient Titration Kit for Patients Taking Valproate**
1186 **(Blue XR Kit)**

1187 25 mg, yellow with a white center, round, biconvex, film-coated tablets printed on one
1188 face in black ink with “LAMICTAL” and “XR 25” and 50 mg, green with a white center, round,
1189 biconvex, film-coated tablets printed on one face in black ink with “LAMICTAL” and “XR 50”;
1190 blisterpack of 21/25-mg tablets and 7/50-mg tablets (NDC 0173-0758-00).

1191 **LAMICTAL XR (lamotrigine) Patient Titration Kit for Patients Taking**
1192 **Carbamazepine, Phenytoin, Phenobarbital, or Primidone, and Not Taking Valproate**
1193 **(Green XR Kit)**

1194 50 mg, green with a white center, round, biconvex, film-coated tablets printed on one
1195 face in black ink with “LAMICTAL” and “XR 50”; 100 mg, orange with a white center, round,
1196 biconvex, film-coated tablets printed on one face in black ink with “LAMICTAL” and “XR
1197 100”; and 200 mg, blue with a white center, round, biconvex, film-coated tablets printed on one
1198 face in black ink with “LAMICTAL” and “XR 200”; blisterpack of 14/50-mg tablets, 14/100-mg
1199 tablets, and 7/200-mg tablets (NDC 0173-0759-00).

1200 **LAMICTAL XR (lamotrigine) Patient Titration Kit for Patients Not Taking**
1201 **Carbamazepine, Phenytoin, Phenobarbital, Primidone, or Valproate (Orange XR Kit)**

1202 25 mg, yellow with a white center, round, biconvex, film-coated tablets printed on one
1203 face in black ink with “LAMICTAL” and “XR 25”; 50 mg, green with a white center, round,
1204 biconvex, film-coated tablets printed on one face in black ink with “LAMICTAL” and “XR 50”;
1205 and 100 mg, orange with a white center, round, biconvex, film-coated tablets printed on one face
1206 in black ink with “LAMICTAL” and “XR 100”; blisterpack of 14/25-mg tablets, 14/50-mg
1207 tablets, and 7/100-mg tablets (NDC 0173-0760-00).

1208 **Storage:** Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP
1209 Controlled Room Temperature].

1210 **17 PATIENT COUNSELING INFORMATION**

1211 *See FDA-approved patient labeling (Medication Guide).*

1212 **17.1 Rash**

1213 Prior to initiation of treatment with LAMICTAL XR, the patient should be instructed that
1214 a rash or other signs or symptoms of hypersensitivity (e.g., fever, lymphadenopathy) may herald
1215 a serious medical event and that the patient should report any such occurrence to a physician
1216 immediately.

1217 **17.2 Suicidal Thinking and Behavior**

1218 Patients, their caregivers, and families should be counseled that AEDs, including
1219 LAMICTAL XR, may increase the risk of suicidal thoughts and behavior and should be advised
1220 of the need to be alert for the emergence or worsening of symptoms of depression; any unusual
1221 changes in mood or behavior; or the emergence of suicidal thoughts, behavior, or thoughts about
1222 self-harm. Behaviors of concern should be reported immediately to healthcare providers.

1223 **17.3 Worsening of Seizures**

1224 Patients should be advised to notify their physicians if worsening of seizure control
1225 occurs.

1226 **17.4 Central Nervous System Adverse Effects**

1227 Patients should be advised that LAMICTAL XR may cause dizziness, somnolence, and
1228 other symptoms and signs of central nervous system depression. Accordingly, they should be
1229 advised neither to drive a car nor to operate other complex machinery until they have gained
1230 sufficient experience on LAMICTAL XR to gauge whether or not it adversely affects their
1231 mental and/or motor performance.

1232 **17.5 Blood Dyscrasias and/or Acute Multiorgan Failure**

1233 Patients should be advised of the possibility of blood dyscrasias and/or acute multiorgan
1234 failure and to contact their physician immediately if they experience any signs or symptoms of
1235 these conditions [*see Warnings and Precautions (5.3, 5.4)*].

1236 **17.6 Pregnancy**

1237 Patients should be advised to notify their physicians if they become pregnant or intend to
1238 become pregnant during therapy. Patients should be advised to notify their physicians if they
1239 intend to breastfeed or are breastfeeding an infant.

1240 Patients should also be encouraged to enroll in the NAAED Pregnancy Registry if they
1241 become pregnant. This registry is collecting information about the safety of antiepileptic drugs
1242 during pregnancy. To enroll, patients can call the toll-free number 1-888-233-2334 [*see Use in*
1243 *Specific Populations (8.1)*].

1244 **17.7 Oral Contraceptive Use**

1245 Women should be advised to notify their physicians if they plan to start or stop use of
1246 oral contraceptives or other female hormonal preparations. Starting estrogen-containing oral
1247 contraceptives may significantly decrease lamotrigine plasma levels and stopping estrogen-
1248 containing oral contraceptives (including the pill-free week) may significantly increase
1249 lamotrigine plasma levels [*see Warnings and Precautions (5.8), Clinical Pharmacology (12.3)*].
1250 Women should also be advised to promptly notify their physicians if they experience adverse
1251 reactions or changes in menstrual pattern (e.g., break-through bleeding) while receiving
1252 LAMICTAL XR in combination with these medications.

1253 **17.8 Discontinuing LAMICTAL XR**

1254 Patients should be advised to notify their physicians if they stop taking LAMICTAL XR
1255 for any reason and not to resume LAMICTAL XR without consulting their physicians.

1256 **17.9 Aseptic Meningitis**

1257 Patients should be advised that LAMICTAL XR may cause aseptic meningitis. Patients
1258 should be advised to notify their physicians immediately if they develop signs and symptoms of
1259 meningitis such as headache, fever, nausea, vomiting, stiff neck, rash, abnormal sensitivity to
1260 light, myalgia, chills, confusion, or drowsiness while taking LAMICTAL XR.

1261 **17.10 Potential Medication Errors**

1262 Medication errors involving LAMICTAL have occurred. In particular the names
1263 LAMICTAL or lamotrigine can be confused with the names of other commonly used
1264 medications. Medication errors may also occur between the different formulations of
1265 LAMICTAL. To reduce the potential of medication errors, write and say LAMICTAL XR

1266 clearly. Depictions of the LAMICTAL XR Extended-Release Tablets can be found in the
1267 Medication Guide. Each LAMICTAL XR tablet has a distinct color and white center, and is
1268 printed with “LAMICTAL XR” and the tablet strength. These distinctive features serve to
1269 identify the different presentations of the drug and thus may help reduce the risk of medication
1270 errors. LAMICTAL XR is supplied in round, unit-of-use bottles with orange caps containing 30
1271 tablets. The label on the bottle includes a depiction of the tablets that further communicates to
1272 patients and pharmacists that the medication is LAMICTAL XR and the specific tablet strength
1273 included in the bottle. The unit-of-use bottle with a distinctive orange cap and distinctive bottle
1274 label features serves to identify the different presentations of the drug and thus may help to
1275 reduce the risk of medication errors. **To avoid a medication error of using the wrong drug or**
1276 **formulation, patients should be strongly advised to visually inspect their tablets to verify**
1277 **that they are LAMICTAL XR each time they fill their prescription and to immediately talk**
1278 **to their doctor/pharmacist if they receive a LAMICTAL XR tablet without a white center**
1279 **and without “LAMICTAL XR” and the strength printed on the tablet as they may have**
1280 **received the wrong medication** [see *Dosage Forms and Strengths (3), How Supplied/Storage*
1281 *and Handling (16)*].

1282
1283 LAMICTAL XR and DiffCORE are trademarks of GlaxoSmithKline.

1284
1285



GlaxoSmithKline

1286
1287 GlaxoSmithKline
1288 Research Triangle Park, NC 27709

1289
1290 ©2011, GlaxoSmithKline. All rights reserved.

1291
1292 Month Year
1293 LXR:xPI

1294
1295

1296 MEDICATION GUIDE

1297
1298 LAMICTAL[®] (la-MIK-tal) XR[™]
1299 (lamotrigine)
1300 Extended-Release Tablets

1301

1302 Read this Medication Guide before you start taking LAMICTAL XR and each time you get a
1303 refill. There may be new information. This information does not take the place of talking with

1304 your healthcare provider about your medical condition or treatment. If you have questions about
1305 LAMICTAL XR, ask your healthcare provider or pharmacist.

1306

1307 **What is the most important information I should know about LAMICTAL XR?**

1308 **1. LAMICTAL XR may cause a serious skin rash that may cause you to be hospitalized or**
1309 **even cause death.**

1310 There is no way to tell if a mild rash will become more serious. A serious skin rash can
1311 happen at any time during your treatment with LAMICTAL XR, but is more likely to happen
1312 within the first 2 to 8 weeks of treatment. Children between 2 to 16 years of age have a
1313 higher chance of getting this serious skin rash while taking LAMICTAL XR. LAMICTAL
1314 XR is not approved for use in children less than 13 years old.

1315 The risk of getting a serious skin rash is higher if you:

- 1316 • take LAMICTAL XR while taking valproate [DEPAKENE® (valproic acid) or
1317 DEPAKOTE® (divalproex sodium)].
- 1318 • take a higher starting dose of LAMICTAL XR than your healthcare provider prescribed.
- 1319 • increase your dose of LAMICTAL XR faster than prescribed.

1320 **Call your healthcare provider right away if you have any of the following:**

- 1321 • **a skin rash**
- 1322 • **blistering or peeling of your skin**
- 1323 • **hives**
- 1324 • **painful sores in your mouth or around your eyes**

1325 These symptoms may be the first signs of a serious skin reaction. A healthcare provider
1326 should examine you to decide if you should continue taking LAMICTAL XR.

1327 **2. Other serious reactions, including serious blood problems or liver problems.**

1328 LAMICTAL XR can also cause other types of allergic reactions or serious problems that may
1329 affect organs and other parts of your body like your liver or blood cells. You may or may not
1330 have a rash with these types of reactions. Call your healthcare provider right away if you
1331 have any of these symptoms:

- 1332 • fever
- 1333 • frequent infections
- 1334 • severe muscle pain
- 1335 • swelling of your face, eyes, lips, or tongue
- 1336 • swollen lymph glands
- 1337 • unusual bruising or bleeding
- 1338 • weakness, fatigue
- 1339 • yellowing of your skin or the white part of your eyes

1340 **3. Like other antiepileptic drugs, LAMICTAL XR may cause suicidal thoughts or actions**
1341 **in a very small number of people, about 1 in 500.**

1342 **Call a healthcare provider right away if you have any of these symptoms, especially if**
1343 **they are new, worse, or worry you:**

- 1344 • thoughts about suicide or dying
- 1345 • attempt to commit suicide
- 1346 • new or worse depression
- 1347 • new or worse anxiety
- 1348 • feeling agitated or restless
- 1349 • panic attacks
- 1350 • trouble sleeping (insomnia)
- 1351 • new or worse irritability
- 1352 • acting aggressive, being angry, or violent
- 1353 • acting on dangerous impulses
- 1354 • an extreme increase in activity and talking (mania)
- 1355 • other unusual changes in behavior or mood

1356 **Do not stop LAMICTAL XR without first talking to a healthcare provider.**

- 1357 • Stopping LAMICTAL XR suddenly can cause serious problems.
- 1358 • Suicidal thoughts or actions can be caused by things other than medicines. If you have
- 1359 suicidal thoughts or actions, your healthcare provider may check for other causes.

1360 **How can I watch for early symptoms of suicidal thoughts and actions?**

- 1361 • Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or
- 1362 feelings.
- 1363 • Keep all follow-up visits with your healthcare provider as scheduled.
- 1364 • Call your healthcare provider between visits as needed, especially if you are worried
- 1365 about symptoms.

1366 **4. LAMICTAL XR may rarely cause aseptic meningitis, a serious inflammation of the**
1367 **protective membrane that covers the brain and spinal cord.**

1368 **Call your healthcare provider right away if you have any of the following symptoms:**

- 1369 • headache
- 1370 • fever
- 1371 • nausea
- 1372 • vomiting
- 1373 • stiff neck
- 1374 • rash
- 1375 • unusual sensitivity to light
- 1376 • muscle pains
- 1377 • chills

- 1378 • confusion
1379 • drowsiness

1380 Meningitis has many causes other than LAMICTAL XR, which your doctor would check for
1381 if you developed meningitis while taking LAMICTAL XR.

1382 **LAMICTAL XR can have other serious side effects.** For more information ask your
1383 healthcare provider or pharmacist. Tell your healthcare provider if you have any side effect
1384 that bothers you. Be sure to read the section below entitled “What are the possible side
1385 effects of LAMICTAL XR?”

1386 **5. Patients prescribed LAMICTAL have sometimes been given the wrong medicine**
1387 **because many medicines have names similar to LAMICTAL, so always check that you**
1388 **receive LAMICTAL XR.**







1389 Taking the wrong medication can cause serious health problems. When your healthcare
1390 provider gives you a prescription for LAMICTAL XR:

- 1391 • Make sure you can read it clearly.
1392 • Talk to your pharmacist to check that you are given the correct medicine.
1393 • Each time you fill your prescription, check the tablets you receive against the pictures of
1394 the tablets below.

1395 These pictures show the distinct wording, colors, and shapes of the tablets that help to
1396 identify the right strength of LAMICTAL XR. Immediately call your pharmacist if you
1397 receive a LAMICTAL XR tablet that does not look like one of the tablets shown below, as
1398 you may have received the wrong medication.
1399

1400

LAMICTAL XR (lamotrigine) Extended-Release Tablets

 <p>25 mg, yellow with white center</p> <p>Imprinted with LAMICTAL XR 25</p>	 <p>50 mg, green with white center</p> <p>Imprinted with LAMICTAL XR 50</p>	 <p>100 mg, orange with white center</p> <p>Imprinted with LAMICTAL XR 100</p>
 <p>200 mg, blue with white center</p> <p>Imprinted with LAMICTAL XR 200</p>	 <p>250 mg, purple with white center</p> <p>Imprinted with LAMICTAL XR 250</p>	 <p>300 mg, gray with white center</p> <p>Imprinted with LAMICTAL XR 300</p>

1401

1402 **What is LAMICTAL XR?**

1403 LAMICTAL XR is a prescription medicine used:

- 1404
- 1405 • together with other medicines to treat primary generalized tonic-clonic seizures and partial onset seizures in people 13 years or older.
 - 1406 • alone when changing from other medicines used to treat partial seizures in people 13 years or older.
- 1407

1408 It is not known if LAMICTAL XR is safe or effective in children under the age of 13. Other
1409 forms of LAMICTAL can be used in children 2 to 12 years.

1410

1411 **Who should not take LAMICTAL XR?**

1412 You should not take LAMICTAL XR if you have had an allergic reaction to lamotrigine or to
1413 any of the inactive ingredients in LAMICTAL XR. See the end of this leaflet for a complete list
1414 of ingredients in LAMICTAL XR.

1415

1416 **What should I tell my healthcare provider before taking LAMICTAL XR?**

1417 Before taking LAMICTAL XR, tell your healthcare provider about all of your medical
1418 conditions, including if you:

- 1419
- 1420 • have had a rash or allergic reaction to another antiseizure medicine.
 - 1421 • have or have had depression, mood problems, or suicidal thoughts or behavior.
 - 1422 • have had aseptic meningitis after taking LAMICTAL (lamotrigine) or LAMICTAL XR.
 - are taking oral contraceptives (birth control pills) or other female hormonal medicines. Do

1423 not start or stop taking birth control pills or other female hormonal medicine until you have
1424 talked with your healthcare provider. Tell your healthcare provider if you have any changes
1425 in your menstrual pattern such as breakthrough bleeding. Stopping these medicines may
1426 cause side effects (such as dizziness, lack of coordination, or double vision). Starting these
1427 medicines may lessen how well LAMICTAL XR works.

1428 • are pregnant or plan to become pregnant. It is not known if LAMICTAL XR will harm your
1429 unborn baby. If you become pregnant while taking LAMICTAL XR, talk to your healthcare
1430 provider about registering with the North American Antiepileptic Drug Pregnancy Registry.
1431 You can enroll in this registry by calling 1-888-233-2334. The purpose of this registry is to
1432 collect information about the safety of antiepileptic drugs during pregnancy.

1433 • are breastfeeding. LAMICTAL XR can pass into your breast milk. You and your healthcare
1434 provider should decide if you should take LAMICTAL XR or breastfeed.

1435 Tell your healthcare provider about all the medicines you take or if you are planning to take a
1436 new medicine, including prescription and non-prescription medicines, vitamins, and herbal
1437 supplements. If you use LAMICTAL XR with certain other medicines, they can affect each
1438 other, causing side effects.

1439

1440 **How should I take LAMICTAL XR?**

1441 • Take LAMICTAL XR exactly as prescribed.
1442 • Your healthcare provider may change your dose. Do not change your dose without talking to
1443 your healthcare provider.

1444 • Do not stop taking LAMICTAL XR without talking to your healthcare provider. Stopping
1445 LAMICTAL XR suddenly may cause serious problems. For example, if you have epilepsy
1446 and you stop taking LAMICTAL XR suddenly, you may get seizures that do not stop. Talk
1447 with your healthcare provider about how to stop LAMICTAL XR slowly.

1448 • If you miss a dose of LAMICTAL XR, take it as soon as you remember. If it is almost time
1449 for your next dose, just skip the missed dose. Take the next dose at your regular time. **Do not**
1450 **take two doses at the same time.**

1451 • You may not feel the full effect of LAMICTAL XR for several weeks.

1452 • If you have epilepsy, tell your healthcare provider if your seizures get worse or if you have
1453 any new types of seizures.

1454 • LAMICTAL XR can be taken with or without food.

1455 • Do not chew, crush, or divide LAMICTAL XR.

1456 • Swallow LAMICTAL XR tablets whole.

1457 • If you have trouble swallowing LAMICTAL XR tablets, tell your healthcare provider
1458 because there may be another form of LAMICTAL you can take.

1459 • If you receive LAMICTAL XR in a blisterpack, examine the blisterpack before use. Do not
1460 use if blisters are torn, broken, or missing.

1461

1462 **What should I avoid while taking LAMICTAL XR?**

1463 Do not drive a car or operate complex, hazardous machinery until you know how LAMICTAL
1464 XR affects you.

1465

1466 **What are possible side effects of LAMICTAL XR?**

1467 • See “What is the most important information I should know about LAMICTAL XR?”

1468 Common side effects of LAMICTAL XR include:

1469 • dizziness

1470 • tremor

1471 • double vision

1472 • nausea

1473 • vomiting

1474 • trouble with balance and coordination

1475 • anxiety

1476 Other common side effects that have been reported with another form of LAMICTAL include
1477 headache, sleepiness, blurred vision, runny nose, and rash.

1478 Tell your healthcare provider about any side effect that bothers you or that does not go away.

1479 These are not all the possible side effects of LAMICTAL XR. For more information, ask your
1480 healthcare provider or pharmacist.

1481 Call your doctor for medical advice about side effects. You may report side effects to FDA at
1482 1-800-FDA-1088.

1483

1484 **How should I store LAMICTAL XR?**

1485 • Store LAMICTAL XR at room temperature between 59°F to 86°F (15°C to 30°C).

1486 • **Keep LAMICTAL XR and all medicines out of the reach of children.**

1487

1488 **General information about LAMICTAL XR**

1489 Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.

1490 Do not use LAMICTAL XR for a condition for which it was not prescribed. Do not give

1491 LAMICTAL XR to other people, even if they have the same symptoms you have. It may harm
1492 them.

1493 This Medication Guide summarizes the most important information about LAMICTAL XR. If

1494 you would like more information, talk with your healthcare provider. You can ask your

1495 healthcare provider or pharmacist for information about LAMICTAL XR that is written for

1496 healthcare professionals.

1497 For more information, go to www.lamictalxr.com or call 1-888-825-5249.

1498

1499 **What are the ingredients in LAMICTAL XR?**

1500 Active ingredient: lamotrigine.
1501 Inactive ingredients: glycerol monostearate, hypromellose, lactose monohydrate, magnesium
1502 stearate, methacrylic acid copolymer dispersion, polyethylene glycol 400, polysorbate 80, silicon
1503 dioxide (25 mg and 50 mg tablets only), titanium dioxide, triethyl citrate, carmine (250 mg tablet
1504 only), iron oxide black (50 mg, 250 mg, and 300 mg tablets only), iron oxide yellow (25 mg, 50
1505 mg, and 100 mg tablets only), iron oxide red (100 mg tablet only), FD&C Blue No. 2 Aluminum
1506 Lake (200 mg and 250 mg tablets only). Tablets are printed with edible black ink.

1507
1508 **This Medication Guide has been approved by the U.S. Food and Drug Administration.**

1509
1510 LAMICTAL XR is a trademark of GlaxoSmithKline.
1511 DEPAKENE and DEPAKOTE are registered trademarks of Abbott Laboratories.

1512
1513
1514  GlaxoSmithKline

1515 GlaxoSmithKline
1516 Research Triangle Park, NC 27709

1517
1518 ©2011, GlaxoSmithKline. All rights reserved.

1519
1520 Revised November 2011
1521 LXR:xMG